U.S. patent application number 10/742782 was filed with the patent office on 2004-07-29 for novel opiate compounds, methods of making and methods of use.
This patent application is currently assigned to Research Triangle Institute. Invention is credited to Carroll, Frank I., Mascarella, S. Wayne, Thomas, James B..
Application Number | 20040146518 10/742782 |
Document ID | / |
Family ID | 27373095 |
Filed Date | 2004-07-29 |
United States Patent
Application |
20040146518 |
Kind Code |
A1 |
Carroll, Frank I. ; et
al. |
July 29, 2004 |
Novel opiate compounds, methods of making and methods of use
Abstract
The present application relates to novel opioid receptor
antagonists and agonists, methods of making these compounds, and
methods of use thereof.
Inventors: |
Carroll, Frank I.; (Durham,
NC) ; Thomas, James B.; (Efland, NC) ;
Mascarella, S. Wayne; (Hillsborough, NC) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
Research Triangle Institute
Research Triangle Park
NC
|
Family ID: |
27373095 |
Appl. No.: |
10/742782 |
Filed: |
December 23, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10742782 |
Dec 23, 2003 |
|
|
|
09623872 |
Nov 27, 2000 |
|
|
|
09623872 |
Nov 27, 2000 |
|
|
|
PCT/US99/05131 |
Mar 9, 1999 |
|
|
|
60077402 |
Mar 10, 1998 |
|
|
|
60107902 |
Nov 10, 1998 |
|
|
|
Current U.S.
Class: |
424/184.1 |
Current CPC
Class: |
C07D 221/22 20130101;
C07D 211/22 20130101; C07D 211/58 20130101; C07D 221/08
20130101 |
Class at
Publication: |
424/184.1 |
International
Class: |
A61K 039/00 |
Claims
What is claimed as new and is desired to be secured by Letters
Patent of the United States is:
1. A compound represented by formula (I): 17wherein R.sub.1 is
hydrogen, an alkyl group, an aryl group, or an aralkyl group;
R.sub.2 is hydrogen, an alkyl group, an aryl group, or an alkaryl
group; and R.sub.3 is 18each X is, independently, halogen, --OH,
--OR, an alkyl group, an aryl group, --NH.sub.2, --NHR,
--N(R).sub.2, --CF.sub.3, --CN or --C(O)NH.sub.2, --C(O)NHR or
--C(O)N(R).sub.2; each R is, independently, an alkyl group, an aryl
group or an alkaryl group, wherein when X is --N(R).sub.2 the R
groups may, together, form a cyclic alkyl group; n is 0 or an
integer from 1 to 5; and R.sub.a is hydrogen or an alkyl group, or
a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R.sub.1 is hydrogen, a
C.sub.1-4 alkyl group, a phenyl group, or an aralkyl group; R.sub.2
is hydrogen or a C.sub.1-4 alkyl group; and n is 0, 1, 2, 3 or
4.
3. The compound of claim 2, wherein R.sub.1 is hydrogen or a
C.sub.1-4 alkyl group; and n is 0, 1, 2, 3 or 4.
4. The compound of claim 3, wherein R.sub.1 is hydrogen or a
C.sub.1-3 alkyl group; R.sub.2 is hydrogen or a methyl group; n is
1, 2, or 3, and at least one X is --OH, --OCH.sub.3 or --F.
5. The compound of claim 4, wherein at least one X is --OH.
6. A compound represented by formula (II): 19R.sub.1 is an alkyl
group or aralkyl group; and R.sub.3, R.sub.4, R.sub.5, R.sub.6 are
each, independently, hydrogen, an alkyl group, --OH, --NH.sub.2,
--NHR, --N(R).sub.2, halogen, --OR, --CF.sub.3, --CN, --NO.sub.2,
or --NHC(O)R, wherein when any of R.sub.3, R.sub.4, R.sub.5, or
R.sub.6 is N(R).sub.2 the R groups may, together, form a cyclic
alkyl group; each R is, independently, an alkyl group, an aryl
group, or an alkaryl group; and R.sub.7 is hydrogen or an alkyl
group, or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6, wherein R.sub.1 is a C.sub.1-8 alkyl
group or an aryl-C.sub.1-4alkyl group; at most three of R.sub.3,
R.sub.4, R.sub.5, R.sub.6 are each, independently, an alkyl group,
--OH, --NH.sub.2, --NHR, --N(R).sub.2, halogen, --OR, --CF.sub.3,
--CN, --NO.sub.2, or --NHC(O)R; and R.sub.7 is hydrogen or a
C.sub.1-8 alkyl group.
8. The compound of claim 7, wherein R.sub.1 is a C.sub.1-8 alkyl
group or a phenyl-C.sub.1-4 alkyl group; at most two of R.sub.3,
R.sub.4, R.sub.5, and R.sub.6 are each, independently, an alkyl
group, --OH, --NH.sub.2, --NHR, --N(R).sub.2, halogen, --OR,
--CF.sub.3, --CN, --NO.sub.2, or --NHC(O)R; R.sub.7 is a C.sub.1-8
alkyl group.
9. The compound of claim 8, wherein R.sub.1 is a C.sub.1-4 alkyl
group or an aryl-C.sub.1-3 alkyl group; one of R.sub.3, R.sub.4,
R.sub.5, or R.sub.6 is an alkyl group, --OH, --NH.sub.2, --NHR,
--N(R).sub.2, halogen, --OR --CF.sub.3, --CN, --NO.sub.2, or
--NHC(O)R; and R.sub.7 is a C.sub.1-4 alkyl group.
10. The compound of claim 9, wherein R.sub.3, R.sub.4, R.sub.5, and
R.sub.6 are hydrogen.
11. A compound represented by formula (III): 20where R.sub.1 is an
alkyl group or an aralkyl group; R.sub.2 is hydrogen, an alkyl
group, an aralkyl group, .dbd.O, --NH.sub.2, --NHR, --N(R).sub.2,
--NHC(O)R, --NRC(O)R, --NHC(O)R.sub.5, or --NRC(O)R.sub.5; R.sub.3
and R.sub.4 may be hydrogen or methyl, with the proviso that when
R.sub.3 is methyl then R.sub.4 is hydrogen and when R.sub.3 is
hydrogen then R.sub.4 is methyl; each R is, independently, an alkyl
group, an aryl group, or an alkaryl group; and R.sub.5 is 21each X
is, independently, halogen, --OH, --OR, an alkyl group, an aryl
group, --NH.sub.2, --NHR, --N(R).sub.2, --CF.sub.3, --CN,
--C(O)NH.sub.2, --C(O)NHR, or --C(O)N(R).sub.2; each R is,
independently, an alkyl group, an aryl group, or an alkaryl group;
n is 0 or an integer from 1 to 5; and R.sub.a is hydrogen or an
alkyl group, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 11, wherein R.sub.1 is a C.sub.1-8 alkyl
group or an aryl-C.sub.1-4 alkyl group; R.sub.3 is methyl; and
R.sub.4 is hydrogen.
13. The compound of claim 12, wherein R.sub.1 is a C.sub.1-8 alkyl
group or an phenyl-C.sub.1-4 alkyl group.
14. The compound of claim 11, wherein R.sub.1 is a C.sub.1-8 alkyl
group or an aryl-C.sub.1-4alkyl group; R.sub.3 is hydrogen; and
R.sub.4 is methyl.
15. The compound of claim 14, wherein R.sub.1 is a C.sub.1-8 alkyl
group or an phenyl-C.sub.1-4 alkyl group.
16. The compound of claim 11, wherein R2 is .dbd.O.
17. A compound represented by formula (IV): 22where R.sub.a and
R.sub.b are each, independently, hydrogen or an alkyl group, or
R.sub.a and R.sub.b, together, form a cycloalkyl group; each X is,
independently, an alkyl group; O is a five- or six-membered aryl or
heteroaryl group; each Z is, independently, an alkyl group, --OH,
--OR, halogen, --CF.sub.3, --CN, --NH.sub.2, --NHR, or
--N(R).sub.2, wherein when Z is --N(R).sub.2 the R groups may,
together, form a cyclic alkyl group; each R is, independently, an
alkyl group, an aryl group, or an alkaryl group; each W is an alkyl
group; n is 0 or an integer from 1 to 4; y is 0 or an integer from
1 to 5; z is 0 or an integer from 0 to 8; and R.sub.5 is an alkyl
group, alkenyl group, or aralkyl group, or a pharmaceutically
acceptable salt thereof.
18. The compound of claim 17, wherein R.sub.a and R.sub.b are each,
independently, hydrogen or a C.sub.1-8 alkyl group, or R.sub.a and
R.sub.b, together, form a cycloalkyl group; each X is,
independently, a C.sub.1-8 alkyl group; O is a five-membered
heteroaryl group or a six-membered aryl or heteroaryl group each W
is a C.sub.1-8 alkyl group; n is 0, 1 or 2; y is 0 an integer from
1 to 3; z is 0 an integer from 1 to 4; and R.sub.5 is a C.sub.1-8
alkyl group, a C.sub.3-8 alkenyl group, or an aryl-C.sub.1-4 alkyl
group.
19. The compound of claim 18, wherein O is a five-membered
heteroaryl group containing up to 3 heteroatoms, a six-membered
aryl group or a six-membered heteroaryl group containing up to
three heteroatoms.
20. The compound of claim 19, wherein the heteroatoms are each,
independently, nitrogen, oxygen or sulfur.
21. The compound of claim 20, wherein R.sub.a and R.sub.b are each,
independently, hydrogen or a C.sub.1-4 alkyl group, or R.sub.a and
R.sub.b, together, form a cycloalkyl group; each X is,
independently, a C.sub.1-4 alkyl group; n is 0, 1 or 2; y is 0, 1
or 2; z is 0 an integer from 1 to 4; and R.sub.5 is a C.sub.1-8
alkyl group, a C.sub.3-8 alkenyl group, or a phenyl-C.sub.1-4 alkyl
group.
22. The compound of claim 21, wherein O is a six-membered aryl
group; and z is an integer from 1 to 4.
23. A method of binding opioid receptors, comprising administering
an effective amount of the compound of claim 1 to a mammalian
subject in need thereof.
24. A method of binding opioid receptors, comprising administering
an effective amount of the compound of claim 6 to a mammalian
subject in need thereof.
25. A method of binding opioid receptors, comprising administering
an effective amount of the compound of claim 11 to a mammalian
subject in need thereof.
26. A method of binding opioid receptors, comprising administering
an effective amount of the compound of claim 17 to a mammalian
subject in need thereof.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
[0002] The present invention relates to novel opioid receptor
antagonists and agonists, methods of making these compounds, and
methods of use.
[0003] 2. Description of the Background
[0004] The opioid receptor system has been extensively studied over
the past eight decades, driven primarily by a search for analgesics
that do not possess the abuse potential associated with morphine.
While these studies were unsuccessful, our understanding of the
opioid system has increased tremendously. A significant
breakthrough in our understanding of this system came about as a
realization that the pharmacology of opioids is receptor based.
From this vantage point, the focus of research turned to
identifying receptor subtypes with the ultimate goal of assigning
specific physiological function to individual receptors. Today, the
receptor system is known to be composed of the three distinct
subtypes OP.sub.1, OP.sub.2, and OP.sub.3 (delta, kappa and mu), as
each of these have been cloned and been shown to derive from three
different chromosomes. For a discussion of opioid receptors, see
Kirk-Othmer Encyclopedia of Chemical Technology, Volume 17, Fourth
Edition, 1996, pp. 858-881. There is however less however as to the
number of subtypes within each of the main branches and while much
has been learned along these lines, the process of assigning
function to subtypes is still an area of active investigation.
[0005] The opioid receptor system has been extensively studied over
the past eight decades driven primarily by a search for analgesics
that do not possess the abuse potential associated with morphine.
While this effort has been unsuccessful to date, recent studies
have highlighted the delta opioid receptor system as holding the
greatest potential for success. Principally, agonists acting
through the delta opioid receptor have been shown to modulate pain
while minimizing many of the side-effects associated with morphine
which acts primarily at the mu opioid receptor. These unwanted
side-effects include physical dependence, respiratory depression,
and gastrointestinal motility problems. These findings have led to
a dramatic increase in the research efforts directed toward the
production of potent, highly delta receptor selective agonists. The
bulk of this effort has been in discovering small molecules as
opposed to peptides due to their enhanced stability in vivo and
their ability to penetrate the central nervous system.
[0006] I.
[0007] The discovery of potent, highly receptor-selective opioid
pure antagonists has been a goal of medicinal chemists for many
years..sup.1,2 As molecular probes, antagonists have served as
useful tools in the study of both the structure as well as the
physiological functions of the highly complex opioid receptor
system. Much has been accomplished as evidenced by the elegant work
of Portoghese and coworkers over the past decade which ultimately
has led to the discovery of the naltrexone-based kappa and delta
receptor subtype-selective antagonists norbinaltorphimine.sup.3 (1,
nor-BNI) and naltrindole.sup.4 (2, NTI), respectively. Following
Portoghese's lead, workers at SmithKline Beecham recently reported
that the octahydroisoquinoline (3, SB 205588) was a
second-generation, highly potent and selective delta antagonist
formally derived form naltrindole fragmentation..sup.5 One specific
research aim has been the discovery of opioid receptor selective
reversibly binding ligands from the N-substituted
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)pi- peridine (4a) class of
compounds that display pure antagonist activity..sup.6 These
compounds will be useful as molecular probes for the opioid
receptor as well as potential drug candidates for the treatment of
substance abuse and other CNS disorders..sup.7 While mu antagonists
have for years been used in drug abuse therapy, recent findings
suggest that kappa antagonists could provide a more effective,
long-lasting treatment strategy..sup.8 A great variety of
N-substituted derivatives of 4a has been prepared, but until the
recent demonstration of mu selectivity for 5a,.sup.9 none had shown
selectivity between the opioid receptor subtypes. Since the pure
antagonist activity of these compounds is not dependent on the
N-substituent, multiple changes to this part of the molecule would
be expected to affect binding affinity and possibly receptor
selectivity but not alter its fundamental antagonist character.
This feature distinguishes this class of antagonist from the
morphone-based compounds, which display pure antagonist behavior
only with N-substituents such as allyl or cyclopropylmethyl but not
methyl, ethyl, or phenethyl..sup.10 It is currently believed that
the N-substituent in 4a interacts with a lipophilic binding domain
which has been described as either very large or quite malleable
since a multitude of different types of N-substituent changes
provided ligands displaying high binding affinity..sup.11 It has
also been determined that maximum potency and selectivity for the
mu opioid receptor is achieved when the N-substituent incorporates
a lipophilic entity (phenyl or cyclohexyl ring) separated from the
piperidine nitrogen by three atoms as illustrated by compounds
5a-d..sup.9,11 The synthesis of .kappa.-selective compounds remains
an important goal.
[0008] II.
[0009] Derivatives of N-substituted
(.+-.)-trans-3,4-dimethyl-4-(3-hydroxy- phenyl)piperidine, such as
6 and 7, are known to posses nonselective potent opioid pure
antagonist activity..sup.12-16 Early investigations of the
phenylpiperidine class of opioid antagonists identified the
3-methyl substituent and its trans relative relationship to the
4-substituent as being both necessary and sufficient to impart
antagonist activity to the agonist
4-(3-hydroxyphenyl)piperidine..sup.12 This feature distinguished
the phenylpiperidines from the oxymorphones which rely on
particular N-substituents (i.e. allyl, cyclopropylmethyl) for
expression of opioid antagonist activity..sup.17 Further studies
demonstrated that the N-substituent in the phenylpiperidine
antagonists controls their potency and efficacy..sup.15
Accordingly, there remains a need for compounds which have similar
therapeutic effects as the trans-3,4-dimethyl-4-(3-hyd-
roxyphenyl)piperidines, but are based on different structural
elements. 12
[0010] III.
[0011] Numerous structural types of opioid agonists have been
discovered, and several such as methadone, meperidine, fentanyl,
and pentazocine as well as others have become important drugs for
the treatment of pain..sup.10 However, there are only a few
structural types that show potent, opioid pure antagonist
activity..sup.10,7 A resurgence in heroin use in recent years
coupled with the demonstrated effectiveness of opioid antagonists
for the treatment of other substances of abuse has spurred new
interest in the development of novel antagonists for opioid
receptors..sup.16
[0012] The oxymorphone-related compounds such as naloxone (8a) and
naltrexone (8b), where the antagonist activity is dependent upon
the N-substituent, have received considerable attention over the
past few decades..sup.10 For example, pioneering studies by
Portoghese and coworkers lead to the development of the
prototypical kappa and delta opioid receptor antagonists,
norbinaltorphimine (1, nor-BNI) and naltrindole (2, NTI). In
contrast, the N-substituted
trans-3,4-dimethyl-(3-hydroxyphenyl)piperidine (9a-d) class of pure
antagonist has received relatively little attention. Studies with
the N-methyl analog 9a as well as many other N-substituted analogs
such as 9b, 9c (LY255582), and 9d showed that the pure antagonist
activity was dependent on the 3-methyl substituent and its trans
relative relationship to the 4-methyl substituent on the piperidine
ring and, unlike the oxymorphone class, was independent of the
nature of the N-substituent..sup.7,16,17,6,13,14 Interestingly, the
3,4-dimethyl cis isomer 9e was found to be a mixed
agonist-antagonist. May and coworkers.sup.18 reported that
2,9.alpha.-dimethyl-5-(3-hydroxyphenyl)mor- phan (10a), which has
the 9-methyl group in a configuration comparable to the
cis-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (9e) with the
5-(3-hydroxyphenyl) group locked in an equatorial conformation
relative to the piperidine ring in the morphan structure, was a
weak but pure antagonist.
[0013] Neither 2,9.beta.-dimethyl-5-(3-hydroxyphenyl)morphan (10b)
nor 2,4.beta.-dimethyl-5(3 hydroxyphenyl)morphan (10g) have not
been reported, due to a lack of synthetic accessibility to these
structural isomers. Accordingly, the successful synthetic
preparation of 2,9.beta.-morphans and 2,4.beta.-morphans remains an
important goal of in the field opioid receptor-binding compounds.
3
[0014] IV.
[0015] In search of analgesics possessing a reduced side-effect
profile relative to morphine, much effort has bee expended towards
finding opioids which operate via .delta. or .kappa. opioid
receptors as opposed to the .mu. opioid receptor which meditates
the actions of morphine and its congeners..sup.10 BW373U86
(11).sup.19 and SNC-80 (12).sup.20 represent one class of opioid
agonists discovered to be selective for the .delta. opioid
receptor. Due to the lack of a clear opioid message substructure
(i.e., a tyramine component similar to the enkephalins), compounds
11 and 12 have been referred to as non-classical opioid
ligands..sup.5 The piperazine subunit of 11 and 12 is not commonly
found in compounds showing activity at the opioid receptors. In
contrast, piperidine ring compounds are found in many different
classes of opioids..sup.27 If the internal nitrogen atom in
compounds 11 or 12 is transposed with the benzylic carbon,
piperidine ring analogs such as 13 would be obtained. Even though
there are common structural elements between structures 11 or 12
and 13, the expected difference between in basicity between the
piperidinyl amino group of 11 or 12 and the di-phenyl substituted
amine of 13 is sufficient such that it cannot be predicted whether
similarity to suggest that 13 would interact with opioid receptors
similar to 11 or 12. It is also interesting to note that compound
13 has some structural elements in common with cis-3-methylfentanyl
(14),.sup.21,22 a non-classical opioid ligand selective for the mu
opioid receptor. Accordingly, the preparation of compound 13 and
related structures remains an important goal. 4
REFERENCES
[0016] (1) Dhawan, B. N.; Cesselin, F.; Raghubir, R.; Reisine, T.;
Bradley, P. B.; Portoghese, P. S.; Hamon, M. International Union of
Pharmacology. XII. Classification of opioid receptors. Pharmacol.
Rev. 1996, 48, 567-592.
[0017] (2) Martin, W. R. The evolution of concepts of opioid
receptors. In The Opiate Receptors, Pasternak, G. W. Eds.; Humana
Press Inc.: New Jersey, 1988, pp. 3-22.
[0018] (3) Portoghese, P. S.; Nagase, H.; Lipkowski, A. W.; Larson,
D. L.; Takemori, A. E. Binaltorphimine-related bivalent ligands and
their kappa opioid receptor antagonist selectivity [published
erratum appears in J. Med. Chem. 1988 October;31(10):2056]. J. Med.
Chem. 1988, 31, 836-841.
[0019] (4) Portoghese, P. S. An approach to the design of
receptor-type-selective non-peptide antagonists of peptidergic
receptors: .delta. opioid antagonists. J. Med. Chem. 1991, 34(6),
1757-1762.
[0020] (5) Dondio, G.; Ronzoni, S.; Eggleston, D. S.; Artico, M.;
Petrillo, P.; Petrone, G.; Visentin, L.; Farina, C.; Vecchietti,
V.; Clarke, G. D. Discovery of a novel class of substituted
pyrrolooctahydroisoquinolines as potent and selective .delta.
opioid agonists, based on an extension of the message-address
concept. J. Med. Chem. 1997, 40, 3192-3198.
[0021] (6) Zimmerman, D. M.; Nickander, R.; Horng, J. S.; Wong, D.
T. New structural concepts for narcotic antagonists defined in a
4-phenylpiperidine series. Nature 1978, 275, 332-334.
[0022] (7) Zimmerman, D. M.; Leander, J. D. Invited perspective,
selective opioid receptor agonists and antagonists: Research tools
and potential therapeutic agents. J. Med. Chem. 1990, 33,
895-902.
[0023] (8) Rothman, R. B.; Gorelick, D. A.; Eichmiller, P. R.;
Hill, B. H.; Norbeck, J.; Liberto, J. G. An open-label study of a
functional opioid kappa antagonist in the treatment of opioid
dependence. In Problems of Drug Dependence, 1997: Proceedings of
the 59th Annual Scientific Meeting, The College on Problems of Drug
Dependence, Inc., Harris, L. S. Eds.; U.S. Department of Health and
Human Services: Rockville, Md., 1997; Vol. 178, pp. 309.
[0024] (9) Thomas, J. B.; Mascarella, S. W.; Rothman, R. B.;
Partilla, J. S.; Xu, H.; McCullough, K. B.; Dersch, C. M.;
Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Investigation of
the N-substituent conformation governing potency and .mu. receptor
subtype-selectivity in
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid
antagonists. J. Med. Chem. 1998, 41(11), 1980-1990.
[0025] (10) Aldrich, J. V. Analgesics. In Burger's Medicinal
Chemistry and Drug Discovery, Wolff, M. E. Eds.; John Wiley &
Sons, Inc.: 1996; Vol. 3: Therapeutic Agents.
[0026] (11) Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw,
W. N.; Wong, D. T.; Cantrell, B. E.; Johnson, B. G.; Reel, J. K.;
Snoddy, J. D.; Takemori, A. E.; Zimmerman, D. M.
3,4-Dimethyl-4-(3-hydroxyphenyl)piperid- ines: Opioid antagonists
with potent anorectant activity. J. Med. Chem. 1993, 36(20),
2842-2850.
[0027] (12) Zimmerman, D. M.; Smits, S.; Nickander, R. Further
investigation of novel 3-methyl-4-phenylpiperidine narcotic
antagonists. In Proceedings of the 40th Annual Scientific Meeting
of the Committee on Problems of Drug Dependence, 1978, pp.
237-247.
[0028] (13) Zimmerman, D. M.; Smits, S. E.; Hynes, M. D.; Cantrell,
B. E.; Leander, J. D.; Mendelsohn, L. G.; Nickander, R. Drug
Alcohol Depend. 1985, 14, 381-402.
[0029] (14) Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw,
W. N.; Wong, D. T.; Zimmerman, D. M.; Gidda, S. J.; Cantrell, B.
E.; Scoepp, D. D.; Johnson, B. G.; Leander, J. D. J. Med. Chem.
1994, 37, 2262-2265.
[0030] (15) Evans, D. A.; Mitch, C. H.; Thomas, R. C.; Zimmerman,
D. M.; Robey, R. L. Application of metalated enamines to alkaloid
synthesis. An expedient approach to the synthesis of morphine-based
analgesics. J. Am. Chem. Soc. 1980, 102, 5955-5956.
[0031] (16) Kreek, M. J. Opiates, opioids and addiction. Mol.
Psychiatry 1996, 1(3), 232-254.
[0032] (17) Zimmerman, D. M.; Gidda, J. S.; Cantrell, B. E.;
Schoepp, D. D.; Johnson, B. G.; Leander, J. D. Discovery of a
potent, peripherally selective trans-3,4-dimethyl-4-(3
hydroxyphenyl)piperidine opioid antagonist for the treatment of
gastrointestinal motility disorders. J. Med. Chem. 1994, 37(15),
2262-2265.
[0033] (18) Awaya, H.; May, E. L.; Aceto, M. D.; Merz, H.; Rogers,
M. E.; Harris, L. S. Racemic and optically active
2,9-dimethyl-5-(m-hydroxypheny- l)morphans and pharmacological
comparison with the 9-demethyl homologues. J. Med. Chem. 1984, 27,
536-539.
[0034] (19) Chang, K. J.; Rigdon, G. C.; Howard, J. L.; McNutt, R.
W. A novel potent and selective nonpeptidic delta opioid receptor
agonist, BW373U86. J. Pharm. Exp. Ther. 1993, 267, 852-857.
[0035] (20) Calderon, S. N.; Rothman, R. B.; Porreca, F.;
Flippen-Anderson, J. L.; McNutt, R. W.; Xu, H.; Smith, L. E.;
Bilsky, E. J.; Davis, P.; Rice, K. C. Probes for narcotic receptor
mediated phenomena 19. Synthesis of
(+)-4-[(.alpha.R)-.alpha.-(2S,5R)-4-allyl-2,5--
dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC
80) A highly selective, nonpeptide .delta. opioid receptor agonist.
J. Med. Chem. 1994, 37, 2125-2128.
[0036] (21) Van Bever, W. F.; Niemegeers, C. J. E.; Janssen, P. A.
J. Synthetic analgesics. Synthesis and pharmacology of the
diastereoisomers of
N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and
N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide.
J. Med. Chem. 1974, 17(10), 1047-1051.
[0037] (22) Xu, H.; Kim, C.-H.; Zhu, Y. C.; Weber, R. J.; Rice, K.
C.; Rothman, R. B. (+)-cis-Methylfentanyl and its analogs bind
pseudoirreversibly to the mu opioid binding site: Evidence for
pseudoallosteric modulation. Neuropharmacology 1991, 30,
455-462.
SUMMARY OF THE INVENTION
[0038] It is an object of the present invention to provide novel
compounds which bind to opioid receptors.
[0039] It is another object of the present invention to provide
novel compounds which are opioid receptors antagonists that bind
with high affinity.
[0040] It is another object of the present invention to provide
novel opiates that are selective for the kappa receptor as compared
to the delta and mu receptors.
[0041] It is another object of the present invention to provide
novel opiates that are selective for the mu and kappa receptors as
compared to the delta receptor.
[0042] It is another object of the present invention to provide
novel opiates that are selective for the delta receptor as compared
to the mu and kappa receptors.
[0043] It is another object of the present invention to provide
novel opiates that are pure antagonists at the mu, delta and kappa
receptors.
[0044] It is another object of the present invention to provide
methods of making the novel compounds.
[0045] It is another object of the present invention to provide
methods of treating a variety of disease states with the novel
opiate compounds of the present invention.
[0046] The objects of the present invention may be accomplished
with compounds represented by formula (I), or pharmaceutically
acceptable salts thereof: 5
[0047] where
[0048] R.sub.1 is hydrogen, an alkyl group, an aryl group, or an
aralkyl group;
[0049] R.sub.2 is hydrogen, an alkyl group, an aryl group, or an
alkaryl group; and
[0050] R.sub.3 is 6
[0051] each X is, independently, halogen, --OH, --OR, an alkyl
group, an aryl group, --NH.sub.2, --NHR, --N(R).sub.2, --CF.sub.3,
--CN or --C(O)NHR, or --C(O)NHR, or --C(O)N(R).sub.2;
[0052] each R is, independently, an alkyl group, an aryl group or
an alkaryl group;
[0053] n is 0 or an integer from 1 to 5; and
[0054] R.sub.a is hydrogen or an alkyl group.
[0055] The objects above may also be accomplished with compounds
represented by formula 7
[0056] (II): or pharmaceutically acceptable salts thereof,
[0057] where
[0058] R.sub.1 is an alkyl group or aralkyl group; and
[0059] R.sub.3, R.sub.4, R.sub.5, R.sub.6 are each, independently,
hydrogen, an alkyl group, --OH, --NH.sub.2, --NHR, --N(R).sub.2,
halogen, --OR, --CF.sub.3, --CN, --NO.sub.2, or --NHC(O)R;
[0060] each R is, independently, an alkyl group, an aryl group, or
an alkaryl group; and
[0061] R.sub.7 is hydrogen or an alkyl group.
[0062] The objects of the present invention may be also
accomplished with compounds represented by formula (III), or
pharmaceutically acceptable salts thereof: 8
[0063] where
[0064] R.sub.1 is an alkyl group or an aralkyl group;
[0065] R.sub.2 is hydrogen, an alkyl group, an aralkyl group,
.dbd.O, --NH.sub.2, --NHR, --N(R).sub.2, --NHC(O)R, --NRC(O)R,
--NHC(O)R.sub.5, or --NRC(O)R.sub.5;
[0066] R.sub.3 and R.sub.4 may be hydrogen or methyl, with the
proviso that when R.sub.3 is methyl then R.sub.4 is hydrogen and
when R.sub.3 is hydrogen then R.sub.4 is methyl;
[0067] each R is, independently, an alkyl group, an aryl group, or
an alkaryl group; and
[0068] R.sub.5 is 9
[0069] each X is, independently, halogen, --OH, --OR, an alkyl
group, an aryl group, --NH.sub.2, --NHR, --N(R).sub.2, --CF.sub.3,
--CN, --C(O)NH.sub.2, --C(O)NHR, or --C(O)N(R).sub.2;
[0070] each R is, independently, an alkyl group, an aryl group, or
an alkaryl group;
[0071] n is 0 or an integer from 1 to 5; and
[0072] R.sub.a is hydrogen or an alkyl group.
[0073] The objects above may be accomplished with compounds
represented by formula (IV), or pharmaceutically acceptable salts
thereof: 10
[0074] where
[0075] R.sub.a and R.sub.b are each, independently, hydrogen or an
alkyl group, or R.sub.a and R.sub.b, together, form a cycloalkyl
group;
[0076] each X is, independently, an alkyl group;
[0077] O is a five- or six-membered aryl or heteroaryl group;
[0078] each Z is, independently, an alkyl group, --OH, --OR,
halogen, --CF.sub.3, --CN, --NH.sub.2, --NHR, or --N(R).sub.2;
[0079] each R is, independently, an alkyl group, an aryl group, or
an alkaryl group;
[0080] each W is an alkyl group;
[0081] n is 0 or an integer from 1 to 4;
[0082] y is 0 or an integer from 1 to 5;
[0083] z is 0 an integer from 1 to 8; and
[0084] R.sub.5 is an alkyl group, alkenyl group, or aralkyl
group.
[0085] A more complete appreciation of the invention and many of
the attendant advantages thereof will be readily obtained as the
same becomes better understood by reference to the following
detailed description when considered in connection with the
accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0086] FIG. 1: Synthesis of compounds represented by formula
(II).
[0087] FIG. 2: Synthesis of compounds represented by formula (III).
(A) synthesis of compounds in which R.sub.3 is methyl
(9.beta.-compounds). (B) synthesis of compounds in which R.sub.4 is
methyl (4.beta.-compounds).
[0088] FIG. 3: Retrosynthetic analysis for the synthesis of
compounds represented by formula (IV).
[0089] FIG. 4: Synthesis of compounds represented by formula
(IV).
[0090] FIG. 5: Synthesis of compounds (7) as described in Example
1.
[0091] FIG. 6: Data from screening of library described in Example
1 at 100 nM against the kappa-selective ligand [.sup.3H]U69,593
(percent inhibition).
[0092] FIG. 7: Comparison of ratios of radioligand binding and
GTP.gamma.S assays for compound 8, naltrexone, nor-BNI, 5d, and
5a-c described in Example 1, the N-trans-cinnamyl derivatives of
4b. The radioligand and GTP.gamma.S binding data for 5a-d were
taken from ref. 9 cited in Example 1.
[0093] FIG. 8: Synthesis of compounds (7) and (8) as described in
Example 2.
[0094] FIG. 9: Structural representation of (a) Naltrexone, (b)
3,4-dimethyl-4-(3-hydroxyphenyl)piperidine, and (c)
8a-methyl-4a-(3-hydroxyphenyl)-octahydrobenzo[e]isoquinoline
(Example 2).
[0095] FIG. 10: Structure of
(.+-.)-[2-phenethyl-8a-methyl-4a-(3-hydroxyme-
thyl)]octahydrobenzo[e]isoquinoline (8) HCl described in Example 2
by single crystal X-ray analysis.
[0096] FIG. 11: Synthesis of compound (18) as described in Example
3.
[0097] FIG. 12: Synthesis of compound (21) as described in Example
3.
[0098] FIG. 13: Synthesis of compound (5c) as described in Example
4.
[0099] FIG. 14: X-Ray structure of (5b) described in Example 4
drawn using the experimentally determined coordinates.
[0100] FIG. 15: Conformational representation of naltrexone (1b),
N-substituted 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine, and
2-alkyl-9.beta.-5-(3-hydroxyphenyl)morphan. These compounds are
described in Example 4.
[0101] FIG. 16: Synthesis of compound (17) as described in Example
5.
[0102] FIG. 17: Synthesis of compound (3) as described in Example
6.
[0103] FIG. 18: Synthesis of 4.beta.-5-phenylmorphans as described
in Example 7.
DETAILED DESCRIPTION OF THE INVENTION
[0104] The present invention relates to a group of compounds that
contain a piperidinyl, or a bridged piperidinyl group. The
inventive compounds have been found to have a variety of different
activities when bound to opioid receptors.
[0105] Compounds of Formula (I)
[0106] In formula (I), R.sub.1 is hydrogen, an alkyl group or an
aralkyl group. As used throughout this disclosure, the terms "alkyl
group" or "alkyl radical" encompass all structural isomers thereof,
such as linear, branched and cyclic alkyl groups and moieties.
Unless stated otherwise, all alkyl groups described herein may have
1 to 8 carbon atoms, inclusive of all specific values and subranges
therebetween, such as 2, 3, 4, 5, 6, or 7 carbon atoms. As used
herein, the term "aralkyl group" refers to an aryl moiety bonded to
an alkyl radical. The aryl moiety may have 6 to 20 carbon atoms.
The aryl moiety may contain only carbon and hydrogen atoms.
Alternatively, the aryl moiety may contain heteroatoms, for example
1, 2, or 3 heteroatoms (e.g., oxygen, nitrogen, and sulfur). A
particularly preferred aryl moiety is phenyl-. The alkyl radical of
the aralkyl group may as described above when R.sub.1 is an alkyl
group. The alkyl group or moiety and/or the aryl moiety may be
substituted. Suitable substituents include halogens (F, Cl, Br and
I), alkyl groups (e.g., C.sub.1-C.sub.8), alkoxy groups (e.g.,
C.sub.1-C.sub.8 alkoxy groups), --CF.sub.3, --CN, --NH.sub.2,
--NHR, or --N(R).sub.2. The R groups are, independently, an alkyl
group (such as described for R.sub.1 in formula (I) above), an aryl
group (such as phenyl) or an aralkyl group group (such as benzyl).
In groups in compounds of formula (I)-(IV) where two R groups are
bonded to the same atom, i.e., --N(R).sub.2, the R groups may,
together, form a cyclic alkyl group. Such a cyclic alkyl group may,
preferably, contain 2 to 8 carbon atoms, with 4 or 5 carbon atoms
particularly preferred.
[0107] Preferably, R.sub.1 is unsubstituted. In a preferred
embodiment, R.sub.1 is a C.sub.1-C.sub.8 alkyl group or a
C.sub.6-C.sub.10 aryl-C.sub.1-C.sub.8-alkyl group. In a more
preferred embodiment, R.sub.1 is a C.sub.1-C.sub.4 alkyl group or a
phenyl-C.sub.1-C.sub.4-alkyl group. Even more preferably, R.sub.1
is a C.sub.1-C.sub.3 alkyl group or a phenyl-C.sub.1-C.sub.3alkyl
group. Most preferably, R.sub.1 is a methyl group, an isopropyl
group, or a phenethyl group.
[0108] R.sub.2 in formula (I) may be hydrogen, an alkyl group, an
aryl group or an alkaryl group. Suitable alkyl and alkaryl groups
are as described for R.sub.1 above. The aryl group may be as
described for the aryl moiety of R.sub.1 above. Preferably, R.sub.2
is hydrogen.
[0109] R.sub.3 in formula (I) is one of the following groups:
11
[0110] In these groups, the phenyl ring may be unsubstituted (n is
0) or substituted with 1, 2, 3, 4, or 5 X groups. each X is,
independently, halogen (e.g., chlorine or fluorine), --OH, --OR, an
alkyl group (such as described for R.sub.1 in formula (I) above),
an aryl group (such as phenyl), --NH.sub.2, --NHR, --N(R).sub.2,
--CF.sub.3, --CN, --C(O)NH.sub.2, --C(O)NHR, or --C(O)N(R).sub.2.
The R groups are, independently, an alkyl group (such as described
for R.sub.1 in formula (I) above), an aryl group (such as phenyl)
or an aralkyl group group (such as benzyl). Preferred X groups are
chlorine, fluorine, --OH, --OCH.sub.3 and --NH.sub.2. Preferably, n
is 1. The X group(s) may be located at the ortho, meta and para
positions. The para position is preferred, especially when X is
--OH.
[0111] R.sup.a in the formulas above may be hydrogen or an alkyl
group. Suitable alkyls are as described for R.sub.1 in formula (I)
above. Preferably, R.sub.a is hydrogen or methyl.
[0112] The absolute configuration of the carbon atom to which
R.sub.1 is bonded may be (R) or (S). The (S) configuration is
preferred.
[0113] The compounds of formula (I) are preferably opiates with
preferential affinity for the .mu./.kappa. opioid receptors and
comparably less affinity for .delta. receptors. In a preferred
embodiment, these compounds are pure antagonists. The ratio of
affinity for the .delta. receptor to the .kappa. receptor
(.delta./.kappa.) may be at least 1.5, preferably at least 2.0,
more preferably at least 20, still more preferably at least 100,
even still more preferably at least 750 and most preferably at
least 800. The .mu./.kappa. ratio may be 0.002 to 500.
[0114] The compounds of formula (I) may be prepared using
well-known synthetic techniques by condensing an acid of the
formula R.sub.3--CO.sub.2H with an amine represented by the
formula: 12
[0115] The acid is preferably converted into an activated ester in
order to couple with the amine. A BOP ester is preferred. In a
particularly preferred embodiment, a variety of compounds within
the scope of formula (I) may be simultaneously synthesized and
evaluated using well-established combinatorial synthesis
techniques, for example, as described in Example 1.
[0116] Compounds of Formula (II)
[0117] In formula (II), R.sub.1 is an alkyl group or an aralkyl
group. These groups may be as defined for R.sub.1 in formula (I).
In a preferred embodiment, R.sub.1 is a C.sub.1-C.sub.8 alkyl group
or a C.sub.6-C.sub.10 aryl-C.sub.1-C.sub.8-alkyl group. In a more
preferred embodiment, R.sub.1 is a C.sub.1-C.sub.4 alkyl group or a
phenyl-C.sub.1-C.sub.4-alkyl group. Even more preferably, R.sub.1
is a C.sub.1-C.sub.2 alkyl group or a phenyl-C.sub.1-C.sub.3-alkyl
group. Most preferably, R.sub.1 is a methyl group or a phenethyl
group.
[0118] R.sub.7 is hydrogen or an alkyl group, preferably an alkyl
group. Suitable alkyl groups are as described above for R.sub.1.
Preferably, R.sub.7 is methyl.
[0119] The substituents R.sub.3, R.sub.4, R.sub.5 and R.sub.6 on
the fused aromatic ring may be, independently, hydrogen, an alkyl
group, --OH, --NH.sub.2, --NHR, --N(R).sub.2, halogen (e.g.,
fluorine and chlorine), --OR, --CF.sub.3, --CN, --NO.sub.2, or
--NHC(O)R. The R groups are, independently, an alkyl group (such as
described for R.sub.1 in formula (I) above), an aryl group (such as
phenyl) or an aralkyl group group (such as benzyl). Methyl and
ethyl are the more preferred alkyl groups, and methyl is most
preferred. Methoxy is a preferred --OR group. In one embodiment,
R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each hydrogen. In another
embodiment, at most three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6
are other than hydrogen. In another embodiment, at most two of
R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are other than hydrogen. In
yet another embodiment, only one of R.sub.3, R.sub.4, R.sub.5 and
R.sub.6 is other than hydrogen. In an embodiment where the fused
aromatic ring contains alkyl groups, one, two or three of R.sub.3,
R.sub.4, R.sub.5 and R.sub.6 are alkyl groups.
[0120] The stereochemical relationship between R.sub.7 and the
hydroxyphenyl group may be cis or trans. The cis stereochemistry is
preferred. All optical isomers of these compounds are within the
scope of the present invention.
[0121] The compounds of formula (II) are opiates which are
preferably pure opioid receptor antagonists. In a particularly
preferred embodiment, the opiates are selective for the mu and/or
kappa receptor as compared to delta receptors. The .delta./.kappa.
selectivity may be at least 2:1, but is preferably higher, such as
at least 5:1, 10:1, 20:1, 25:1, 30:1; or 50:1. The .delta./.mu.
selectivity may be at least 2:1, but is preferably higher, such as
at least 5:1, 10:1, 15:1, 20:1, 25:1,30:1, or 50:1
[0122] The compounds of formula (II) may be prepared, for example,
as shown FIG. 1. These compounds may also be prepared as described
in Examples 2 and 3 with appropriate modification of the various R
groups.
[0123] Compounds of Formula (III)
[0124] In formula (III), R.sub.1 may be an alkyl group or an
aralkyl group. These groups may be as defined for R.sub.1 in
formula (I). In a preferred embodiment, R.sub.1 is a
C.sub.1-C.sub.8 alkyl group or a C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.8-alkyl group. In a more preferred embodiment,
R.sub.1 is a C.sub.1-C.sub.4 alkyl group or a
phenyl-C.sub.1-C.sub.4-alkyl group. Even more preferably, R.sub.1
is a C.sub.1-C.sub.2 alkyl group or a phenyl-C.sub.1-C.sub.3-alkyl
group. Most preferably, R.sub.1 is larger than a methyl group, such
as a phenethyl group.
[0125] R.sub.2 in these compounds may be hydrogen, an alkyl group,
an aralkyl group, .dbd.O, --NH.sub.2, --NHR, --N(R).sub.2,
--NHC(O)R, --NRC(O)R, --NHC(O)R.sub.5, or --NRC(O)R.sub.5. The
alkyl or aralkyl group may be as described for R.sub.1 in formula
(I). The R groups are, independently, an alkyl group (such as
described for R.sub.1 in formula (I) above), an aryl group (such as
phenyl) or an aralkyl group group (such as benzyl). The R.sub.5
group of formula (III) has the same structure for R.sub.3 in
formula (I) discussed above. All of the embodiments described for
R.sub.3 in formula (I) apply to R.sub.5 in formulla (III).
Preferably, R.sub.2 is hydrogen, an alkyl group, or an amido group,
i.e., --NHC(O)R.sub.5, or --NRC(O)R.sub.5. More preferably, R.sub.2
is hydrogen or an amido group.
[0126] R.sub.3 and R.sub.4 may be hydrogen or methyl. However, when
R.sub.3 is methyl then R.sub.4 is hydrogen and when R.sub.3 is
hydrogen then R.sub.4 is methyl.
[0127] The compounds of formula (III) are preferably opiates which
are opioid receptor pure antagonists. When R.sub.2 is hydrogen,
these compounds have a preferential affinity for the .mu.
receptors, as compared to .kappa. or .delta. receptors. In this
embodiment, the .mu./.delta. selectivity may be at least 2:1, but
is preferably higher, e.g., at least 5:1, 10:1, 25:1, 50:1, 100:,
150:1 or 200:1. In this embodiment, the .mu./.kappa. selectivity
may be at least 2:1, 5:1, 10:1 or 25:1. When R2 is an amido group,
the .delta./.mu. selectivity may be at least 2:1, but is preferably
higher, e.g., at least 5:1, 10:1, 25:1 or 50:1.
[0128] The compounds of formula (III) may be synthesized, for
example, as shown in FIG. 2. The synthesis of compounds in which
R.sub.3 is methyl (9.mu.-compounds) is shown in FIG. 2A. Compounds
in which R.sub.4 is methyl (4.beta.-compounds) may be synthesized
as shown in FIG. 2B. For specific examples of such preparations,
see the following Examples 3-5 and 7.
[0129] Compounds of Formula (IV)
[0130] R.sub.a and R.sub.b are each, independently, hydrogen or an
alkyl group. The alkyl group may be as described for R.sub.1 in
formula (I). Preferably, R.sub.a and R.sub.b are ethyl.
Alternatively, R.sub.a and R.sub.b, together, form a cycloalkyl
group. Suitable cycloalkyl groups include those having 3 to 7
carbon atoms. Cycloalkyl groups having four or five carbon atoms
are especially preferred.
[0131] Each X, if present, may be an alkyl group. Suitable alkyl
groups are as described for R.sub.1 in formula (I) above. The
number of X groups, determined by the variable n, may be 0, 1, 2, 3
or 4. Preferably, n is 0.
[0132] The group O is a five- or six-membered aryl or heteroaryl
group. Phenyl is the preferred aryl group. Suitable heteroaryl
groups may have one, two, three or four heteroatoms, e.g.,
nitrogen, oxygen or sulfur. Specific examples of heteroaryl groups
include pyridine, pyridazine, pyrimidine, pyrazine, traiazine
(e.g., 1,2,3-; 1,2,4-; 1,3,5-), 1,2,4,5-tetrazine, furan,
thiophene, oxazole, isothiazole, thiadazole, pyrazole, pyrrole, and
imidazole.
[0133] Preferably, O is a phenyl group. These compounds are
represented by the formula: 13
[0134] Each Z, if present, is, independently, an alkyl group, --OH,
--OR, halogen, --CF.sub.3, --CN, --NH.sub.2, --NHR, or
--N(R).sub.2. The R groups are, independently, an alkyl group (such
as described for R.sub.1 in formula (I) above), an aryl group (such
as phenyl) or an aralkyl group group (such as benzyl) Suitable
alkyl groups are as described for R.sub.1 in formula (I) above. The
number of Z groups, determined by the variable y, may be 0, 1, 2,
3, 4, or 5. Preferably, y is 1 or 0. More preferably, y is 0.
[0135] Each W, if present, is an alkyl group. Suitable alkyl groups
are as described for R.sub.1 in formula (I) above. Preferably, W is
a methyl. The number of alkyl groups on the piperdine ring is
determined by z. The variable z may be 0 or an integer from 1 to 8,
inclusive of 2, 3, 4, 5, 6, or 7. Preferably, z is 1, 2, or 3. In a
preferred embodiment, at least one W group is bonded to a carbon
atom adjacent to the carbon atom bearing the diamino substituent.
The stereochemical relationship between this W group and the
diamino substituent may be cis or trans. When multiple W groups are
present on the piperdine ring, the stereochemical relationship
between W the groups may be cis or trans.
[0136] In formula (IV), R.sub.5 is an alkyl group, an alkenyl
group, or an aralkyl group. The alkyl group and/or the aralkyl
group may be as defined for R.sub.1 in formula (I). Preferably,
these groups have 1 to 8 carbon atoms, more preferably 1 to 5
carbon atoms. The alkenyl group may have up to three double bonds,
more preferably, up to two double bonds, and, most preferably, one
double bond. An alkenyl group is preferred. Most preferably,
R.sub.5 is an allyl group.
[0137] The compounds formula (IV) are opiates which are preferably
agonists that are selective for the delta receptor. The
.delta./.mu. selectivity may be at least 2:1, but is preferably
higher, e.g., at least 5:1, 10:1, 25:1, 50:1, 100:1 or 200:1. The
.delta./.kappa. selectivity may be at least 2:1, but is preferably
higher, e.g., at least 5:1, 10:1, 25:1, 50:1, 100:1, 200:1, 250:1
or 500:1.
[0138] The compounds of formula (IV) may be synthesized, for
example, in accordance with the retrosynthetic analysis shown in
FIG. 3. An example of a reaction sequence to obtain compounds of
formula (IV) is shown in FIG. 4. For specific examples of syntheses
of compounds of formula (IV), see the Example 6 below.
[0139] Compounds (I)-(IV) may be in the form of a pharmaceutically
acceptable salt via protonation of the amine with a suitable acid.
The acid may be an inorganic acid or an organic acid. Suitable
acids include, for example, hydrochloric, hydroiodic, hydrobromic,
sulfuric, phosphoric, citric, acetic and formic acids.
[0140] The receptor selectivities discussed above are determined
based on the binding affinities at the receptors indicated.
[0141] The compounds of the present invention may be used to bind
opioid receptors. Such binding may be accomplished by contacting
the receptor with an effective amount of the inventive compound. Of
course, such contacting is preferably conducted in a aqueous
medium, preferably, at physiologically relevant ionic strength, pH,
etc.
[0142] The inventive compounds may also be used to treat patients
having disease states which are ameliorated by binding opioid
receptors. Such diseases states include heroin addiction, pain,
i.e., the compounds are used analgesics. The compounds of the,
inventive may also be used to reverse mu-induced respiratory
depression, as cytostatica agents, as antimigraine agents, as
immunomodulators, as immunosuppressives, as antiarthritic agents,
as antiallergic agents, as virucides, to treat diarrhea, as
antidepressants, as uropathic agents, as antitussives, as
antiadditive agents, as anti-smoking agents, to treat alcoholism,
as hypotensive agents, or to treat obesity.
[0143] The compounds may be administered in an effective amount by
any of the conventional techniques well-established in the medical
field. For example, the compounds may be administered orally,
intraveneously, or intramuscularly. When so administered, the
inventive compounds may be combined with any of the well-known
pharmaceutical carriers and additives that are customarily used in
such pharmaceutical compositions. For a discussion of dosing forms,
carriers, additives, pharmacodynamics, etc., see Kirk-Othmer
Encyclopedia of Chemical Technology, Fourth Edition, Vol. 18, 1996,
pp. 480-590, incorporated herein by reference. The patient is
preferably a mammal, with human patients especially preferred.
[0144] Having generally described this invention, a further
understanding can be obtained by reference to certain specific
examples which are provided herein for purposes of illustration
only and are not intended to be limiting unless otherwise
specified. In each of the Examples, the numbering of compounds and
references cited are specific to each Example.
EXAMPLES
Example 1
Identification of Opiates Selective for the Opioid Receptors
[0145] Summary
[0146] A three-component library of compounds was prepared in
parallel using multiple simultaneous solution phase synthetic
methodology. The compounds incorporated a
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidi- ne group as one
of the monomers. The other two monomers, which included
N-substituted or unsubstituted Boc protected amino acids and a
range of substituted aryl carboxylic acids, were selected to add
chemical diversity. Screening of these compounds in competitive
binding experiments with the kappa opioid receptor selective ligand
[.sup.3H]U69,593 led to the identification of a .kappa. opioid
receptor selective ligand,
N-{(2'S)-[3-(4-hydroxyphenyl)propanamido]-3'-methylbuty-
l}-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (8, RTI-5989-29).
Additional SAR studies suggested that 8 possesses lipophilic and
hydrogen bonding sites that are important to its opioid receptor
potency and selectivity. These sites appear to exist predominantly
within the kappa receptor since the selectivity arises from a
530-fold loss of affinity of 8 for the mu receptor and an 18-fold
increase in affinity for the kappa receptor relative to the
mu-selective ligand, (+)-N-[trans-4-phenyl-2-but-
enyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (5a). This
degree of selectivity observed in the radioligand binding
experiments was not observed in the functional assay. According to
its ability to inhibit agonist stimulated binding of
[.sup.35S]GTP.gamma.S at all three opioid receptors, compound 8
behaves as a mu/kappa opioid receptor pure antagonist with
negligible affinity for the delta receptor.
[0147] Chemistry
[0148] Coupling of
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (4b) (FIG. 5)
with an appropriate tert-butoxycarbonyl-protected amino acid
(Boc-protected) followed by removal of the Boc-protecting group
with trifuoroacetic acid (TFA) in methylene chloride followed by
reduction using a tetrahydrofuran (THF) solution of borane-dimethyl
sulfide complex gave the intermediate amines (6a-k) in 15-78%
yields (FIG. 5). These intermediates 6 were subjected to column
chromatography or crystallization as necessary to obtain pure
compounds. The final products (7) were prepared in scintillation
vials via amide bond formation by coupling with a wide variety of
commercially available carboxylic acids. A representative list of
such carboxylic acids follows the Experimental section of this
Example. Benzotriazol-1-yl-oxy-tris-(dimethylamino)phosph- onium
hexafluorophosphate (BOP reagent) in THF was employed as the
coupling reagent which provided very clean products after aqueous
work-up. These compounds were used directly in screening without
additional purification. Pure compounds for further SAR analysis
were obtained by purification of library samples or by single
compound synthesis by conventional synthetic methodology and
characterized by MS, .sup.1H NMR, and elemental analyses.
[0149] Results and Discussion
[0150] The results from the screening of the 288-compound library
in competitive binding against the kappa opioid receptor selective
ligand [.sup.3H]U69,593 are illustrated graphically in FIG. 6.
Several compounds showed significant inhibition of radioligand
binding at 100 nM with 8 (plate 4, well 20, 71%) being the best
(FIG. 6). The data for % inhibition of [.sup.3H]U69,593 binding by
selected library compounds 8-23 at 100 nM are listed in Table 1.
14
[0151] A comparative analysis of the structures related to
compounds 9-23, which have less binding affinity relative to 8,
readily illustrates the importance for kappa receptor binding of
each structural subunit of group R.sub.3 (Table 1). Compound 9, a
diastereomer of 8, where the carbon to which the R.sub.1 isopropyl
group is connected has the opposite stereochemistry, shows less
binding affinity (11%) for the opioid kappa receptor. The
sensitivity to orientation (R or S) at this stereogenic center
suggests that the isopropyl group may be working in tandem with
another structural feature of the R.sub.3 unit to both increase
binding in 8 and decrease binding in 9. The difference in affinity
of compounds 8 (71%) and 10 (28%) suggests that the 4 hydroxyl
substituent in 8 is more effective for high kappa binding affinity.
Furthermore, the weaker inhibition displayed by compounds 11 (20%)
and 12 (25%) possessing meta and ortho hydroxyl substituents
respectively, pinpoints the para placement of the para-hydroxyl
group as the optimum position. The fact that compound 19, which
lacks the isopropyl group but has the para-hydroxyphenylpropionic
substituent, shows less affinity (11% vs. 71%) relative to 8, adds
additional support to the importance of the R.sub.1 isopropyl and
4-hydroxyphenyl groups to the kappa-selective binding. The low
affinity of compound 20 (20%) which has a methyl substituent in
position (R.sub.1) shows that a methyl group may be less effective
than the isopropyl group. This strengthens the notion that both the
isopropyl group (R.sub.1) and the 4-hydroxyphenyl group for R.sub.3
are working together to elicit high affinity binding at the kappa
opioid receptor in compound 8. The results for compound 13 (6%)
suggests that two methylene groups are more effective between the
phenyl ring and the amide carbonyl in diversity element R.sub.3,
presumably because the para-hydroxyl group cannot reach its site of
interaction in the truncated derivative. Furthermore, the lower
inhibition of binding for compound 14 (15%) which incorporates a
trans double bond in the connecting chain shows that the length of
the chain is not optimal to impart high binding affinity, implying
that flexibility is also preferred in this carbon chain to provide
proper ligand and receptor alignment. The lower affinity of the
4-fluoro derivative 15 (26%) and the 4-methoxy derivative 18 (16%)
supports the suggestion that a hydrogen bond exists between ligand
8 and the receptor with compound 8 donating the hydrogen. This is
further supported by the lower affinity of the 3,4-dihydroxyl
derivative 16 (31%) which can hydrogen bond internally and the
3-methoxy-4-hydroxy derivative 17 (42%) whose hydrogen bond could
be sterically encumbered by interference from an adjacent methoxy
group. Interestingly, all compounds having methyl and not hydrogen
as the second diversity element. R.sub.2, 21 (0%), 22 (1%), and 23
(7%) displayed very low binding affinity usually at baseline (DMSO
blank) levels. Apparently, position R.sub.2 is preferably
unsubstituted. These results suggest that the amide group may be
part of a separate hydrogen-bonding interaction to place the key
R.sub.1 isopropyl and R.sub.3 p-hydroxyphenyl rings in their
correct positions for strong interaction with the receptor.
Alternatively, the N-methyl substituent may be decrease ligand
affinity through repulsive steric interactions.
[0152] Taken together, the data suggests that the high binding
affinity displayed by 8 results from a combination of several
structural features present in its N-substituent. These include a
4-hydroxyl group in the pendant phenyl ring of group R.sub.3, the
length and flexibility of the carbon chain connecting this ring to
the amide carbonyl and the presence of a beta (position R.sub.1)
isopropyl group with an S configuration at the adjacent stereogenic
center. The data analysis suggests that the principle stabilizing
interactions could be related to binding of the hydroxyl and
isopropyl substituents with the other atoms of the N-substituent
substructure acting to hold these two binding elements in optimum
overlapping positions within the receptor site. Alternatively, the
isopropyl group could be acting to bias the conformation of
molecule to provide the best alignment of the
4-hydroxyphenylpropionic acid side-chain with its binding site.
[0153] In order to gain additional SAR information, a pure sample
of 8 along with compounds 24-27 which vary at the R.sub.1 position
alone was prepared for study. Table 2 lists the K.sub.i values for
these derivatives at the mu and kappa opioid receptors along with
the K.sub.i values for the mu-selective reference compound 5a,
naltrexone, and the kappa-selective antagonist nor-BNI. The delta
receptor assay was not performed for compounds 24-27 as all
previous derivatives of 8 had shown no affinity for this receptor
subtype. This study revealed that 8 not only actively binds the
kappa receptor (K.sub.i=6.9 nM) but also possessed a 57-fold
selectivity for the kappa vs. the mu receptor (K.sub.i=393 nM) and
>870-fold selectivity for the kappa vs. the delta receptor
(K.sub.i>5700 nM). Compound 8 thus displays a high degree of
opioid kappa receptor subtype selectivity..sup.1,2 Nor-BNI (1) has
a higher affinity for the kappa receptor than 8 and has a greater
kappa selectivity relative to the mu receptor. However, 8 is more
selective for the kappa receptor relative to the delta receptor. A
part of these differences could be due to the use of different
tissues and radioligands.
[0154] The data for the beta isobutyl substituent compound 24,
which results formally from insertion of a methylene between the
isopropyl group and its adjacent stereogenic center of compound 8,
displays a loss of affinity for the kappa receptor while
maintaining the same affinity for the mu receptor as compound 8.
The net effect is a loss of selectivity between the mu and kappa
receptor subtypes. Compound 26 (R.sub.1=cyclohexyl) shows a similar
loss of affinity for the kappa receptor with a gain in affinity for
the mu receptor resulting in a similar loss of selectivity.
Compound 25 with an R.sub.1 sec-butyl group shows a slight decrease
in both kappa and mu potency but retains selectivity, though its
magnitude is lower relative to 8. Compound 27 (R.sub.1=benzyl)
displayed a binding profile completely different from that seen in
8 with a tremendous increase in mu potency and concomitant loss of
kappa potency. This was not unexpected since compound 27, prepared
from the amino acid phenylalanine, possesses an N-substituent with
a phenyl ring separated from the piperidine ring by three methylene
groups which are known to favor mu binding..sup.1,2 It was for this
reason that phenylalanine was excluded from use in the library
synthesis. Overall, the behaviors of the various R.sub.1
derivatives of 8 indicate that the size of the lipophilic group in
position R.sub.1 is important to both the potency and receptor
subtype selectivity of the ligand. Furthermore, the data supports
the hypothesis that the isopropyl group in 8 is not simply biasing
the conformation of side-chain but is instead interacting with the
receptor directly in a ligand stabilizing interaction.
[0155] The agonist/antagonist activity of compound 8 was measured
by determining its ability to either stimulate or reverse opioid
agonist stimulated binding of the nonhydrolyzable GTP analog,
[.sup.35S]GTP.gamma.S, in all three opioid receptor assays (Table
3)..sup.3 Table 3 includes data obtained for naltrexone, the
standard nonselective opioid pure antagonist, nor-BNI, the
prototypical kappa-selective antagonist, and the potent,
mu-favoring opioid antagonist (5a). The kappa selectivity displayed
by compound 8 in the inhibition of radioligand binding assay was
not observed in the [.sup.35S]GTP.gamma.S functional assay. This is
not an a typical situation; radioligand binding results often
differ substantially from those seen in functional assays but this
typically involves agonists. The antagonists, naltrexone, normally
display K.sub.i (radioliand)/K.sub.i (GTP.gamma.S) binding ratios
near unity whereas ratios greater than unity have been observed for
antagonists of the N-substituted
trans-3,4-dimethyl-4-(3-hydroxypheny- l)piperidine series..sup.1
This phenomenon is illustrated graphically in FIG. 7. The
trans-cinnamyl derivatives 5a-c and compound 5d display K;
(radioligand)/K.sub.i (GTP.gamma.S) binding ratios greater than
unity in the mu and kappa receptor assays which is distinctly
different from the response demonstrated by naltrexone. In the
present case compound 8 is found to behave like naltrexone in the
kappa receptor assays with a ratio near unity which is far
different from the behavior seen for 5a-c and 5d, which show ratios
of 118, 228, 63, and 85, respectively. In the mu receptor assay on
the other hand, compound 8 with a ratio of 54 behaves like 5a-c an
d 5d which give ratios of 19, 66, 43, and 15. This differential
response of 8 in the [.sup.35S]GTP.gamma.S assay is sufficiently
large so as to erode the kappa receptor selectivity observed for 8
in the radioligand binding assays. Note that the K.sub.i
(radioligand)/K.sub.i (GTP) binding ratios for nor-BNI at the mu
and kappa receptor are 2.8 and 7.36, respectively.
CONCLUSIONS
[0156] The identification of compound 8, which displays a highly
selective kappa vs. mu receptor inhibition of radioligand binding
profile and a potent mu/kappa opioid antagonist profile,
demonstrates the effectiveness of the biased library approach to
lead compound generation. Since both the mu and kappa receptors may
be important in heroin abuse, compound 8 should be useful as a
treatment medication for heroin abuse.
[0157] Experimental Section
[0158] Melting points were determined on a Thomas-Hoover capillary
tube apparatus and are not corrected. Elemental analyses were
obtained by Atlantic Microlabs, Inc. and are within .+-.0.4% of the
calculated values. All optical rotations were determined at the
sodium D line using a Rudolph Research Autopol III polarimeter
(1-dm cell). .sup.1H NMR spectra were determined on a Bruker WM-250
spectrometer using tetramethylsilane as an internal standard.
Silica gel 60 (230-400 mesh) was used for all column
chromatography. Mass spectral data was obtained using a Finnegan
LCQ electrospray mass spectrometer in positive ion mode at
atmospheric pressure. All reactions were followed by thin-layer
chromatography using Whatman silica gel 60 TLC plates and were
visualized by UV, charring using 5% phosphomolybdic acid in ethanol
and/or exposure to iodine vapor. All solvents were reagent grade.
Tetrahydrofuran and diethyl ether were dried over sodium
benzophenone ketyl and distilled prior to use. Methylene chloride
was distilled from calcium hydride prior to use.
[0159] General Method for the Introduction of Diversity Elements
R.sub.1 and R.sub.2 into Structure 6.
(+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)pip- eridine (4b) (11.5
mmol), the appropriate Boc-protected amino acid (11.5 mmol) and BOP
reagent (11.5 mmol) were combined in THF (150 mL) at room
temperature, and to this was immediately added triethylamine (TEA)
or diisopropylethylamine (25.3 mmol). After stirring for 1 h, the
reaction mixture was poured into ethyl ether (500 mL) and water
(150 mL) in a separatory funnel. The mixture was shaken and the
aqueous layer removed. This procedure was repeated using 150 mL
saturated NaHCO.sub.3 and 150 mL brine. The organic layer was
diluted with hexane until cloudy and dried (Na.sub.2SO.sub.4),
concentrated under reduced pressure, then dissolved in 100 mL
chloroform (stored over K.sub.2CO.sub.3), and concentrated again.
This was placed on a high vacuum system to remove residual solvent
yielding a foamy yellow/white solid.
[0160] After remaining under vacuum on the pump overnight, this
unpurified material was dissolved in methylene chloride 45 mL and
cooled to -20.degree. C. (methanol/ice). To this was added neat
trifluoroacetic acid in 10 mL portions over 2 min to give a total
addition of 30 mL. The entire mixture was stirred for exactly 30
min and then the cooling bath was removed for exactly 30 min. At
this point, the reaction mixture was poured into a 1 L beaker
containing a large stir bar and a rapidly agitated mixture of
saturated bicarbonate solution (400 mL) and chloroform (150 mL).
After completed addition, the pH of the mixture was verified to be
10 and adjusted with solid sodium bicarbonate if necessary. This
mixture was poured into a separatory funnel. Any precipitated
organic compounds were rinsed into the separatory funnel using a
small amount of methanol. The beaker was then rinsed with a small
amount of water which was added to the separatory funnel. The
layers were agitated, separated, and the aqueous layer extracted
five additional times using 3:1 methylene chloride:THF. It was
observed that compounds with small groups R.sub.1 required
additional extractions and/or sodium chloride saturation of the
aqueous layer. The combined organic layers were dried over sodium
sulfate and the solvent removed at reduced pressure. The material
was then placed on a high vacuum pump to yield a yellow foamy
solid.
[0161] Unpurified material from the deprotection step was dissolved
in THF (150 mL) and cooled to -20.degree. C. (methanol/ice). To
this stirred mixture was added a solution of borane dimethylsulfide
complex, 2M in THF (110 mmol) dropwise. The solution was then
heated to reflux and held for 3 h after which time, the solution
was cooled to -20.degree. C. and to this was carefully added
methanol (72 mL) dropwise. This mixture was stirred for 1 h at room
temperature, 16.4 mL of 1M HCl in ethyl ether was added, the
solution was allowed to stir for 30 min, and the solvents removed
on a rotary evaporator. The resulting residue was partitioned
between 3:1 methylene chloride:tetrahydofuran and water, the pH was
adjusted to 10 with saturated sodium bicarbonate, and the aqueous
layer was saturated with sodium chloride and extracted several
times with 3:1 methylene chloride:tetrahydofuran. The combined
organic layers were dried over sodium sulfate and the solvent
removed. This material was purified by flash chromatography on a
silica gel column which was prepared by slurry packing with
chloroform. The impure compounds were loaded on the column as a
chloroform solution. Elution proceeded with neat chloroform
followed by 3% methanol up to 10% methanol in chloroform as needed
to elute the desired compounds. Product fractions were combined and
the solvent was removed on a rotary evaporator. This material was
dissolved in a minimum of hot ethyl acetate and allowed to
crystallize. Crystalline material was isolated by filtration
followed by washing with a small amount of ice-cold ethyl acetate
and used directly in the next step after drying overnight in a
vacuum oven.
[0162] Introduction of Diversity Element R.sub.3 into Structure 7.
The appropriate pure diamine 6, produced in the previous step (0.05
mmol.times.the number of derivatives being prepared), was dissolved
in THF (2 mL.times.the number of derivatives being prepared) and to
this was added TEA (0.1 mmol.times.the number of derivatives being
prepared). Then, into prelabeled, 20-mL scintillation vials
containing a stir bar was added one of the chosen carboxylic acids
(0.05 mmol). To this was added the appropriate fraction of the
diamine/TEA/THF mixture followed by 50 .mu.L of a 1M solution of
BOP reagent in dimethylformamide (DMF). The vial was then capped
with a telfon-lined lid and stirred for 1 h at room temperature.
After this time, 4 mL of ethyl ether and 2 mL of water were added
to the vial. After shaking and allowing the layers to settle, the
aqueous layer was withdrawn with a pipette. Next, 2 mL of saturated
sodium bicarbonate solution was added and the procedure repeated.
This was followed by a similar wash with saturated sodium chloride
solution. Sodium sulfate was added to the vial, and after drying,
the mixture was pipetted into a preweighed, prelabeled 20-mL
scintillation vial via a 6-in Pasteur pipette containing a small
cotton plug. Following this, 2 mL of chloroform was added to the
drying agent and the vial shaken after which the chloroform rinse
was filtered as above. The collecting vials were placed under a
nitrogen outlet and allowed to evaporate. Once the solvent was
removed, the vials were placed in a high vacuum desiccator and
allowed to remain overnight. The vials were reweighed, and the
crude yield determined by difference. Since pilot studies showed
that the BOP-coupling reaction produced very clean samples, the
products were used without further purification, and the purity was
taken to be 100%.
[0163] Prior to screening, all compounds were diluted to a
concentration of 10 mM in dimethylsulfoxide (DMSO). Dilution was
accomplished by determining the mean mmol/vial for each batch of 20
reactions using an Excel 3.0 spreadsheet. Weights deviating from
the mean by >.+-.10% were grouped into a second and third set
above and below the mean. These were also averaged within the same
parameters. Any compounds not falling within the above sets were
diluted individually according to their weight. This procedure
permitted sample dilution to be accomplished using a minimum number
of different volume deliveries of DMSO. Once diluted to 10 mM, 1-mL
samples from each vial were withdrawn and placed in rows A and E
(one compound/well) of a 1 mL.times.96-well polypropylene
microtiter plate. Serial dilution was then performed using Matrix
multichannel pipettors which provided a 1-mM solution in rows B and
F and a 0.1-mM solution in rows C and G. Once all of the compounds
were transferred to plates and diluted to the proper concentration,
the plates were placed in the refrigerator prior to assay.
[0164]
N-(2'-Aminoethyl)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine
(6a). Prepared from N-(tert-butoxy)-glycine and
(+)-(3R,4R)-dimethyl-4-(3- -hydroxyphenyl)piperidine according to
the general procedure in 15% yield: .sup.1H NMR (MeOH-d4) .delta.
7.13-7.062 (t, 1H, J=8.1 Hz), 6.77-6.74 (m, 2H), 6.59-6.55 (m, 1H),
3.31-3.29 (m, 1H), 2.83-2.70 (m, 3H), 2.5 (d, 2H, J=3.1 Hz),
2.46-2.27 (m, 3H), 2.00 (s, 1H), 1.6 (d, 2H, J=3.1 Hz), 1.68 (d,
1H, J=13.7 Hz), 1.29 (s, 3H), 0.89 (d, 3H, J=7.0 Hz); .sup.13C NMR
(MeOH-d4) .delta. 158.5, 152.9, 130.0, 117.9, 113.9, 113.3, 61.6,
57.1, 51.5, 40.2, 39.5, 39.1, 32.0, 28.2, 16.7. MS (electrospray)
M+1=249. Calculated=249.
[0165]
N-(2'-Methylaminoethyl)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperid-
ine (6b). Prepared from N-(tert-butoxy)-sarcosine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 32% yield: .sup.1H NMR (MeOH-d4) .delta. 7.9
(t, 1H, J=7.7 Hz), 6.77 (d, 1H), 6.74 (s, 11H), 6.58 (d, 1H),
2.95-2.90 (m, 1H), 2.87-2.82 (m, 2H), 2.66 (dd, 1H), 2.61-2.55 (m,
2H), 2.54 (s, 3H), 2.52 (td, 1H), 2.37 (td, 1H), 2.03-2.00 (m, 1H),
1.69 (brd, 1H), 1.30 (s, 3H), 0.89 (d, 3H, J=7.0 Hz); .sup.13C NMR
(MeOH-d4) .delta. 130.0, 118.0, 113.8, 113.3, 57.4, 56.7, 51.1,
48.2, 40.2, 39.4, 35.0, 31.9, 28.1, 16.6. MS (electrospray)
M+1=263. Calculated=263.
[0166]
N-[(2'S)-Aminopropyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidin-
e (6c). Prepared from N-(tert-butoxy)-L-alanine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 56% yield: .sup.1H NMR (MeOH-d4) .delta.
7.11-7.08 (t, 1H, J=7.7), 6.78-6.76 (d, 1H), 6.74 (s, 1H),
6.59-6.57 (d, 1H), 2.953-2.902 (m, 1H), 2.874-2.826 (m, 2H),
2.676-2.647 (dd, 1H), 2.618-2.559 (m, 2H), 2.548 (s, 3H),
2.541-2.400 (td, 1H), 2.342-2.284 (td, 1H), 2.030-2.002 (m, 1H),
1.613-1.587 (brd, 1H), 1.303 (s, 3H), 0.800-0.786 (d, 3H, J=7.0);
.sup.13C NMR (MeOH-d4) d 130.0, 118.0, 113.8, 113.3, 57.4, 56.7,
51.1, 48.2, 40.2, 39.4, 35.0, 31.9, 28.1, 16.6. MS (electrospray)
M+1=263. Calculated=263.
[0167]
N-[(2'S)-(Methylamino)propyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)p-
iperidine (6d). Prepared from
N-(tert-butoxy)-N-methyl-L-alanine.sup.17 and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 33% yield: .sup.1H NMR (MeOH-d4) .delta. 7.18
(t, 1H, J=7.9 Hz), 6.76 (d, 1H), 6.73 (s, 1H), 6.57 (d, 1H),
2.72-2.64 (m, 2H), 2.61-2.47 (m, 3H), 2.36 (s, 3H), 2.34-2.20 (m,
3H), 2.00-1.99 (m, 1H), 1.56 (dd, 1H), 1.29 (s, 3H), 1.03 (d, 3H,
J=6.2 Hz), 0.65 (d, 3H, J=6.9 Hz); .sup.13C NMR (MeOH-d4) .delta.
158.4, 153.3, 130.1, 117.9, 113.7, 113.3, 65.1, 56.0, 52.9, 52.9,
40.0, 39.5, 33.7, 31.9, 28.0, 17.3, 16.7. MS (electrospray)
M+1=277. Calculated=277.
[0168]
N-[(2'S)-Amino-3'-methylbutyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)-
piperidine (6e). Prepared from N-(tert-butoxy)-L-valine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 78% yield: .sup.1H NMR (MeOH-d4) .delta.
7.126-7.062 (t, 1H), 6.769-6.735 (m, 2H), 6.603-6.558 (m, 1H),
2.657-2.179 (m, 8H), 2.000 (brs, 1H), 1.583-1.502 (m, 2H), 1.294
(s, 3H), 0.978-0.912 (q, 6H), 0.789-0.761 (d, 3H); .sup.13C NMR
(MeOH-d4).delta. 158.5, 153.3, 130.1, 117.8, 113.8, 113.3, 63.4,
55.8, 54.1, 53.3, 40.0, 39.5, 33.1, 31.9, 28.1, 19.6, 19.2, 16.8.
MS (electrospray) M+1=291. Calculated=291.
[0169]
N-[(2'R)-Amino-3'-methylbutyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)-
piperidine (6f). Prepared from N-(tert-butoxy)-D-valine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 62% yield: .sup.1H NMR (MeOH-d4), .delta.
7.11-7.08 (t, 1H), 6.78-6.76 (d, 1H), 6.74 (s, 1H), 6.59-6.57 (dd,
1H), 3.139-3.097 (m, 1H), 2.953 (brs, 1H), 2.894-2.865 (dd, 1H),
2.546-2.500 (m, 2H), 2.401-2.292 (m, 3H), 2.046-2.034 (brm, 1H),
1.894-1.827 (sext, 1H), 1.62-1.30 (m, 1H), 1.311 (s, 3H),
1.042-1.006 (dd, 6H), 0.834-0.820 (d, 3H); .sup.13C NMR (MeOH-d4)
.delta. 152.9, 130.1, 118.0, 113.8, 113.3, 59.8, 58.8, 55.2, 50.0,
40.4, 39.4, 31.6, 31.1, 28.0, 18.8, 18.5, 16.5. MS (electrospray)
M+1=291. Calculated=291.
[0170]
N-[(2'S)-Amino-4'-methylpentyl]-(3R,4R)-dimethyl-4-(3hydroxyphenyl)-
piperidine (6g). Prepared from N-(tert-butoxy)-L-leucine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 56% yield: .sup.1H NMR (MeOH-d4) .delta. 7.09
(t, 1H, J=7.9 Hz), 6.76 (d, 1H, J=7.9 Hz), 6.73 (s, 1H), 6.57 (dd,
1H, J=2.2, 7.9 Hz), 3.03-2.97 (m, 1H), 2.73 (d, 1H, J=11.2 Hz),
2.64 (d, 1H, J=11.1 Hz), 2.56 (td, 1H, J=2.5, 12.0 Hz), 2.48 (dd,
1H, J=2.7, 11.4 Hz), 2.33 (td, 1H, J=4.5, 12.7 Hz), 2.25 (dd, 1H.
J=3.6, 12.4 Hz), 2.19-2.15 (m, 1H), 2.01-2.00 (m, 1H), 1.75 (sept,
1H, J=6.6 Hz), 1.56 (d, 1H. J=13.0 Hz), 1.29 (s, 3H), 1.27-1.15 (m,
2H). 0.94-0.91 (m, 6H), 0.07 (d, 3H, J=7.0 Hz); .sup.13C NMR
(MeOH-d4).delta. 158.3, 153.3, 130.1, 117.9, 113.7, 113.2, 65.7,
56.0, 53.1, 46.5, 45.2, 40.0, 39.5, 31.9, 28.0, 25.8, 23.7, 22.6,
16.7. MS (electrospray) M+1=305. Calculated=305.
[0171]
N-[(2'S)-Amino-3'-methylpentyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl-
)piperidine (6h). Prepared from N-(tert-butoxy)-L-isoleucine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 47% yield: .sup.1H NMR (MeOH-d4) .delta. 7.19
(t, 1H, J=7.9 Hz), 6.76 (d, 1H, J=8.1 Hz), 6.73-6.73 (m, 1H),
6.58-6.56 (dd, 1H, J=2.1, 7.9 Hz), 2.86-2.82 (m, 1H), 2.75-2.73 (m,
1H), 2.65-2.57 (m, 2H), 2.502-2.474 (dd, 1H, J=2.8, 11.4 Hz),
2.40-2.23 (m, 3H), 2.02-2.00 (m, 1H), 1.59-1.50 (m, 2H), 1.46-1.41
(m, 1H), 1.30 (s, 3H), 1.24-1.17 (m, 1H), 0.98-0.87(m, 6H), 0.78
(d, 3H, J=7.0 Hz); .sup.13C NMR (MeOH-d4) .delta. 158.3, 153.2,
130.1, 117.9, 113.7, 113.3, 61.9, 55.9, 53.1, 52.9, 49.0, 40.0,
39.5, 39.3, 31.9, 28.0, 26.6, 16.7, 15.1, 11.8. MS (electrospray)
M+1=305. Calculated=305.
[0172] N
[(2'S)-Amino-2'-cyclohexylethyl]-(3R,4R)-dimethyl-4-(3-hydroxyphe-
nyl)piperidine (6i). Prepared from
N-(tert-butoxy)-L-cyclohexylglycine and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 63% yield: .sup.1H NMR (MeOH-d4) .delta. 7.18
(t, 1H. J=7.9), 6.76 (d, 1H, J=7.8 Hz), 6.75 (s, 1H), 6.57 (d, 1H,
J=7.8 Hz), 2.74-2.70 (m, 2H), 2.63-2.55 (m, 2H), 2.47-2.45(d, 1H,
J=10.0 Hz), 2.48 (dd, 1H, J=2.9, 12.4 Hz), 2.36 (td, 1H, J=4.3,
12.6 Hz), 2.23 (t, 1H, J=11.6 Hz), 2.00 (m, 1H), 1.76-1.74(m, 3H),
1.67(d, 2H, J=11.9 Hz), 1.57(d, 1H. J=13.0 Hz), 1.39-1.16 (m, 7H),
1.09 (quint, 2H, J=12.4 Hz), 0.77 (d, 3H, J=6.8 Hz); .sup.13C NMR
(MeOH-d4) .delta. 158.3, 153.3, 130.1, 117.9, 113.7, 113.3, 162.6,
55.8, 53.4, 53.1, 42.9, 40.0, 39.5, 31.9, 30.9, 30.5, 30.2, 28.0,
27.6, 27.4, 16.7. MS (electrospray) M+1=331. Calculated=331.
[0173]
N-[(2'S)-Methylamino-2'-phenylethyl]-(3R,4R)-dimethyl-4-(3-hydroxyp-
henyl)-piperidine (6j). Prepared from
N-(tert-butoxy)-N-methyl-phenylglyci- ne.sup.13 and
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to the
general procedure in 44% yield: .sup.1H NMR (MeOH-d4) .delta.
7.34-7.22 (m, 5H), 7.13 (t, 1H, J=8.2 Hz), 6.80-6.77 (m, 2H),
6.61-6.69 (m, 1H), 3.63 (dd, 1H, J=3.7, 12.6 Hz), 2.73 (brd, 2H,
J=7.6 Hz), 2.64-2.52 (m, 3H), 2.38 (dd, 2H, J=3.6, 12.6 Hz), 2.25
(s, 3H), 2.04 (brd, 1H, J=6.3 Hz), 1.59 (d, 1H, J=12.9), 1.312 (s,
3H), 0.818-0.790 (d, 3H, J=6.9); .sup.13C NMR (MeOH-d4) .delta.
147.3, 142.5, 131.5, 119.5, 119.0, 118.0, 107.4, 103.2, 102.7,
68.7, 68.233, 67.7, 55.2, 52.9, 45.1, 42.5, 42.5, 29.2, 28.9, 24.2,
21.3, 17.7. MS (electrospray) M+1=339. Calculated=339.
[0174]
N-[(2'S)-Amino-3'-phenylpropyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl-
)piperidine (6k). Prepared froth N-(tert-butoxy)-L-phenylalanine
and (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine according to
the general procedure in 44% yield: .sup.1H NMR (MeOH-d4) .delta.
7.29 (t, 1H, J=7.4 Hz), 7.24-7.06 (m, 5H), 6.75-6.71 (m, 2H),
6.57-6.55(m, 1H), 3.86-3.84 (m, 5H), 3.22-3.94 (m, 1H), 2.83-2.69
(m, 2H), 2.63-2.39 (m, 5H), 2.35-2.24 (m, 2H), 1.97 (t, 1H, J=6.4
Hz), 1.54 (t, 1H, J=12.7 Hz), 1.27 (s, 3H), 0.74 (dd, 3H, J=6.95,
21.04 Hz); .sup.13C NMR (MeOH-d4) .delta. 158.3, 153.3, 139.9,
130.6, 130.3, 130.0, 129.6, 129.2, 127.5, 127.1, 118.0, 117.9,
113.8, 113.7, 113.2, 65.0, 64.7, 61.0, 57.3, 56.1, 52.9, 52.1,
50.5, 49.5, 49.3, 49.2, 49.0, 48.8, 48.7, 48.5, 41.9, 41.5, 40.3,
40.0, 39.4, 31.9, 28.0, 1, 6.7. MS (electrospray) M+1=339.
Calculated=339.
[0175]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-3'-methylbutyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine (8). Prepared from compound
6e and 3-(4-hydroxyphenyl)propionic acid according to the general
procedure above in 74% yield and purified by silica gel
chromatography. The hydrochloride salt was prepared using 1M HCl in
ethyl ether/methanol and precipitated from ethyl acetate: mp
136-140.degree. C.; .sup.1H NMR (free base). CD3OD .delta. 7.16 (t,
J=7.94, Hz, 1H), 7.04 (d, J=8.45 Hz, 2H), 6.76 (d, J=7.78 Hz, 1H),
6.72-6.69 (m, 2H), 6.65 (dd, J=8.04, 1.76 Hz, 1H), 4.02-3.98 (m,
1H), 3.57 (d, J=12.5 Hz, 1H), 3.40 (ddd, J=2.90, 11.6, 13.4 Hz,
2H), 3.03 (dd, J=10.5, 13.4 Hz, 1 Hz), 2.84 (t, 7.07 Hz, 2H), 2.60
(t, 7.58 Hz, 2H), 2.43 (dt, J=13.21, 4.9 Hz, 1H), 2.36-2.35 (m,
1H), 1.85 (d, J=14.5 Hz, 1H), 1.87-1.76 (m, 1H), 1.42 (s, 3H), 0.92
(t, J=6.98 Hz, 6H), 0.815 (d, J=7.53, 3H); .sup.13C NMR, CD3OD
.delta. 176.3, 159., 157.7, 153.8, 133.8, 131.3, 131.0, 118.9,
117.1, 114.6, 114.2, 62.0, 57.2, 53.2, 52.8, 40.9, 40.3, 33.1,
33.1, 32.5, 31.7, 28.8, 20.6, 18.9, 17.3. MS (electrospray)
M+1=439. Anal. (C.sub.27H.sub.39ClN.sub.2O.sub.3.-
smallcircle.1.5H.sub.2O): C, H, N.
[0176] Compounds cited in Table 1 were removed from the library and
purified by silica gel chromatography. The purity of the library
sample was determined according to the formula [(mg isolated
sample/mg crude mass sample) X 100].
[0177]
N-{(2'R)-[3-(4-Hydroxyphenyl)propanamido]-3'-methylbutyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine (9). Prepared from compound
6f and 3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (85%); .sup.1H NMR (MeOH-d4) .delta. 7.83 (s,
3H), 7.13-7.00 (m, 3H), 6.77-6.67 (m, 4H), 6.61-6.57 (m, 1H),
3.96-3.89 (m, 1H), 2.86-2.78 (m, 3H), 2.62-2.58 (m, 1H), 2.48 (d,
3H, J=8.0 Hz), 2.36-2.14 (m, 4H), 1.94 (brd, 1H, J=6.3 Hz), 1.76
(sept, 1H, J=5.5 Hz), 1.51 (brd, 1H, J=11.0 Hz), 1.26 (s, 3H),
0.84-0.74 (m, 9H). MS (electrospray) M+1=439. Calculated=439.
[0178]
N-{(2'S)-[(3-Phenylpropanamido)-3'-methyl]butyl}-(3R,4R)-dimethyl-4-
-(3hydroxyphenyl)piperidine (10). Prepared from compound 6e and
3-phenylpropionic acid according to the general procedure. Purity
(87%); .sup.1H NMR (MeOH-d4) .delta. 7.25-7.22 (m, 2H), 7.17-7.13
(m, 4H), 6.82 (s, 1H), 6.76 (d, 1H, J=7.8 Hz), 6.70-6.68 (m, 1H),
5.74 (s, 1H), 4.02-3.97 (m, 1H), 2.99-2.87 (m, 2H), 2.74-2.69 (m,
1H), 2.64 (brd, 1H, J=1.3 Hz), 2.57-2.40 (m, 6H), 2.27-2.21 (m,
2H), 2.17 (s, 3H), 1.92-1.87 (m, 2H), 1.56 (d, 1H, J=13.0 Hz), 1.28
(s, 3H), 0.81 (t, 6H, J=6.8 Hz), 0.69 (d, 3H, J=6.8 Hz). MS
(electrospray) M+1=423. Calculated=423.
[0179]
N-{(2'S)-[3-(3-Hydroxyphenyl)propanamido]-3'-methylbutyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine(11). Prepared from compound
6e and 3-(3-hydroxyphenyl)propionic acid according to the general
procedure. Purity (84%); .sup.1H NMR (MeOH-d4) .delta. 7.24-7.23
(m, 1H), 7.13-7.03 (m, 3H), 6.76-6.57 (m, 5H), 3.32-3.29 (m, 4H),
2.85-2.17 (m, 8H), 1.97 (brs, 1H), 1.75-1.73 (m, 1H), 1.57 (brd,
1H, J=12.3 Hz), 1.28 (s, 3H) 0.863 (t, 6H, J=6.5 Hz), 0.72 (d, 3H,
J=7.0). MS (electrospray) M+1=439. Calculated=439.
[0180]
N-{(2'S)-[3-(2-Hydroxyphenyl)propanamido]-3'-methylbutyl}(3R,4R)-di-
methyl-4-(3-hydroxyphenyl)piperidine (12). Prepared from compound
6e and 3-(2-hydroxyphenyl)propionic acid according to the general
procedure. Purity (85%); .sup.1H NMR (CDCl3-d) .delta. 7.04-6.82
(m, 3H), 6.66-6.65 (m, 2H), 6.48-6.39 (m, 3H), 3.97-3.94 (m, 1H),
2.87-2.84 (m, 2H), 2.76 (d, 1H, J=11 Hz), 2.56-2.22 (m, 8H),
1.94-1.93 (brm, 1H), 1.80 (sextet, 1H, J=6.9 Hz), 1.52 (d, 1H,
J=13.3 Hz), 1.26 (s, 3H), 0.84 (dd, 6H, J=13.1 Hz), 0.75 (d, 3H,
J=6.9 Hz). MS (electrospray) M+1=439. Calculated=439.
[0181]
N-{(2'S)-[(4-Hydroxyphenyl)acetamido]-3'-methylbutyl}-(3R,4R)-dimet-
hyl-4-(3-hydroxyphenyl)piperidine (13). Prepared from compound 6e
and 4-hydroxyphenylacetic acid according to the general procedure.
Purity (88%); .sup.1H NMR (MeOH-d4) .delta. 7.14-7.06 (m, 3H),
6.67-6.69 (m, 4H), 6.58 (d, 1H, J=8.1 Hz), 3.95-3.92 (m, 1H),
3.32-3.30 (m, 2H), 2.70-2.60 (m, 1H), 2.56-2.47 (m, 1H), 2.41-2.15
(m, 6H), 1.90 (brs, 1H), 1.81-1.74 (m, 1H), 1.51 (d, 2H, J=12.5
Hz), 1.25 (s, 3H), 0.86 (t, 6H, J=6.7 Hz), 0.67 (d, 3H, J=6.9 Hz).
MS (electrospray) M+1=425. Calculated=425.
[0182]
N-{(2'S)-[trans-3-(4-Hydroxyphenyl)acrylamido]-3'-methylbutyl}-(3R,-
4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (14). Prepared from
compound 6e and trans-3-(4-hydroxyphenyl)cinnamic acid according to
the general procedure. Purity (85%); .sup.1H NMR (MeOH-d4) .delta.
7.25-7.37 (m, 3H), 7.11-7.04 (m, 1H), 6.79-6.72 (m, 4H), 6.56 (d,
1H, J=9.5 Hz), 6.47 (d, 1H, J=12.7 Hz), 4.10 (m, 1H), 2.80 (m, 1H),
2.64 (m, 1H), 2.54-2.26 (m, 5H), 1.95 (m, 2H), 1.56 (d, 1H,
J=13.1), 1.28 (s, 3H), 0.94 (t, 6H, J=6.8 Hz), 0.70 (d, 3H, J=6.9)
MS (electrospray) M+1=437. Calculated=437.
[0183]
N-{(2'S)-[3-(4-Fluorophenyl)propanamido]-3'-methylbutyl}-(3R,4R)-di-
methyl-4-(3-hydroxyphenyl)piperidine (15). Prepared from compound
6e and 3-(4-fluorophenyl)propionic acid according to the general
procedure. Purity (89%); .sup.1H NMR (MeOH-d4) .delta. 7.23-7.17
(m. 2H), 7.69 (t, 1H, J=8.0 Hz), 6.99-6.92 (m, 2H), 6.76-6.73 (m,
2H), 6.60-6.54 (m, 1H), 3.96-3.90 (m, 1H), 2.88 (t, 2H, J=7.7),
2.76 (d, 1H, J=10.3 Hz), 2.65-2.32 (m, 8H), 1.97 (brs, 1H),
1.73-1.69 (m, 1H), 1.54 (d, 1H, J=12.1 Hz), 1.27 (s, 3H), 0.80 (t,
6H, J=5.8 Hz), 0.71 (d, 3H, J=6.9 Hz). MS (electrospray) M+1=441.
Calculated=441.
[0184]
N-{(2'S)-[3-(3,4-Dihydroxyphenyl)propanamido]-3'-methylbutyl}-(3R,4-
R)-dimethyl-4-(3-hydroxyphenyl)piperidine (16). Prepared from
compound 6e and 3-(3,4-dihydroxyphenyl)propionic acid according to
the general procedure. Purity (78%); .sup.1H NMR (MeOH-d4) .delta.
7.09 (t, 1H, J=7.9 Hz), 6.76-6.73 (m, 2H), 6.67-6.49 (m, 4H), 3.92
(brs, 1H), 2.74 (t, 3H, J=7.6 Hz), 2.63-2.59 (m, 1H), 2.51-2.15 (m,
7H), 1.94 (brs, 1H), 1.75-1.70 (m, 1H), 1.55 (d, 1H, J=12.1 Hz),
1.27 (s, 3H), 0.82 (t, 6H, J=6.4 Hz), 0.71 (d, 3H, J=6.9 Hz). MS
(electrospray) M+1=455. Calculated=455.
[0185] N-{(2'S)-[3-(3-,
Methoxy-4-hydroxypheny)propanamido]-3'-methylbutyl-
}-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (17). Prepared
from compound 6e and 3-(3-methoxy-4-hydroxyphenyl)propionic acid
according to the general procedure. Purity (87%); .sup.1H NMR
(MeOH-d4) d 7.15 (t, 1H, J=7.7 Hz), 6.81-6.76 (m, 3H), 6.67 (d, 3H,
J=3.3 Hz), 3.98 (brm, 1H), 3.80 (s, 3H), 2.86-2.69 (m, 3H),
2.53-2.22 (m, 8H), 1.89 (brs, 2H), 1.55 (d, 1H, J=12.0 Hz), 1.27
(s, 3H), 0.82 (dd, 6H, J=6.6, 3.2 Hz), 0.67 (d, 3H, J=6.9 Hz). MS
(electrospray) M+1=469. Calculated=469.
[0186]
N-{(2'S)-[3-(3-Methoxyphenyl)propanamido]-3'-methylbutyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine (18). Prepared from compound
6e and 3-(3-methoxyphenyl)propionic acid according to the general
procedure. Purity (88%); .sup.1H NMR (MeOH-d4) .delta. 7.30-7.12
(m, 4H), 6.9-6.8 (m, 4H), 3.95 (brs, 1H), 3.76 (s, 3H), 2.96 (d,
2H, J=6.8 Hz), 2.86-2.72 (m, 5H), 2.65-2.61 (m, 1H), 2.56-2.14 (m,
7H), 1.91(brs, 1H), 1.73-1.71 (m, 1H), 1.52 (d, 1H, J=13.0 Hz),
1.26 (s, 3H), 0.81 (t, 6H, J=6.7 Hz), 0.67 (d, 3H, J=6.9 Hz). MS
(electrospray) M+1=453. Calculated=453.
[0187]
N-{2'-[3-(4-Hydroxyphenyl)propanamido]ethyl}-(3R,4R)-dimethyl-4-(3--
hydroxyphenyl)piperidine (19). Prepared from compound 6a and
3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (82%); .sup.1H NMR (MeOH-d4) .delta. 7.13-6.99
(m, 3H), 6.79-6.67 (m, 4H), 6.59 (dd, 1H, J=7.3, 1.8 Hz), 3.32-3.25
(m, 3H), 2.83-2.77 (m, 3H), 2.58 (s, 2H), 2.46-2.15 (m, 6H), 1.98
(brs, 1H), 1.58(brd, 1H, J=12.8 Hz), 1.29 (s, 3H), 0.76 (d, 3H,
J=7.0 Hz). MS (electrospray) M+1=397. Calculated=397.
[0188]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]propyl}-(3R,4R)-dimethyl-4-
-(3-hydroxyphenyl)piperidine (20). Prepared from compound 6c and
3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (88%); .sup.1H NMR (MeOH-d4) .delta. 7.77 (s,
1H), 7.08 (t, 1H. J=8.1 Hz), 6.98 (d, 2H, J=8.4 Hz), 6.74-6.67 (m,
4H), 6.7 (d, 1H, J=7.5 Hz), 4.03 (dd, 1H, J=6.4 Hz), 2.81-2.70 (m,
3H), 2.49 (s, 2H), 2.44-2.26 (m, 4H), 2.16 (td, 2H, J=3.7, 10.9
Hz), 1.92-1.89 (m, 1H), 1.50 (d, 1H, J=12.3 Hz), 1.23 (s, 3H), 1.04
(d, 3H, J=6.4 Hz), 0.71 (d, 3H, J=6.9 Hz). MS (electrospray)
M+1=411. Calculated=411.
[0189]
N-{2'-[3-(4-Hydroxyphenyl)-N-methylpropanamido]ethyl}-(3R,4R)-dimet-
hyl-4-(3-hydroxyphenyl)piperidine (21). Prepared from compound 6b
and 3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (78%); .sup.1H NMR (MeOH-d4) .delta. 7:84 (s,
1H), 7.18-7.00 (m, 3H), 6.77-6.69 (m, 4H), 6.60 (d, 1H, J=8.1 Hz),
3.47-3.27 (m, 2H), 2.92-2.90 (m, 3H), 2.82-2.77 (m, 3H), 2.67-2.54
(m, 3H), 2.47-2.18 (m, 3H), 1.96 (brs, 1H), 1.58-1.49 (m, 3H), 1.27
(d, 3H, J=2.91 Hz), 0.73 (t, 3H, J=6.5 Hz). MS (electrospray)
M+1=411. Calculated=411.
[0190]
N-{(2'S)-[3-(4-Hydroxyphenyl)-N-methylpropanamido]propyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine (22). Prepared from compound
6d and 3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (89%); .sup.1H NMR (MeOH-d4) .delta. 7.09 (t, 1H,
J=7.9 Hz), 6.99 (d, 2H, J=8-2 Hz), 6.78-6.66 (m, 4H), 6.58-6.56 (m,
1H), 4.92-4.86 (m, 1H), 2.74 (s, 3H), 2.27-2.17 (m, 2H), 1.96-1.95
(brm, 1H), 1.55 (brd, 1H, J=14.3 Hz), 1.27 (s, 3H), 1.02 (d, 3H,
J=6.7 Hz), 0.66 (d, 3H, J=6.9 Hz). MS (electrospray) M+1=425.
Calculated=425.
[0191]
N-{(2'S)-[3-(4-Hydroxyphenyl)-N-methylpropanamido]-2'-phenylethyl}--
(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (23). Prepared
according to the general procedure using compound 6j and
3-(4-hydroxyphenyl)propionic acid according to the general
procedure. Purity (86%); .sup.1H NMR (MeOH-d4) .delta. 7.69-7.66
(m, 1H), 7.45-7.42 (m, 1H), 7.32-6.97 (m, 7H), 6.76 (d, 1H, J=9.4
Hz), 6.73 (s, 1H), 6.66-6.64 (m, 1H), 6.59-6.57 (m, 1H), 6.05 (q,
1H, J=5.5 Hz), 3.00-2.71 (m, 9H), 2.65-2.63 (m, 2H), 2.29 (td, 1H,
J=4.3, 8.4 Hz), 2.01-2.00 (brm, 1H), 1.59 (brd, 1H, J=12.0 Hz),
1.32-1.28 (m, 6H), 0.71 (d, 3H, J=6.9 Hz). MS (electrospray)
M+1=487. Calculated=487.
[0192]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamidol]-4'-methylpentyl}-(3R,4R)-
-dimethyl-4-(3-hydroxyphenyl)piperidine (24). Prepared according to
the general coupling procedure (though on a 3-mmol scale) using
compound 6g and 3-(4-hydroxyphenyl)propionic acid in 85% yield.
Crude products were then purified by silica gel chromatography
using 10-25% methanol in chloroform: .sup.1H NMR (MeOH-d4) .delta.
7.85 (s, 1H), 7.26-7.06 (m, 6H), 6.97 (d, 2H, J=8.5 Hz), 6.76-6.66
(m, 3H), 6.58 (d, 1H, J=7.2 Hz), 4.27 (t, 1H, J=7.3 Hz), 2.84-2.23
(m, 10H), 1.93 (brd, 1H, J=7.2 Hz), 1.52 (d, 1H, J=12.0 Hz), 1.25
(s, 3H), 1.05 (t, 1H, J=7.2 Hz), 0.74 (d, 3H, J=6.9 Hz); .sup.13C
NMR (MeOH-d4) .delta. 164.0, 147.5, 143.0, 142.6, 129.0, 122.3,
119.9, 119.6, 119.3, 118.5, 116.5, 107.3, 105.5, 103.0, 102.2,
51.6, 46.1, 40.8, 29.4, 29.3, 29.3, 28.7, 21.4, 21.0, 17.3. Anal.
(C.sub.28H.sub.40N.sub.2O.sub.3): C, H, N.
[0193]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-3'-methylpentyl}-(3R,4R)--
dimethyl-4-(3-hydroxyphenyl)piperidine (25). Prepared according to
the general procedure (though on a 3-mmol scale) using compound 6H
and 3-(4-hydroxyphenyl)propionic acid in 81% yield. Crude products
were then purified by silica gel chromatography using 10-25%
methanol in chloroform: .sup.1H NMR (MeOH-d4) .delta. 7.59 (s, 1H),
6.90-6.76 (m, 3H), 6.52-6.45 (m, 3H), 6.36 (d, 1H, J=7.6 Hz), 3.89
(brs, 1H), 2.56-2.54 (m, 3H), 2.39-1.95 (m, 9H), 1.70 (brs, 1H),
1.32-1.10 (m, 3H), 1.03 (s, 5H), 0.65-0.61 (m, 8H), 0.52-0.42 (m,
3H); .sup.13C NMR (MeOH-d4) .delta. 163.8, 147.5, 146.0, 142.6,
122.2, 119.7, 119.4, 107.4, 105.5, 103.1, 102.6, 68.7, 53.7, 46.2,
41.0, 39.4, 39.1, 35.4, 33.4, 29.5, 28.9, 28.7, 21.5, 21.2, 17.5,
15.1, 13.3, 11.9. Anal. (C.sub.28H.sub.40N.sub.2O.sub.3- ): C, H,
N.
[0194]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-2'-cyclohexylethyl}-(3R,4-
R)-dimethyl-4-(3-hydroxyphenyl)piperidine. (26). Prepared according
to the general procedure (though on a 3-mmol scale) using compound
6i and 3-(4-hydroxyphenyl)propionic acid in 87% yield. Crude
products were then purified by silica gel chromatography using
10-25% methanol in chloroform: .sup.1H NMR (MeOH-d4) .delta.
7.85-7.82 (m, 2H), 7.11-6.97 (m, 3H), 6.74-6.56 (m, 5H), 3.99-3.97
(m, 1H), 2.81-2.75 (m, 3H), 2.54 (m, 1H), 2.44-2.12 (m, 7H), 1.94
(brs, 1H), 1.54-1.26 (m, 3H), 1.25 (s, 3H), 1.02-0.68 (m, 10H);
.sup.13C NMR (MeOH-d4) .delta. 164.1, 147.5, 146.0, 142.6, 122.2,
119.7, 119.4, 107.3, 105.5, 103.1, 102.5, 68.7, 49.4, 45.5, 41.3,
40.9, 29.4, 28.8, 28.4, 21.5, 21.1, 17.4, 15.4. Anal.
(C.sub.30H.sub.24N.sub.2O.sub.3): C, H, N.
[0195]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanainido]-3'-phenylpropyl}-(3R,4R)-
-dimethyl-4-(3-hydroxyphenyl)piperidine (27). Prepared according to
the general procedure (though on a 3-mmol scale) using compound 6k
and 3-(4-hydroxyphenyl)propionic acid in 82% yield. Crude products
were then purified by silica gel chromatography using 10-25%
methanol in chloroform: .sup.1H NMR (MeOH-d4) .delta. 7.88(s, 1H),
7.12-7.00 (m, 3H), 6.76-6.66 (m, 4H), 6.59-6.55 (m, 1H), 3.90 (m,
1H), 2.78 (q, 3H, J=7.0 Hz), 2.62-2.56 (m, 1H), 2.47-2.24(m, 6H),
1.66-1.50 (m, 6H), 1.26 (s, 3H), 1.16-1.03 (m, 3H), 0.88-0.84 (m,
2H), 0.71 (d, 3H, J=6.9 Hz); .sup.13C NMR (MeOH-d4) .delta. 164.1,
147.5, 146.0, 142.6, 122.1, 119.8, 119.4, 107.3, 105.5, 103.1,
102.6, 68.7, 50.1, 45.6, 41.2, 41.1, 31.7, 29.4, 28.8, 21.5, 21.1,
20.3, 18.4, 17.4, 16.8. Anal. (C.sub.31H.sub.28N.sub.2O.sub.3): C,
H, N.
[0196] Opioid Binding Assays. Mu binding sites were labeled using
[.sup.3H][D-Ala.sup.2-MePhe.sup.4,Gly-ol.sup.5]enkephalin
([.sup.3H]DAMGO) (2.0 nm, SA=45.5 Ci/mmol), and delta binding sites
were labeled using [.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkephalin
(2.0 nM, SA=47.5 Ci/mmol) using rat brain membranes prepared as
described..sup.4 Kappa-1 binding sites were labeled using
[.sup.3H]U69,593 (2.0 nM, SA=45.5 Ci/mmol) and guinea pig membranes
pretreated with BIT and BIT to deplete the mu and delta binding
sites..sup.5
[0197] [.sup.3H]DAMGO binding proceeded as follows: 12.times.75 mm
polystyrene test tubes were prefilled with 100 .mu.L of the test
drug which was diluted in binding buffer (BB: 10 mM Tris-HCl, pH
7.4, containing 1 mg/mL BSA), followed by 50 .mu.L of BB, and 100
.mu.L of [.sup.3H]DAMGO in a protease inhibitor cocktail (10 mM
Tris-HCl, pH 7.4, which contained bacitracin (1 mg/mL), bestatin
(100 .mu.g/mL), leupeptin (40 .mu.g/mL), and chymostatin (20
.mu.g/mL). Incubations were initiated by the addition of 750 .mu.L
of the prepared membrane preparation containing 0.2 mg/mL of
protein and proceeded for 4 to 6 h at 25.degree. C. The ligand was
displaced by 10 concentrations of test drug, in triplicate,
2.times.. Nonspecific binding was determined using 20 .mu.M
levallorphan. Under these conditions, the, K.sub.d of
[.sup.3H]DAMGO binding was 4.35 nM. Brandel cell harvesters were
used to filter the samples over Whatman GF/B filters, which were
presoaked in wash-buffer (ice-cold 10 mM Tris-HCl, pH 7.4).
[0198] [.sup.3H][D-Ala.sup.2, D-Leu.sup.5]enkephalin binding
proceeded as follows: 12.times.75 mm polystyrene test tubes were
prefilled with 100 .mu.L of the test drug which was diluted in BB,
followed by 100 .mu.L of a salt solution containing choline
chloride (1 M, final concentration of 100 mM), MnCl2 (30 mM, final
concentration of 3.0 mM), and, to block mu sites, DAMGO (1000 nM,
final concentration of 100 nM), followed by 50 .mu.L of
[.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkephalin in the protease
inhibitor cocktail. Incubations were initiated by the addition of
750 .mu.L of the prepared membrane preparation containing 0.41
mg/mL of protein and proceeded for 4 to 6 h at 25.degree. C. The
ligand was displaced by 10 concentrations of test drug, in
triplicate, 2.times.. Nonspecific binding was determined using 20
.mu.M levallorphan. Under these conditions the K.sub.d of
[.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkepha- lin binding was 2.95 nM.
Brandel cell harvesters were used to filter the samples over
Whatman GF/B filters, which were presoaked in wash buffer (ice-cold
10 mM Tris-HCl, pH 7.4).
[0199] [.sup.3H]U69,593 binding proceeded as follows: 12.times.75
mm polystyrene test tubes were prefilled with 100 .mu.L of the test
drug which was diluted in BB, followed by 50 .mu.L of BB, followed
by 100 .mu.L of [.sup.3H]U69,593 in the standard protease inhibitor
cocktail with the addition of captopril (1 mg/mL in 0.1N acetic
acid containing 10 mM 2-mercapto-ethanol to give a final
concentration of 1 .mu.g/mL). Incubations were initiated by the
addition of 750 .mu.L of the prepared membrane preparation
containing 0.4 mg/mL of protein and proceeded for 4 to 6 h at
25.degree. C. The ligand was displaced by 10 concentrations of test
drug, in triplicate, 2.times.. Nonspecific binding was determined
using 1 .mu.M U69,593. Under these conditions the K.sub.d of
[.sup.3H]U69,593 binding was 3.75 nM. Brandel cell harvesters were
used to filter the samples over Whatman GF/B filters, which were
presoaked in wash buffer (ice-cold 10 mM Tris-HCl, pH 7.4)
containing 1% PEI.
[0200] For all three assays, the filtration step proceeded as
follows: 4 mL of the wash buffer was added to the tubes, rapidly
filtered and was followed by two additional wash cycles. The
tritium retained on the filters was counted, after an overnight
extraction into ICN Cytoscint cocktail, in a Taurus beta counter at
44% efficiency.
[0201] [.sup.35S]-GTP-.gamma.-S Binding Assay. Ten frozen guinea
pig brains (Harlan Bioproducts for Science, Inc, Indianapolis,
Ind.) were thawed, and the caudate putamen were dissected and
homogenized in buffer A (3 mL/caudate) (Buffer A=10 mM Tris-HCl, pH
7.4 at 4.degree. C. containing 4 .mu.g/mL leupeptin, 2 .mu.g/mL
chymostatin, 10 .mu.g/mL bestatin, and 100 .mu.g/mL bacitracin)
using a polytron (Brinkman) at setting 6 until a uniform suspension
was achieved. The homogenate was centrifuged at 30,000.times.g for
10 min at 4.degree. C. and the supernatant discarded. The membrane
pellets were washed by resuspension and centrifugation twice more
with fresh buffer A, aliquotted into microfuge tubes, and
centrifuged in a Tomy refrigerated microfuge (model MTX 150) at
maximum speed for 10 min. The supernatants were discarded, and the
pellets were stored at -80.degree. C. until assayed.
[0202] For the [.sup.35S]GTP-.gamma.-S binding assay, all drug
dilutions were made up in buffer B [50 mM TRIS-HCl, pH 7.7/0.1%
BSA]. Briefly, 12.times.75 mm polystyrene test tubes received the
following additions: (a) 50 .mu.L buffer B with or without an
agonist, (b) 50 .mu.L buffer B with or without 60 .mu.M
GTP-.gamma.-S for nonspecific binding, (c) 50 .mu.L buffer B with
or without an antagonist, (d) 50 .mu.L salt solution which
contained in buffer B 0.3 nM [.sup.35S]GTP-.gamma.-S, 600 mM NaCl,
600 .mu.M GDP, 6 mM dithiothreitol, 30 mM MgCl.sub.2, and 6 mM
EDTA, and (e) 100 .mu.L membranes in buffer B to give a final
concentration of 10 .mu.g per tube. The final concentration of the
reagents were 100 mM NaCl, 5 mM MgCl.sub.2, 1 mM EDTA, 1 mM
dithiothreitol, 100 .mu.M GDP, 0.1% BSA, 0.05-0.1 nM
[.sup.35S]GTP-.gamma.-S, 500 nM or 10 .mu.M agonists, and varying
concentrations (at least 10 different concentrations) of
antagonists. The reaction was initiated by the addition of
membranes and terminated after 4 h by addition of 3 mL ice-cold
(4.degree. C.) purified water (Milli-Q uv-Plus, Millipore) followed
by rapid vacuum filtration through Whatman GF/B filters presoaked
in purified water. The filters were then washed once with 5 mL
ice-cold water. Bound radioactivity was counted by liquid
scintillation spectroscopy using a Taurus (Micromedic) liquid
scintillation counter at 98% efficiency after an overnight
extraction in 5 mL Cytoscint scintillation fluid. Nonspecific
binding was determined in the presence of 10 .mu.M GTP-.gamma.-S.
Assays were performed in triplicate, and each experiment was
performed at least 3.times..
[0203] Data Analysis. The data of the two separate experiments
(opioid binding assays) or three experiments
([.sup.35S]-GTP-.gamma.-S assay) were pooled and fit, using the
nonlinear least-squares curve-fitting language MLAB-PC (Civilized
Software, Bethesda, Md.), to the two-parameter logistic
equation.sup.6 for the best-fit estimates of the IC.sub.50 and
slope factor. The K.sub.i values were then determined using the
equation: IC.sub.50/1+([L]/K.sub.d).
1 % Inhibition Data for Compounds of Formula (I) in a Kappa
Receptor Assay R.sub.1 R.sub.2 R.sub.3 (acid) % Inhibition H H PA5
13 H H BA1 20 H H BA2 20 H H BA4 21 H H BA6 32 H H BA8 11 H H BA9
24 H H BA10 28 H H BA12 6 H H BA13 9 H H BA14 11 H H BA16 11 H H
BA22 2 H H BA23 13 H H BA24 2 H H BA25 6 H H AA2 1 H H AA4 0 H H
PP1 9 H H PP2 23 H H PP3 17 H H PP4 1 H H PP5 8 H H PP6 14 H H PP12
29 H H PP15 19 H H FA1 13 H H FA2 9 H H FA3 50 H H FA4 33 H H FA5
39 H H FA6 27 H H FA7 29 H H FA8 35 H H FA9 33 H H FA10 8 H H HA1
20 H H HA2 42 H H HA3 9 H H HA4 15 H H HA5 20 H H OA23 8 H H PB1 37
H H CA2 35 H H CA10 23 H H CA11 13 H H CA12 15 H H PA38 14 H H CA19
10 H H CA20 12 H H CA22 19 H H CA38 27 H H PA9 18 H H PA10 9 H H
PA13 25 H H PA15 17 H H PA18 16 H H PA23 9 H H PA27 18 H H PA28 9 H
H PA29 10 H H PA32 22 H H PA3 20 H H PA4 11 H H PA7 9 H H PA17 13 H
H PA22 19 H H PA8 23 H H NA1 16 H H NA2 6 H H NA3 13 H H NA4 1 H H
NA5 10 H H NA6 2 H H NA7 2 H H NA8 15 H H NA9 26 H H NA10 22 H H
NA11 15 H H BA7 2 H H PA38 5 H H AA1 8 H H AA2 6 H H AA4 3 H H PP6
11 H CH.sub.3 BA4 12 H CH.sub.3 BA10 13 H CH.sub.3 BA1 6 H CH.sub.3
CA1 9 H CH.sub.3 CA5 6 H CH.sub.3 PA37 5 H CH.sub.3 PA5 11 H
CH.sub.3 PA14 0 H CH.sub.3 PA32 0 H CH.sub.3 PP2 0 H CH.sub.3 PP5 0
H CH.sub.3 PP6 0 H CH.sub.3 PP1 0 H CH.sub.3 PP7 0 H CH.sub.3 BA11
0 H CH.sub.3 CA4 0 .alpha.i-Pr H BA4 9 .alpha.i-Pr H BA5 19
.alpha.i-Pr H BA8 0 .alpha.i-Pr H BA7 5 .alpha.i-Pr H BA11 0
.alpha.i-Pr H BA12 0 .alpha.i-Pr H BA13 26 .alpha.i-Pr H BA15 1
.alpha.i-Pr H BA19 0 .alpha.i-Pr H BA20 0 .alpha.i-Pr H BA21 3
.alpha.i-Pr H CA1 0 .alpha.i-Pr H CA10 0 .alpha.i-Pr H CA11 0
.alpha.i-Pr H CA7 0 .alpha.i-Pr H PA5 6 .alpha.i-Pr H PA7 14
.alpha.i-Pr H PA9 0 .alpha.i-Pr H PA10 0 .alpha.i-Pr H PA13 10
.alpha.i-Pr H PA15 4 .alpha.i-Pr H PA18 7 .alpha.i-Pr H PA22 0
.alpha.i-Pr H PA27 18 .alpha.i-Pr H PA28 6 .alpha.i-Pr H CA16 0
.alpha.i-Pr H CA18 0 .alpha.i-Pr H PA29 1 .alpha.i-Pr H PP1 28
.alpha.i-Pr H PP2 3 .alpha.i-Pr H PP3 27 .alpha.i-Pr H PP4 18
.alpha.i-Pr H PP5 20 .alpha.i-Pr H PP6 70 .alpha.i-Pr H PP7 13
.alpha.i-Pr H PP8 17 .alpha.i-Pr H PP12 23 .alpha.i-Pr H PP15 26
.alpha.i-Pr H PP16 31 .alpha.i-Pr H PP17 43 .alpha.i-Pr H CA5 4
.alpha.i-Pr H CA7 16 .alpha.i-Pr H CA12 15 .alpha.i-Pr H PA8 21
.alpha.i-Pr H PA23 6 .alpha.i-Pr H PA32 13 .alpha.i-Pr H BA1 3
.alpha.i-Pr H CA4 3 .alpha.i-Pr H PA18 7 .alpha.i-Pr H NA1 14
.alpha.i-Pr H NA2 3 .alpha.i-Pr H NA3 16 .alpha.i-Pr H NA4 43
.alpha.i-Pr H NA5 61 .alpha.i-Pr H NA6 1 .alpha.i-Pr H NA7 22
.alpha.i-Pr H NA8 3 .alpha.i-Pr H NA9 33 .alpha.i-Pr H NA10 3
.alpha.i-Pr H NA11 34 .alpha.i-Pr H BA7 25 .alpha.i-Pr H PA38 4
.alpha.i-Pr H AA1 3 .alpha.i-Pr H AA2 4 .alpha.i-Pr H AA4 13
.alpha.i-Pr H CA2 5 .alpha.i-Pr H FA1 5 .alpha.i-Pr H FA2 6
.alpha.i-Pr H FA3 9 .alpha.i-Pr H FA4 17 .alpha.i-Pr H FA5 10
.alpha.i-Pr H FA6 10 .alpha.i-Pr H FA7 10 .alpha.i-Pr H FA8 27
.alpha.i-Pr H FA9 14 .alpha.i-Pr H FA10 6 .alpha.i-Pr H HA1 6
.alpha.i-Pr H HA2 1 .alpha.i-Pr H HA3 0 .alpha.i-Pr H HA4 10
.alpha.i-Pr H HA5 10 .alpha.i-Pr H OA23 0 .alpha.i-Pr H PB1 7
.alpha.i-Pr H PA14 8 .beta.i-Pr H PP4 52 .beta.i-Pr H PP6 11
.beta.i-Pr H PP8 10 .beta.i-Pr H PP12 50 .beta.i-Pr H PP15 24
.beta.i-Pr H PP16 8 .beta.i-Pr H PP17 10 .beta.i-Pr H PP18 5
.alpha.CH.sub.3 H PP6 11 .alpha.CH.sub.3 CH.sub.3 CA1 3
.alpha.CH.sub.3 CH.sub.3 CA2 0 .alpha.CH.sub.3 CH.sub.3 CA8 0
.alpha.CH.sub.3 CH.sub.3 CA14 0 .alpha.CH.sub.3 CH.sub.3 CA15 1
.alpha.CH.sub.3 CH.sub.3 CA19 0 .alpha.CH.sub.3 CH.sub.3 CA20 10
.alpha.CH.sub.3 CH.sub.3 CA24 5 .alpha.CH.sub.3 CH.sub.3 CA28 0
.alpha.CH.sub.3 CH.sub.3 CA30 7 .alpha.CH.sub.3 CH.sub.3 BA1 7
.alpha.CH.sub.3 CH.sub.3 BA4 7 .alpha.CH.sub.3 CH.sub.3 BA8 8
.alpha.CH.sub.3 CH.sub.3 BA13 8 .alpha.CH.sub.3 CH.sub.3 BA19 8
.alpha.CH.sub.3 CH.sub.3 BA20 5 .alpha.CH.sub.3 CH.sub.3 BA21 5
.alpha.CH.sub.3 CH.sub.3 BA23 6 .alpha.CH.sub.3 CH.sub.3 BA25 5
.alpha.CH.sub.3 CH.sub.3 PA5 6 .alpha.CH.sub.3 CH.sub.3 PA8 1
.alpha.CH.sub.3 CH.sub.3 PA10 0 .alpha.CH.sub.3 CH.sub.3 PA19 0
.alpha.CH.sub.3 CH.sub.3 PA21 0 .alpha.CH.sub.3 CH.sub.3 PA27 4
.alpha.CH.sub.3 CH.sub.3 PA28 0 .alpha.CH.sub.3 CH.sub.3 PA29 1
.alpha.CH.sub.3 CH.sub.3 PA32 0 .alpha.CH.sub.3 CH.sub.3 PA14 0
.alpha.CH.sub.3 CH.sub.3 PP1 6 .alpha.CH.sub.3 CH.sub.3 PP4 2
.alpha.CH.sub.3 CH.sub.3 PP5 3 .alpha.CH.sub.3 CH.sub.3 PP7 1
.alpha.CH.sub.3 CH.sub.3 PP8 0 .alpha.CH.sub.3 CH.sub.3 PP10 5
.alpha.CH.sub.3 CH.sub.3 BAL1 0 .alpha.CH.sub.3 CH.sub.3 GAB1 0
.alpha.CH.sub.3 CH.sub.3 INP1 0 .alpha.CH.sub.3 CH.sub.3 CA13 1
.alpha.CH.sub.3 CH.sub.3 PA17 0 .alpha.CH.sub.3 CH.sub.3 PA9 10
.alpha.CH.sub.3 CH.sub.3 BA24 2 .alpha.CH.sub.3 CH.sub.3 PP2 5
.alpha.CH.sub.3 CH.sub.3 PP3 1 .alpha.CH.sub.3 CH.sub.3 PP6 1
.alpha.CH.sub.3 CH.sub.3 PA20 4 .alpha.Ph CH.sub.3 CA1 0 .alpha.Ph
CH.sub.3 CA4 0 .alpha.Ph CH.sub.3 CA9 1 .alpha.Ph CH.sub.3 CA14 0
.alpha.Ph CH.sub.3 CA15 3 .alpha.Ph CH.sub.3 CA19 0 .alpha.Ph
CH.sub.3 CA20 2 .alpha.Ph CH.sub.3 BA1 3 .alpha.Ph CH.sub.3 BA2 0
.alpha.Ph CH.sub.3 BA4 0 .alpha.Ph CH.sub.3 PA14 3 .alpha.Ph
CH.sub.3 PA19 0 .alpha.Ph CH.sub.3 PP1 4 .alpha.Ph CH.sub.3 PP2 4
.alpha.Ph CH.sub.3 OA1 9 .alpha.Ph CH.sub.3 OA3 4 .alpha.Ph
CH.sub.3 CA2 5 .alpha.Ph CH.sub.3 BA21 7 .alpha.Ph CH.sub.3 PP3 5
.alpha.Ph CH.sub.3 GAB1 11 .alpha.Ph CH.sub.3 BA8 4 .alpha.Ph
CH.sub.3 BA10 0 .alpha.Ph CH.sub.3 BA15 15 .alpha.Ph CH.sub.3 PA8 1
.alpha.Ph CH.sub.3 PA9 0 .alpha.Ph CH.sub.3 PA10 6 .alpha.Ph
CH.sub.3 PA20 6 .alpha.Ph CH.sub.3 PA21 9 .alpha.Ph CH.sub.3 PP6 7
.alpha.Ph CH.sub.3 PP7 0 .alpha.Ph CH.sub.3 PP8 0 .alpha.Ph
CH.sub.3 OA2 0 Amino Alkyl Acids AA1 1-Piperidine Propionic Acid
157.21 AA2 2-N,N-Dimethyl Glycine 103.21 AA3 3-N,N-Dimethyl Amino
Propionic Acid AA4 4-N,N-Dimethyl Amino Butyric Acid 167.64 Benzoic
Acids BA1 Benzoic Acid 122.12 BA2 2-Chlorobenzoic Acid 156.57 BA3
2-Acetamidobenzoic Acid 179.18 BA4 2-Phenoxybenzoic Acid 214.22 BA6
3-Chlorobenzoic Acid 156.57 BA8 3-Phenoxybenzoic Acid 214.22 BA9
3-Hydroxybenzoic Acid 138.12 BA10 4-Chlorobenzoic Acid 156.57 BA7
4-Dimethylaminobenzoic Acid 165.19 BA12 4-Dodecyloxybenzoic Acid
306.45 BA13 4-Butoxybenzoic Acid 212.69 BA14 4-Hydroxybenzoic Acid
138.12 BA16 4-tert-butylbenzoic Acid 178.23 BA18 4-Acetamidobenzoic
Acid 179.18 BA19 o-Anisic Acid 152.15 BA20 m-Anisic Acid 152.15
BA21 p-Anisic Acid 152.15 BA22 2-Benzoylbenoic Acid 226.23 BA23
2-Biphenylbenzoic Acid 98.22 BA24 4-Biphenylbenzoic Acid 98.22 BA25
3-Dimethylaminobenzoic Acid 165.19 BA26 2-Fluorobenzoic Acid 140.11
BA27 3-Nitrobenzoic Acid 167.12 BA28 o-Tolylic Acid 136.15 BA29
m-Tolylic Acid 136.15 BA30 p-Tolylic Acid 136.15 BA31
4-Fluoro-3-nitrobenzoic 185.11 BA32 3,4-Dichlorobenzoic Acid 191.01
BA33 2-Hydroxy Benzoic acid 138.12 BA34 4-Chloro-3-Nitro Benzoic
Acid 201.57 BA35 4-Flurobenzoic Acid 140.11 BA36 2-Nitrobenzoic
acid 167.12 BA37 4-Nitrobenzoic acid 167.12 Cinnamic Acids CA1
a-Methylcinnamic Acid 162.19 CA2 a-Phenylcinnamic Acid 226.4 CA3
2-Bromo-4,5-dimethoxycinnamic Acid 287.11 CA4 2-Chlorocinnamic Acid
182.61 CA5 2,4-Dichlorocinnamic Acid 217.05 CA6
3,4-Dihydroxycinnamic Acid 180.16 CA7 2,4-Dimethoxycinnamic Acid
208.21 CA8 3,5-Di-tert-butyl-4-hydroxy- cinnainic Acid 276.37 CA9
3-Fluorocinnamic Acid 166.15 CA10 2-Hydroxycinnamic Acid 164.16
CA11 3-Hydroxycinnamic Acid 164.16 CA12 4-Hydroxycinnamic Acid
164.16 CA13 2-Methoxycinnamic Acid 178.19 CA14 3-Methoxycinnamic
Acid 178.19 CA15 4-Methoxycinnamic Acid 178.19 CA16
2-Methylcinnamic Acid 162.19 CA17 3-Methylcinnamic Acid 162.19 CA18
4-Methylcinnamic Acid 162.19 CA19 3-(1-Naphthyl)acrylic Acid 224.46
CA20 4-Phenylcinnamic Acid 224.26 CA21 3,4,5-Trimethoxycinnamic
Acid 238.24 CA22 4-Isopropylcinnamic acid 190.24 CA23 2,6-Dichloro
218.063 CA24 3-benzyloxy 254.234 CA25 2-bromo-4,5-dimethoxy 287.12
CA26 2-chloro-6-fluoro 200.6 CA27 alpha-methyl-2,4,5-trimethoxy
252.27 CA28 2-n-hexyloxy 250.22 CA29 5-bromo-2-methoxy 257.09 CA30
2-benzyloxy 254.234 CA31 2,4,5-trimethoxy 238.24 CA32 2,6-difluoro
184.14 CA33 2-t-butylthio 236.157 CA34 2-chloro-5-nitro 227.61 CA35
2,3-dimethoxy 208.21 CA36 3,5-dit-butyl-4-hydroxy 276.37 CA37
2,5-dimethoxy 208.22 CA38 trans-Cinnamic Acid 147 CA39 cis-Cinnamic
Acid 147 Fatty Acids FA1 Acetic Acid 60.05 FA2 Propionic Acid 74.08
FA3 Pivalic Acid 102.13 FA4 1-Phenyl-1-cyclopentane Acid 162.19 FA5
1-Phenyl-1-cyclopropane Acid 190.24 FA6 Isovaleric Acid 102.13 FA7
4-Methylvaleric Acid 116.16 FA8 Cyclopentylacetic Acid 128.17 FA9
Cyclopentylcarboxylic Acid 114.14 FA10 trans-2-Phenyl-1-cyclopropyl
CA 162.19 FA11 Cyclohexane carboxylic Acd 128.17 Hydroxy Acids HA1
2-Hydroxy-3-methyl butyric 118.13 HA2 2-Hydroxy-2-methyl butyric
118.13 HA3 3-Hydroxy butyric 104.11 HA4 3-Hydroxy-4-trunethylamino
butyric 197.66 HA5 2-Phenyl-3-hydroxy propionic 166.18 Nicotinic
Acids NA1 2(n-Amylthio)nicotinic Acid 225.31 NA2 5-Bromonicotinic
Acid 202.01 NA3 6-Chloronicotinic Acid 157.56 NA4 2-Chloronicotinic
Acid 157.56 NA5 2-(Methylthio)nicotinic Acid 169.2 NA6 Nicotinic
Acid 123.11 NA7 Picolinic Acid 123.11 NA8 2-Pyridylacetic Acid HCl
173.6 NA9 3-Pyridylacetic Acid HCl 173.6 NA10 4-Pyridylacetic Acid
HCl 173.6 NA11 2-(Phenylthio)Nicotinic Acid 231.27 NA12
2-Hydroxy-6-methyl Nicotinic 153.14 NA13 3-(3-pyridyl)acrylic acid
149.15 NA14 3-(4-pyridyl)acrylic acid 149.15 Propionic Acid PP1
Phenyl Propionic 150.18 PP2 3,3-Diphenylpropionic Acid 226.28 PP3
3-Phenylbutyric Acid 164.2 PP4 3-(2-Hydroxyphenyl)propion- ic Acid
166.18 PP5 3-(3-Hydroxyphenyl)propionic Acid 166.18 PP6
3-(4-Hydroxyphenyl)propionic Acid 166.18 PP7
3-(3-Methoxyphenyl)propionic Acid 180.2 PP8
3-(4-Methoxyphenyl)propionic Acid 180.2 PP9
3-(3,4,5-Trimethoxyphenyl)propionic Acid 240.26 PP10
3-(2-Methoxyphenyl)propionic Acid 180.2 PP11
3-(2,5-Dimethoxyphenyl)propionic Acid 210.24 PP12
3-(2-Chlorophenyl)propionic Acid 184.62 PP13
3-(4-Aminophenyl)propionic Acid 165.119 PP14
3-(4-Fluorophenyl)propionic Acid 168.17 PP15
3-(3,4-Dihydroxyphenyl)propionic Acid 182.18 PP16
3-(3-Methoxy-4-hydroxyphenyl) 196.2 PP17 3-(3,5-dinotro-4-hydroxy-
phenyl) 256.2 PP18 3-(Pentaflurophenyl)propionic Acid PP19
3-(4-Bocaminophenyl)propionic Acid 265 PP21 2,2-Diphenylpropionic
Acid 226.28 Phenylacetic Acid PA1 4-Aminophenylacetic Acid 151.17
PA2 4-Biphenylacetic Acid 288.55 PA3 2-Bromophenylacetic Acid
215.05 PA4 4-Bromophenylacetic Acid 215.05 PA5
4-(n-Butoxy)phenylacetic Acid 208.26 PA7
3-Chloro-4-hydroxyphenylacetic Acid 186.59 PA8 2-Chlorophenylacetic
Acid 170.6 PA9 3-Chlorophenylacetic Acid 170.6 PA10
4-Chlorophenylacetic Acid 170.6 PA11 2-Chloro-6-fluorophenylacetic
Acid 188.59 PA12 2,4-Dichlorophenylacetic Acid 205.04 PA13
2,6-Dichlorophenylaceti- c Acid 205.04 PA14
3,4-Dichlorophenylacetic Acid 205.04 PA15 2,5-Dimethoxyphenylacetic
Acid 196.2 PA16 3,4-Dimethoxyphenylacetic Acid 196.2 PA17
2,5-Dimethylphenylaceti- c Acid 164.2 PA18 2,4-Dinitrophenylacetic
Acid 226.15 PA19 2-Fluorophenylacetic Acid 154.14 PA20
3-Fluorophenylacetic Acid 154.14 PA21 4-Fluorophenylacetic Acid
154.14 PA22 2-Hydroxyphenylacetic Acid 152.15 PA23
4-Hydroxyphenylacetic Acid 152.15 PA24 2-Methoxyphenylacetic Acid
166.18 PA25 3-Methoxyphenylacetic Acid 166.18 PA26
4-Methoxyphenylacetic Acid 166.18 PA27 2-Methylphenylacetic Acid
150.18 PA28 3-Methylphenylacetic Acid 150.18 PA29
4-Methylphenylacetic Acid 150.18 PA30 2-Nitrophenylacetic Acid
181.15 PA31 4-Nitrophenylacetic Acid 181.15 PA32 Phenylacetic Acid
136.15 PA33 2-Trifluormethylophenylacetic Acid 204.15 PA34
3-Trifluoromethylphenylacetic Acid 204.15 PA35
3,4,5-Trimethoxyphenylacetic Acid 226.23 PA36 4-Ethoxyphenylacetic
Acid 180.22 PA37 Mesitylacetic acid 178.23 PA38 4-Dimethyl Amino PA
PA39 3-Hydroxyphenyl PA PA40 Diphenyl Acetic
REFERENCES
[0204] (1) Thomas, J. B.; Mascarella, S. W.; Rothman, R. B.;
Partilla, J. S.; Xu, H.; McCullough, K. B.; Dersch, C. M.;
Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Investigation of
the N-substituent conformation governing potency and ii receptor
subtype-selectivity in
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid
antagonists. J. Med. Chem. 1998, 41(11), 1980-1990.
[0205] (2) Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw,
W. N.; Wong, D. T.; Cantrell, B. E.; Johnson, B. G.; Reel, J. K.;
Snoddy, J. D.; Takemori, A. E.; Zimmerman, D. M.
3,4-Dimethyl-4-(3-hydroxyphenyl)piperid- ines: Opioid antagonists
with potent anorectant activity. J. Med. Chem. 1993, 36(20),
2842-2850.
[0206] (3) Xu, H.; Lu, Y.-F.; Partilla, J. S.; Brine, G. A.;
Carroll, F. I.; Rice, K. C.; Lai, J.; Porreca, F.; Rothman, R. B.
Opioid peptide receptor studies. 6. The 3-methylfentanyl congeners
RTI-4614-4 and its enantiomers differ in efficacy, potency, and
intrinsic efficacy as measured by stimulation of
[.sup.35S]GTP-.gamma.-S binding using cloned .mu.-opioid receptors.
Analgesia 1997, 3, 35-42.
[0207] (4) Rothman, R. B.; Xu, H.; Seggel, M.; Jacobson, A. E.;
Rice, K. C.; Brine, G. A.; Carroll, F. I. RTI-4614-4: an analog of
(+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for
mu versus delta opioid binding sites. Life Sci. 1991, 48,
PL111-PL-116.
[0208] (5) Rothman, R. B.; Bykov, V.; de Costa, B. R.; Jacobson, A.
E.; Rice, K. C.; Brady, L. S. Interaction of endogenous opioid
peptides and other drugs with four kappa opioid binding sites in
guinea pig brain. Peptides 1990, 11, 311-331.
[0209] (6) Rodbard, D.; Lenox, R. H.; Wray, H. L.; Ramseth, D.
Statistical characterization of the random errors in the
radioimmunoassay dose-response variable. Clin. Chem. 1976, 22,
350-58.
[0210] (7) Takemori et al, J. Pharm. Exp. Ther., 1988, 246 (1),
255-258.
2TABLE 1 Results of Inhibition Screening of Selected Structural
Isomers of Compound 8 Taken from the Library versus Kappa Opioid
Selective Ligand [.sup.3H]U69,593 15 % Inhi- bition at 100 compd R1
R2 X1 X2 S.sub.1 S.sub.2 S.sub.3 nM 8 i-Pr H CH2 CH2 H H OH 71 9
i-Pr.sup..alpha. H CH2 CH2 H H OH 11 10 i-Pr H CH2 CH2 H H H 28 11
i-Pr H CH2 CH2 H OH H 20 12 i-Pr H CH2 CH2 OH H H 25 13 i-Pr H CH2
-- H H OH 6 14 i-Pr H CH.sup.b CH.sup.b H H OH 15 15 i-Pr H CH2 CH2
H H F 26 16 i-Pr H CH2 CH2 H OH OH 31 17 i-Pr H CH2 CH2 H OCH3 OH
42 18 i-Pr H CH2 CH2 H H OCH3 16 19 H H CH2 CH2 H H OH 11 20
CH.sub.3 H CH2 CH2 H H OH 20 21 H CH.sub.3 CH2 CH2 H H OH 0 22
CH.sub.3 CH.sub.3 CH2 CH2 H H OH 1 23 C.sub.6H.sub.5 CH.sub.3 CH2
CH2 H H OH 7 DMSO 4 .sup..alpha.The carbon to which the i-Pr group
is attached has the opposite stereochemistry from that in 8.
.sup.bTrans double bond
[0211]
3TABLE 2 Radioligand Binding Data for 8 and Related Compounds at
Mu, Delta, and Kappa Opioid Receptor Assays 16 Ki (nM .+-. SD)
(-n.sub.H) [.sup.3H] [.sup.3H] compd R DAMGO DADLE [.sup.3H]U69,593
.mu./.kappa. .delta./.kappa. 8 i-Pr 393 .+-. 13.3 >5700 6.91
.+-. 0.55 57 >824 (0.89 .+-. 0.02) (0.81 .+-. 0.05) 24 i-Bu 398
.+-. 72.3 NA 89.3 .+-. 7.03 4.5 (0.91 .+-. 0.16) (0.78 .+-. 0.05)
25 sec-Bu 421 .+-. 30.5 NA 8.84 .+-. 0.30 47 (0.91 .+-. 0.06) (0.87
.+-. 0.02) 26 c-Hex 234 .+-. 25.2 NA 83.1 .+-. 5.7 2.8 (0.84 .+-.
0.08) (0.79 .+-. 0.04) 27 Benzyl 9.6 .+-. 1.18 NA 54.6 .+-. 3.5
0.17 (0.89 .+-. 0.09) (0.86 .+-. 0.04) 5a.sup..alpha. 0.74 .+-.
0.05 322 .+-. 122 .+-. 11.9 0.006 2.6 38.1 (0.89 .+-. 0.09) (0.75
.+-. (0.52 .+-. 0.07) 0.09) 1 (nor- 47.2 .+-. 3.3 42.9 .+-. 11 0.28
.+-. 0.07 181 150 BNI).sup.b,c nal- 1.39 .+-. 0.40 94.9 .+-. 6.6
4.71 .+-. 0.12 0.30 20.1 trexone.sup.b (0.94 .+-. 0.08) (1.01 .+-.
(1.05 .+-. 0.08) 0.09) .sup..alpha.Data taken from ref. 1.
.sup.bData provided for reference; compound is not a derivative of
8. .sup.cData taken from ref. 7. [.sup.3H]DAMGO, [.sup.3H]DPDPE,
and [.sup.3H]U69593 were used as the radioligands for the mu,
delta, and kappa assays, respectively. Guinea pig brain membranes
were used.
[0212]
4TABLE 3 Inhibition by Antagonists of [.sup.35S]GTP.gamma.S Binding
in Guinea Pig Caudate Stimulated by DAMGO (.mu.), SNC80 (.delta.),
and U69,593 (.kappa.) Selective Opioid Agonists. Ki (nM .+-. SD)
(-n.sub.H).sup.a Compd DAMGO.sup.b SNC80.sup.c U69,593.sup.d 8 7.25
.+-. 0.52 450 .+-. 74.1 4.70 .+-. 0.56 (1.11 .+-. 0.08) (1.05 .+-.
0.17) (1.38 .+-. 0.19) 5a.sup.e 0.039 .+-. 0.003 1.48 .+-. 0.094
1.04 .+-. 0.061 (1.06 .+-. 0.07) (1.19 .+-. 0.08) (1.07 .+-. 0.06)
1, nor-BNI 16.75 .+-. 1.47 10.14 .+-. 0.96 0.038 .+-. 0.005 (1.02
.+-. 0.09) (1.18 .+-. 0.12) (0.97 .+-. 0.12) naltrexone 0.93 .+-.
0.21 19.3 .+-. 2.25 2.05 .+-. 0.21 (1.03 .+-. 0.22) (1.05 .+-.
0.17) (1.38 .+-. 0.19) .sup.aSee footnote a from Table 2.
.sup.bDAMGO [(D-Ala.sup.2,MePhe.sup.4,Gly-ol.sup.5)enkep- halin].
Agonist selective for mu opioid receptor. .sup.cSNC-80
([(+)-4-[(.alpha.R)-.alpha.-(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-
-methoxybenzyl]-N,N-diethylbenzamide). Agonist selective for delta
opioid receptor. .sup.dU69,593
[(5.alpha.,7.alpha.,8.beta.)-(-)-N-methyl-
-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]benzeneacetamide].
Agonist selective for kappa opioid receptor. .sup.eData taken from
ref. 1.
[0213] Analyses Appendix
[0214]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-3'-methylbutyl}-(3R,4R)-d-
imethyl-4-(3-hydroxyphenyl)piperidine (8).
[0215] Anal. calcd for
C.sub.27H.sub.39ClN.sub.2O.sub.3.1.5H.sub.2O: C, 64.59; H, 8.43; N,
5.58. Found: C, 64.35; H, 8.12; N, 5.38.
[0216]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-4'-methylpentyl}-(3R,4R)--
dimethyl-4(3 hydroxyphenyl)piperidine (24).
[0217] Anal. calcd for C.sub.28H.sub.40N.sub.2O.sub.3: C, 74.30; H,
8.91; N, 6.19. Found: C, 74.12; H, 9.22; N, 6.30.
[0218]
N-{(2S)-[3-(4-Hydroxyphenyl)propanamido]-3'S-methylpentyl}-(3R,4R)--
dimethyl-4-(3-hydroxyphenyl)piperidine (25).
[0219] Anal. calcd for C.sub.28H.sub.40N.sub.2O.sub.3: C, 74.30; H,
8.91; N, 6.19. Found: C, 74.02; H, 9.20; N, 6.25.
[0220]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-2'-cyclohexylethyl}-(3R,4-
R)-dimethyl-4-(3-hydroxyphenyl)piperidine (26).
[0221] Anal. calcd for C.sub.30H.sub.42N.sub.2O.sub.3: C, 75.28; H,
8.84; N, 5.85. Found: C, 75.18; H, 8.96; N, 5.97.
[0222]
N-{(2'S)-[3-(4-Hydroxyphenyl)propanamido]-3'-phenylpropyl}-(3R,4R)--
dimethyl-4-(3-hydroxyphenyl)piperidine (27).
[0223] Anal. calcd for C.sub.31H.sub.38N.sub.2O.sub.3: C, 76.51; H,
7.87; N, 5.76. Found: C, 76.15; H, 7.99; N, 5.89.
Example 2
N-substituted (.+-.)-1,2,3,4,4a,5,
10,10a-octahydro-4a-(3-hydroxyphenyl)-1-
0a-methylbenzo[g]isoquinolines
[0224] Summary
[0225] Potent, opioid receptor pure antagonist activity has been
demonstrated in the N-substituted
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-
-(3-hydroxyphenyl)-10a-methylbenzo[g]isoquinolines, 7 and 8 (FIG.
8). These compounds share many of the characteristics identified
with the phenylpiperidine antagonists including N-susbstituent
mediated potency and a lack of N-susbstituent mediated antagonism.
Also, like the phenylpiperidines, 7 and 8 display a strong
preference for mu and kappa versus delta opioid receptor binding.
Unlike the phenylpiperidines however, the benzoisoquinoline system
displays a stronger preference for the kappa versus the mu opioid
receptor and a lower overall potency relative to typical
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists.
Together this data suggests a common site of action within the
opioid receptors for compounds 7 and 8 and the
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines.
[0226] Chemistry
[0227] The N-methyl and N-phenethyl derivatives of
(.+-.)-1,2,3,4,4a,5,10,-
10a-octahydro-4a-(3-hydroxyphenyl)-10a-methylbenzo[g]isoquinoline
(7 and 8, respectively) were prepared starting from
tetrahydropyridine (9) according to the method illustrated in FIG.
8..sup.1 Accordingly, 9 was deprotonated with sec-butyl lithium
followed by alkylation with .alpha.,.alpha.'-dichloroxylene. This
material was not isolated but was immediately cyclized with NaI in
refluxing acetonitrile and reduced with sodium borohydride to
provide intermediate 10 in 23% yield. The N-methyl derivative (7)
was then available via O-demethylation employing refluxing HBr in
acetic acid. The N-phenylethyl derivative (8) was prepared from 10
by N-demethylation using phenylchloroformate in refluxing toluene
followed by subjecting the crude carbamate to refluxing HBr in
acetic acid to cleave the urethane and deprotect the phenol.
Conversion of this material to the desired compound (8) was
accomplished by coupling with phenyl acetic acid using
benzotriazol-1-yl-oxy-tris-(dimethylamino)phosph- onium
hexafluorophosphate (BOP reagent) followed by reduction of the
resulting amides using borane in tetrahydrofuran in 2.2% overall
yield.
[0228] Results and Discussion
[0229] Both initial studies and work conducted in this laboratory
have provided strong evidence that the antagonist activity of some
N-substituted piperidine compounds is expressed via a phenyl
equatorial/piperidine chair receptor-ligand interaction as
illustrated in FIG. 9b..sup.2 This stands in contrast to the
phenylaxial/piperidine chair conformation exhibited by naltrexone
(FIG. 9a). The benzoisoquinoline system (FIG. 9c), where a bridge
connects carbons 3 and
[0230] 4 in the piperidine ring, was selected for study because its
structure could potentially maintain the proposed active
conformation of the phenylpiperdines as well as provide sites for
further structural elaboration. Compounds 7 and 8 were therefore
synthesized and tested in both binding and functional assays to
establish the overall effect of this structural change on
antagonist activity and potency.
[0231] The radioligand binding data for the N-methyl and
N-phenethyl derivatives of
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-(3-hydroxyphenyl)--
10a-methylbenzo[g]isoquinolines (7 and 8, respectively) are
provided in Table 4. For comparison, the radioligand binding assay
data for the parent ligands 5 and 6 are given in Table 5..sup.3 As
these data sets are from different assays, the binding data
obtained for naltrexone (3) is provided as a reference standard
from both sets of assays. Inspection of the data reveals a
fundamental shift in the receptor binding preference of the
benzoisoquinolines in favor of the kappa receptor relative to the
phenylpiperidines which typically show greater potency at the mu
receptor. However, the overall preference for mu/kappa binding
relative to delta binding is preserved (the phenylpiperidines
typically show the least preference for the delta receptor, data
not shown). Increasing the size of the N-substituent (conversion of
7 to 8) provides an overall increase in potency at all receptors, a
feature shared by conversion of the phenylpiperidine 5 to 6. The
latter information together with the general receptor binding
preferences suggests that the benzoisoquinoline antagonists
probably interact with the same subsites within the opioid
receptors as do the phenylpiperidines, but the addition of the 3,4
bridge leads to both an increase in affinity for the kappa receptor
as well as a loss of affinity for the mu receptor relative to the
phenylpiperidine antagonists.
[0232] In the functional assay shown in Table 6, compounds 7 and 8
displayed a pattern of activity consistent with the radioligand
binding assay. Thus, inhibition of agonist stimulated [.sup.35
S]GTP.gamma.S binding in guinea pig caudate by 7 and 8, a measure
of functional antagonist activity,.sup.4 was greatest against
U69,593 (kappa receptor) with the potency demonstrated against
DAMGO (mu receptor) being only slightly less. The ability to
inhibit SNC80 (delta receptor) stimulated [.sup.35S]GTP.gamma.S
biding was significantly lower. As in the previous assay,
increasing the size of the N-substituent lead to an increase in
potency. Importantly, neither the N-methyl derivative 7 nor the
N-phenethyl derivative 8 stimulated [.sup.35S]GTP.gamma.S binding
when tested at concentrations as high as 1 .mu.M; the
benzoisoquinoline structure therefore retains opioid pure
antagonist activity.
[0233] In terms of potency, both 7 and 8 demonstrate a decreased
affinity for all of the opioid receptors relative to some of the
more potent phenylpiperidine antagonists. The source of this loss
of activity cannot be immediately established since several
explanations exist. It is possible that these compounds have
greater preference for a phenyl axial/piperidine chair conformation
relative to the phenylpiperidines, though it has been found that 8
exists in the phenylequatorial/piperidine chair conformation in the
solid state (FIG. 10). More likely, the lower potency results from
a lack of activity of one of the enantiomers of 6. Hugh eudismic
ratios are observed in most classes of opioid ligands.
[0234] In summary, potent opioid receptor pure antagonist activity
was demonstrated for
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-(3-hydroxyphenyl-
)-2-phenethyl-10a-methylbenzo[g]isoquinoline (8). Compounds 7 and 8
share many of the characteristics identified with the
phenylpiperidine antagonists including N-substituent mediated
potency and a lack of N-substituent mediated antagonism. Also,
these ligands display a strong preference for mu and kappa versus
delta binding. Unlike the phenylpiperidines, the benzoisoquinolines
display a, stronger preference for the kappa versus the mu receptor
and a lower overall potency as, a racemic mixture, relative to
typical trans-3,4-dimethyl-4-(3-hydroxypheny- l)piperidine
antagonists. Together this data suggests both a common site of
action within the opioid receptors for compounds 7 and 8 and the
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines.
[0235] Experimental
[0236] Melting points were determined on a Thomas-Hoover capillary
tube apparatus and are not corrected. Elemental analyses were
obtained by Atlantic Microlabs, Inc. and are within .+-.0.4% of the
calculated values. .sup.1H and .sup.13C NMR were determined on a
Bruker WM-250 spectrometer using tetramethylsilane as an internal
standard. Radial chromatography was performed on a Harrison
Research Chromatotron model 7924T. All reactions were followed by
thin-layer chromatography using Whatman silica gel 60 TLC plates
and were visualized by UV or by charring using 5% phosphomolybdic
acid in ethanol. All solvents were reagent grade. Tetrahydrofuran
and diethyl ether were dried over sodium benzophepone ketyl and
distilled prior to use. .alpha.,.alpha.'-Dichlorox- ylene,
purchased from Aldrich Chemical Co., was recrystallized from hexane
prior to use.
[0237] (.+-.)-1,2,3,4,4a,5,
10,10a-octahydro-4a-(3-methoxyphenyl)-2,10a-di-
methylbenzo-[g]isoquinoline (10): To a dry three-neck
round-bottomed flask was charged 500 mg (2.3 mmol) of
tetrahydropyridine (9) (CAUTION: read reference 12 and references
cited therein) and 20 mL dry THF. This was cooled to -78.degree.
C., and to this was added 2.4 mL (3.12 mmol) s-BuLi (1.3M in
cyclohexane) via a syringe over 5 min. The flask was then warmed to
-0.degree. C. and aged for 10 min. The flask was then cooled to
-78.degree. C. and cannulated into a mixture of 40 mL dry ethyl
ether and 1.3 g (7.59 mmol) .alpha.,.alpha.'-dichloro xylene at
-50.degree. C. over 20 min. This was aged for 20 min and then
quenched with ice-cold 1N HCl. The contents of the flask were then
transferred to a separatory funnel with ice-cold ether and ice cold
1N HCl. The aqueous layer was removed and stored in an ice bath
while the organic layer was twice extracted with ice-cold 1N HCl.
The combined aqueous layers were placed into a new separatory
funnel and extracted twice with ice-cold ethyl ether to remove
.alpha.,.alpha.'-diochloroxylene. The aqueous layer was then made
basic with 50% NaOH at first and finally saturated NaHCO.sub.3 to
pH 10. The aqueous layer was then extracted 3 times with ice-cold
ethyl ether and then discarded. The ether extracts were dried over
K.sub.2CO.sub.3 and then filtered into a round-bottom flask and the
solvent removed on the rotavap at 0.degree. C. After all of the
solvent was removed, the residue was dissolved in 40 mL sieve dried
CH.sub.3CN, and to this was added 870 mg NaI and 650 mg
K.sub.2CO.sub.3. The flask was then attached to a reflux condenser
and a heating mantle and the system heated under reflux for 3 h.
After this time, the flask was cooled to room temperature and
filtered. The solvent was then removed on a rotavap and the residue
dissolved in 40 mL punctilious ethanol. To this mixture was added
750 mg NaBH.sub.4 in one portion and the mixture allowed to stir
overnight. On the following day, 1N HCl was added to this mixture
until no further evolution of hydrogen was observed. This was
stirred for 10 min, and then 50% NaOH and water were added until
the mixture was clear and basic. The volatiles were then removed on
a rotavap, and the residue was extracted 3 times with 1:1 ethyl
ether:ethyl acetate. This was dried over K.sub.2CO.sub.3 and
Na.sub.2SO.sub.4. After filtration and solvent removal, a small
portion of the crude residue was dissolved in CHCl.sub.3 and
spotted on a silica gel plate. Elution with 50% CMA-80 (80
CHCl.sub.3:18 MeOH: 2 NH.sub.4OH) in CHCl.sub.3 revealed a compound
in the mixture that gave a pale spot when dipped in 5% PMA in EtOH
at about 0.75 Rf. This is the tertiary amine product. No other
tertiary amines were observed in the mixture. .sup.1H NMR of the
crude mixture revealed the desired product as well as starting
material (9) and other undesired products. Chromatography on silica
gel using 12.5% CMA-80 in CHCl.sub.3 gave the desired product in
the early fractions just behind the solvent front but not in the
solvent front. This gave 115 mg of the desired product as a
slightly yellow oil. Yield 15.5%.
[0238] .sup.1H NMR (CDCl.sub.3) .delta. 0.993 (s, 3H); 1.404 (ddd,
1H, J=13.7, 2.6, 2.6 Hz); 2.149 (d, 1H, J=11.6 Hz); 2.229 (d, 1H,
J=17.0 Hz); 2.240 (s, 3H); 2.310 (dd, 1H, J=11.6, 1.5 Hz); 2.379
(ddd, 1H, J=12.1, 12.1, 3.2 Hz); 2.646 (d, 1H, J=17.0 Hz); 2.862
(dd, 1H, J=13.7, 4.7 Hz); 2.885 (d, 1H, J=18.3 Hz); 2.962 (m, 1H);
3.570 (d, 1H, J=18.3 Hz); 3.634 (s, 3H); 6.715 (ddd, 1H, J=8.1,
2.5, 0.9 Hz); 6.839 (m, 2H); 7.048 (d, 1H, J=7.6 Hz); 7.197-7.080
(m, 4H). .sup.13C NMR (CDCl.sub.3) .delta. 158.9, 148.9, 135.9,
135.6, 128.6, 128.36, 128.0, 125.9, 125.5, 120.0, 113.9, 110.8,
64.04, 54.9, 52.2, 46.6, 40.6, 40.11, 35.98, 31.5, 24.4.
[0239]
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-(3-hydroxyphenyl)-2,10a-dim-
ethylbenzo-[g]isoquinoline (7): To a 10 mL single-necked flask was
added 100 mg (0.31 mmol) of
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-(3-methoxyp-
henyl)-2,10a-dimethylbenzo[g]isoquinoline (10) and 0.8 mL of
glacial acetic acid and 0.8 mL of 48% HBr. This mixture was heated
under reflux for 18 h and then cooled to room temperature. The pH
was then adjusted to 10 with cooling starting with 50% NaOH and
finishing with saturated NaHCO.sub.3. This was extracted 2 times
with CHCl.sub.3 and 2 times with 3:1 n-butanol:toluene. Both
extracts were dried over K.sub.2CO.sub.3 and then the solvent was
removed. The material from both extracts was examined by .sup.1H
NMR and was shown to contain the desired product. The material from
the CHCl.sub.3 layer was chromatographed on silica gel eluting with
25% CMA-80 in CHCl.sub.3. This gave 27 mg of the desired product
(7) (28% yield). The residue was dissolved in MeOH, and to this was
added 3 equivalents of 1N HCl in dry ethyl ether. The solvents were
removed, and the residue crystallized from ether/MeOH. The butanol
extracts contained 45 mg of the desired material giving an overall
yield of 74.6%. MP .degree. C. 270-275 (dec). Anal. Calcd for
C.sub.2H.sub.26NOC.smallcircle.0.25H.sub.2O: C, 65.54; H, 7.20; N,
3.64. Found: C, 65.86; H, 7.15; N, 3.42. .sup.1H NMR (DMSO) .delta.
1.014 (s, 3H); 1.587 (d, 1H, J=14.3 Hz); 2.072 (s, 3H); 2.358 (d,
1H, J=17.4. Hz); 2.498 (d, 1H, J=17.4 Hz); 2.734 (s, 3H);
2.924-2.792 (m, 3H); 3.113 (d, 1H, J=13.1 Hz); 3.602 (d, 1H,
J=18.78 Hz); 6.562 (d, 1H, J=8.0 Hz); 6.611 (m, 2H); 6.993 (t, 1H,
J=7.5 Hz); 7.081 (d, 1H, J=7.5 Hz); 7.148 (t, 1H, J=7.8 Hz);
7.269-7.193 (m, 2H); 9.30 (s, 1H); 9.898 (bs 1H). .sup.13C NMR
(DMSO) .delta. 156.7, 146.4, 135.5, 133.3, 128.5, 128.4, 128.2,
126.2, 125.7, 117.6, 114.3, 113.5, 59.2, 49.4, 38.6, 35.4, 35.2,
31.0, 28.7, 22.8.
[0240]
(.+-.)-1,2,3,4,4a,5,10,10a-octahydro-4a-(3-hydroxyphenyl)-2-pheneth-
yl-10a-methylbenzo[g]isoquinoline (8): To 300 mg (0.93 mmol)
intermediate (10) was added 5 mL dry toluene followed by heating to
80.degree. C. To this was added 0.23 mL (1.86 mmol) distilled
phenylchloroformate dropwise via syringe. A precipitate formed, and
the mixture was heated at reflux for 5 h. The mixture was cooled to
room temperature and washed 3 times with 1N NaOH and dried over
sodium sulfate. .sup.1H NMR of the crude mixture indicated that no
starting material was present (no N-methyl signal at 2.25 ppm). The
crude mixture was then dissolved in 4 mL glacial acetic acid and 4
mL 48% HBr. This was heated at reflux for 18 h followed by addition
of water and methyl t-butyl ether (MTBE). The aqueous layer was
removed and extracted two more times with MTBE to remove phenol.
The aqueous layer was then pH adjusted to 10 using 50% NaOH and
saturated sodium bicarbonate and extracted 3 times with 3:1
methylene chloride:tetrahydrofuran (THF) and the organic layer
dried over sodium sulfate. Following removal of solvent, this
highly polar material was dissolved in 15 mL THF, and to this was
added 442 mg (1 mmol) BOP reagent, 0.4 mL triethylamine (2.2 mmol),
and 136 mg (1 mmol) phenyl acetic acid. This was stirred for 3 h
and then diluted with ethyl ether, 40 mL, and washed sequentially
with 15 mL water, 1N HCl, saturated sodium bicarbonate, and brine.
The solution was dried over sodium sulfate and the solvent removed
on a rotary evaporator. The material was then dissolved in
chloroform and filtered through silica gel to remove highly colored
polar impurities to give 142 mg relatively clean material. .sup.1H
NMR of this crude material indicated the presence of rotamers
typical of piperidine amides and urethanes. Reduction of this
compound was accomplished by dissolving in dry THF followed by
addition of 1.16 mL of 2M borane dimethylsulfide in THF. After
heating for 3 h, the mixture was cooled to room temperature, and 2
mL methanol was added and stirred for 1 h. After this time, 1.16 mL
1N HCl in ether was added and stirred for 1 h. The solvent was then
removed on a rotary evaporator and the crude mixture dissolved in
chloroform, saturated sodium bicarbonate, and water. The pH was
adjusted to 10 and the organic layer washed 3 times with water and
then dried over sodium sulfate. The crude residue was
chromatographed on silica gel using 0-10% MeOH in chloroform as
eluent, and this material was crystallized from MeOH/ether as its
HCl salt to give 55.8 mg of the, desired material (0.137 mmol) or
2.2% overall yield. MP .degree. C. 255-265 (dec). Anal. Calcd for
C.sub.28H.sub.32NOCl.smallc- ircle.0.5H.sub.2O: C, 75.91; H, 7.51;
N, 3.16. Found: C, 75.93; H, 7.53; N, 3.17. .sup.1H NMR (DMSO)
.delta. 10.06 (br s, 1H); 9.34 (s, 1H); 7.30 (dd, 2H, J=8.1 Hz, 8.1
Hz); 7.22 (m, 5H); 7.15 (dd, 1H, J=7.7. Hz, 7.7 Hz); 7.08 (d, 1H,
J=7.7 Hz); 6.63 (s, 1H); 6.62 (d, 1H, J=8.1, Hz); 6.55 (d, 1H,
J=8.1 Hz); 3.59 (d, 1H, J=18.9 Hz); 3.50 (d, 1H, J=12.1 Hz); 3.32
(m, 4H); 3.11 (ddd, 1H, J=5.1 Hz, 12.1 Hz, 12.1 Hz); 3.02 (ddd, 1H,
J=5.1 Hz, 12.1 Hz, 12.1 Hz); 2.87 (m, 3H); 2.50 (d, 1H, J=17.4);
2.42 (d, 1H, J=17.4); 1.62 (d, 1H, J=14.3); 1.08 (s, 3H). .sup.13C
NMR (DMSO) .delta. 156.72, 146.44, 137.23, 135.45, 133.38, 128.63,
128.59, 128.56, 128.52, 128.19, 126.71, 126.39, 125.72, 117.55,
114.33, 113.51, 57.27, 57.18, 48.22, 39.46, 38.66, 35.40, 35.21,
29.45, 28.59, 23.06.
REFERENCES
[0241] (1) Evans, D. A.; Mitch, C. H.; Thomas, R. C.; Zimmerman, D.
M.; Robey, R. L. Application of metalated enamines to alkaloid
synthesis. An expedient approach to the synthesis of morphine-based
analgesics. J. Am. Chem. Soc. 1980, 102, 5955-5956. WARNING: Read
the background information relating to analogs of MPTP (i.e., 9)
including Zimmerman et al., J. Med. Chem., 1986, 29, 1517-1520, and
references cited therein.
[0242] (2) Zimmerman, D. M.; Smits, S.; Nickander, R. Further
investigation of novel 3-methyl-4-phenylpiperidine narcotic
antagonists. In Proceedings of the 40th Annual Scientific Meeting
of the Committee on Problems of Drug Dependence, 1978, pp.
237-247.
[0243] (3) Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw,
W. N.; Wong, D. T.; Zimmerman, D. M.; Gidda, S. J.; Cantrell, B.
E.; Scoepp, D. D.; Johnson, B. G.; Leander, J. D. J. Med. Chem.
1994, 37, 2262-2265.
[0244] (4) Xu, H.; Lu, Y. -F.; Partilla, J. S.; Brine, G. A.;
Carroll, F. I.; Rice, K. C.; Lai, J.; Porreca, F.; Rothman, R. B.
Opioid peptide receptor studies. 6. The 3-methylfentanyl congeners
RTI-4614-4 and its enantiomers differ in efficacy, potency, and
intrinsic efficacy as measured by stimulation of
[.sup.35S]GTP-.gamma.-S binding using cloned .mu.-opioid receptors.
Analgesia 1997, 3, 35-42.
5TABLE 4 Radioligand Binding Results in Mu, Delta, and Kappa Opioid
Receptor Assays K.sub.i (nM .+-. SD) Compound [.sup.3H]DAMGO.sup.a
[.sup.3H]DADLE.sup.b [.sup.3H]U69,593.sup.c 7 297 .+-. 23 >5710
166 .+-. 15 (1.02 .+-. 0.07) (0.87 .+-. 0.06) 8 11.2 .+-. 2.7 1270
.+-. 106.sup. 9.8 .+-. 1.7 (0.56 .+-. 0.07) (1.14 .+-. 0.099).sup.
(0.69 .+-. 0.07) 3, naltrexone 1.39 .+-. 0.40 94.9 .+-. 6.6.sup.
4.71 .+-. 0.12 (0.94) (1.01) (1.05) .sup.a[.sup.3H]DAMGO
[(D-Ala.sup.2,MePhe.sup.4,Gly-ol.sup.5)enkephalin]. Tritiated
ligand selective for mu opioid receptor. .sup.b[.sup.3H]DADLE
[(D-Ala.sup.2,D-Leu.sup.5)enkephalin]. Tritiated ligand selective
for delta opioid receptor. .sup.c[.sup.3H]U69,593
(trans-3,4-dichloro-N-methyl[2-(1-pyrrolidinyl)cyc-
lohexyl]benzeneacetamide). Tritiated ligand selective for kappa
opioid receptor.
[0245]
6TABLE 5 Affinities of the 4-Phenylpiperidine Antagonists for the
.mu. and .kappa. Opioid Receptors.sup.a K.sub.i (nM) Compd
[.sup.3H]Nal.sup.b [.sup.3H]EKC.sup.c 5 80 833 6 1.5 52 3,
naltrexone 0.56 3.9 .sup.aData taken from reference 3.
.sup.bNaloxone (.mu. receptor assay). .sup.cEthylketocyclazocine
(.kappa. receptor assay).
[0246]
7TABLE 6 Inhibition by Antagonists of [.sup.35S]GTP.gamma.S Binding
in Guinea Pig Caudate Stimulated by the Opioid Receptor
Subtype-Selective Agonists, DAMGO (.mu.), SNC80 (.delta.), and
U69,593 (.kappa.). K.sub.i (nM .+-. SD) (N) Compound DAMGO
SNC80.sup.a U69,593 7 .sup. 119 .+-. 7.93 .sup. 222 .+-. 30.7 52.60
.+-. 6.38.sup. .sup. (0.94 .+-. 0.06) .sup. (0.78 .+-. 0.09) .sup.
(1.10 .+-. 0.14) 8 10 .+-. 0.91.sup. .sup. 184 .+-. 24.3 .sup. 6.61
.+-. 0.57 .sup. (0.89 .+-. 0.06) .sup. (0.78 .+-. 0.09) .sup. (1.01
.+-. 0.08) 1, naltrexone 0.930 .+-. 0.21.sup. .sup. 19.3 .+-. 2.25
.sup. 2.05 .+-. 0.21 .sup. (1.00 .+-. 0.22) .sup. (1.13 .+-. 0.14)
.sup. (0.76 .+-. 0.05) .sup.aSNC80
([(+)-4-[(.alpha.R)-.alpha.-(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-
-methoxybenzyl]- N,N-diethylbenzamide]). Agonist selective for
delta opioid receptor.
[0247] This Example is described in Thomas et al, Bioorganic and
Medicinal Chemistry Letters 8 (1998) 3149-3152, incorporated herein
by reference.
Example 3
Opioid Receptor Antagonists
[0248] Summary
[0249] Two sets of novel opioid receptor antagonist pharmacophores
have been prepared and demonstrated from a model of opioid
antagonist binding. One is based on a rigid 5-phenylmorphan nucleus
and the other on a more flexible benzoisoquinoline nucleus. Using
modifications of these systems and by comparisons with the related
trans-3,4-dimethyl-4-(3-hydoxyphenyl) piperidines, provides strong
evidence supporting the hypothesis that this class of antagonist
binds the opioid receptors in a phenyl equatorial mode and that the
trans-3-methyl substituent (phenyl piperidine numbering) is an
important element for conversion of agonists into antagonists.
[0250] Chemistry
[0251] The .beta.-5-(3-hydroxyphenyl) morphans were prepared by the
method shown in FIG. 11. Deprotonation of the known compound 10
with sec-butyl lithium followed by alkylation with allyl bromide
cleanly provided intermediate 11 in quantitative yield. This
compound was then cyclized provide 12 in 90% yield as a 2.5:1
mixture of diastereomers. Further experimentation established
conditions which changed the ratio of 12a:12b to 10:1. Compounds
13a,b were then readily available via enamine reduction followed by
separation using radial chromatography. The major isomer 13 was
then O-demethylated to give 14. Since elucidation of the
stereochemistry was not straightforward using NMR techniques,
crystals of the HCl salt of 14 are shown by X-ray analysis to
possess the desired 9.beta.-methyl stereochemistry.
[0252] Compound 13 was also converted to the N-phenylethyl compound
18. N-Demethylation of 13 gave 15 which on O-demethylation yielded
16. Compound 16 was then converted to the N-phenethyl derivative
(18) by the two step procedure involving coupling of 16 with
phenylacetic acid followed by borane-dimethylsulfide reduction of
the intermediate amide 17.
[0253] The benzoisoquinoline compound (20) was also prepared
starting from compound 10 according to the method illustrated in
FIG. 12. Accordingly, 10 was deprotonated with sec-butyl lithium
followed by alkylation with .alpha.,.alpha.'-dichloro-xylene to
give intermediate 19 which was not isolated but was immediately
cyclized with NaI and reduced to provide compound 20 in 13% yield.
O-Demethylation of 20 using hydrogen bromide in acetic acid yielded
21. The structure was established using a combination of NMR
techniques.
[0254] Biological Assay Results
[0255] The new compounds 14, 18, and 21 were shown to bind the
opioid receptors and also were shown to be pure antagonists. The
data supporting these conclusions is presented in Tables 7 and
8.
[0256] Discussion
[0257] The radioligand binding data in Table 7 show that compounds
14, 18, and 21 have affinity for the opioid receptors. 18 is more
potent than 14. The data in Table 8 shows that all three compounds
are pure antagonists.
[0258] Experimental
[0259] All of the solvents used were reagent grade with the
exception of diethyl ether and THF in reactions and these were
distilled from sodium/benzophenone ketyl. NMR spectra were
collected on both a 250 MHz and a 500 MHz Bruker spectrometer. The
melting points reported below are uncorrected.
[0260]
1,2,3,4-Tetrahydro-4-allyl-1,5-dimethyl-4-(m-methoxyphenyl)pyridine
(5): To a solution of 500 mg (2.3 mmol) of tetrahydropyridine 10 in
15 mL of THF at -42.degree. C. was added s-BuLi in cyclohexane
(1.3M, 2.9 mmol). After 1 h, allyl bromide (2.3 mmol) was added,
and the color of the solution changed from dark red to yellow.
After been stirred for 1 hour at -42.degree. C., the mixture was
allowed to warmed to 0.degree. C. and then quenched with water (10
mL). Diethyl ether (10 mL) was added and the aqueous layer was
extracted with ether (2.times.). The combined ether layers were
washed with water (10 mL), saturated NaHCO.sub.3, brine and dried
over Na.sub.2SO.sub.4. Evaporation of solvent afforded 590 mg
(.about.100%) of crude 11. The crude product was used directly in
the next step without further purification. .sup.1H NMR
(CDCl.sub.3) .delta. 7.26 (m, 1H), 7.01 (m, 2H), 6.74 (m, 1H), 5.89
(s, 1H), 5.82 (m, 1H), 5.13 (m, 2H), 3.80 (s, 3H), 2.68-2.40 (m,
3H), 2.55 (s, 3H), 2.22 (m, 1H), 1.66 (m, 2H), 1.52 (s, 3H).
.sup.13C NMR (CDCl.sub.3) .delta. 159.2, 151.1, 136.7, 135.8,
128.7, 119.8, 117.4, 114.3, 110.1, 107.7, 55.1, 46.1, 43.1, 43.0,
41.7, 36.4, 17.3.
[0261]
(1S*,5R*,9R*/S*)-2,9-Dimethlyl-5-(m-methoxyphenyl)-2-azabicyclo[3,3-
,1]non-3-ene (12a/b): A solution of 300 mg (1.17 mmol) of 11 in 6
mL of 85% H.sub.3PO.sub.4/HCO.sub.2H (1:1) was stirred at room
temperature for 72 h. The resulting dark brown mixture was diluted
with water (6 mL) and cooled in ice bath while NaOH (25% w/w) was
added until pH-8. The aqueous solution was extracted with
CHCl.sub.3 (3.times.). The combined organic layers was washed with
aqueous NaHCO.sub.3 and brine and dried over Na.sub.2SO.sub.4.
Evaporation of the solvent gave 270 mg (90%) of crude products 12a
and 12b in a ratio of 2.5:1. The crude products were used directly
in the next step without further purification. .sup.1H NMR
(CDCl.sub.3) of the mixture: .delta.7.24-6.70 (m, 4H), 6.16 (d, 1H,
J=9.2 Hz), 4.34 (d, 1H, J=7.0 Hz), 4.13 (d, 1H, J=9.1 Hz), 3.80 (s,
3H), 2.80(s, 3H), 3.10-1.40(m, 8H), 0.74 (d, 3H, J=8.6 Hz), 0.57
(d, 3H, =8.1 Hz).
[0262]
(1S*,5R*,9R*/S*)-2,9-Dimethyl-5-(m-methoxyphenyl)-2-azabicyclo[3,3,-
1]nonane (13a/b): A solution of 270 mg (1.05 mmol) of 12a and 12b
mixture and acetic acid (1.05 mmol, 0.061 mL) in 5 mL of
dichloroethane was treated with NaBH(OAc).sub.3 under N2
atmosphere. The reaction was stirred at room temperature for 2 h.
The reaction was quenched by adding 10% NaOH to pH.about.10. The
mixture was extracted with ether (3.times.), washed with water and
brine. The organic phase was dried over Na.sub.2SO.sub.4 and
concentrated under reduced pressure. Separation by chromatography
(1% Et3N/EtOAc) gave 135 mg (50%) of 13a and 60 mg (22%) of 13b as
colorless oils. .sup.1H NMR (CDCl.sub.3) of 8: .delta. 7.26 (m,
1H,), 6.94 (m, 2H), 6.70 (m, 1H), 3.80 (s, 3H), 3.05-2.90 (m, 2H),
2.71 (m, 1H), 2.43 (s, 3H), 2.42-2.30 (m, 2H), 2.28-2.15 (m, 1H),
2.00-1.35 (m, 6H), 0.86 (d, 3H, J=8.25 Hz). .sup.1H NMR
(CDCl.sub.3) of 9: .delta. 7.23 (m, 1H,), 6.96 (m, 2H), 6.72 (m,
1H), 3.81 (s, 3H), 3.10-2.98 (m, 2H), 2.90(m, 1H), 2.75 (m, 1H),
2.50 (s, 3H), 2.47 (m, 1H), 2.30-2.06 (m, 2H), 2.05-1.95 (m, 2H),
1.90-1.50 (m, 4H), 0.75 (d, 3H, J=8.56 Hz). .sup.13C NMR
(CDCl.sub.3) of 8: 159.2, 152.0, 128.9, 118.0, 112.3, 109.6, 59.7,
55.1, 51.1, 43.1, 42.5, 40.0, 38.3, 29.1, 25.6, 23.4, 14.8. Anal.
Calcd for Cl.sub.7H.sub.25NO: C, 78.72; H, 9.71; N, 5.40. Found: C,
78.79; H, 9.75; N, 5.34.
[0263]
(1S*,5R*,9R*)-2,9-Dimethyl-5-(m-hydroxyphenyl)-2-azabicyclo[3,3,1]n-
onane(14): Compound 13a was treated with 4 mL of glacial acetic
acid and 4 mL of 48% aqueous hydrobromic acid at reflux temperature
for 20 h. The reaction was cooled to room temperature and diluted
with 10 mL of water. The pH was adjusted to 10 by using 50% NaOH
with ice cooling. The product was extracted into a mixture of 3:1
1-butanol/toluene, dried over Na.sub.2SO.sub.4, and concentrated
under reduced pressure. Separation by chromatography (1/2 CMA 80)
provided 199 mg (84%) of 10 as a white solid. .sup.1H NMR
(CDCl.sub.3) .delta. 7.15 (m, 1H,), 6.87-6.75 (m, 2H), 6.61 (m,
1H), 3.10-2.90(m, 2H), 2.77 (m, 1H), 2.44 (s, 3H), 2.50-2.30 (m,
2H), 2.25-2.10 (m, 1H), 2.00-1.60 (m, 5H), 1.60-1.40 (m, 1H), 0.80
(d, 3H, J=8.3 Hz). .sup.13C NMR (CDCl3) .delta.155.9, 152.0, 129.1,
117.5, 113.0, 112.4, 59.7, 51.0, 43.0, 42.0, 40.2, 38.0, 29.0,
25.6, 23.2, 14.6. Anal. Calcd for
C.sub.16H.sub.23NO.smallcircle.HCl: C, 68.19; H, 8.53; N, 4.97.
Found: C, 68.25; H, 8.53; N, 5.03. The structure of this compound
was determined by single crystal X-ray analysis.
[0264]
(1S*,5R*,9R*)-5-(m-Hydroxyphenyl)-9-methyl-2-azabicyclo[3,3,1]nonan-
e (15): A solution of 200 mg (1.28 mmol) of phenyl chloroformate
was added dropwise to 300 mg (1.16 mmol) of 13a in 10 mL of
dichloromethane at room temperature under a nitrogen atmosphere.
The reaction was refluxed for 6 h. Since the reaction was not
complete by TLC, the solvent was then changed to dichloroethane and
the reflux was continued for another 12 h. The mixture was cooled
to room temperature and concentrated under reduced pressure. The
resulting oil was treated with 10 mL of 1N NaOH and stirred with
slight warming for 15 min. The product carbamate was then extracted
with ether, and the ether layer was washed with 1N HCl and water.
The organic phase was dried over Na.sub.2SO.sub.4 and concentrated
under reduced pressure. The residue was then treated with 5 mL of
ethanol and 1.5 mL of 50% aqueous KOH at reflux for 70 h. The
mixture was cooled and concentrated under reduced pressure. The
resulting concentrate was extracted with ether (2.times.), and the
ether layers were concentrated in vaccuo. The resulting oil was
dissolved into 10 mL of 1 N HCl and washed with ether. The aqueous
layer was then made strongly basic (pH>12) with 50% NaOH with
ice cooling. The desired amine 15 was extracted into ether
(2.times.), and the ether extracts were washed, dried over
Na.sub.2SO.sub.4, and concentrated under reduced pressure to give
207 mg (70%) of crude 11 as light yellow oil. The crude compound 15
was treated with 4 mL of glacial acetic acid and 4 mL of 48%
aqueous hydrobromic acid at reflux temperature for 20 h. The
reaction was cooled to room temperature and diluted with 10 mL of
water. The pH was adjusted to 10 by using 50% NaOH with ice
cooling. The product was extracted into a mixture of 3:1
1-butanol/toluene, dried over Na.sub.2SO.sub.4, and concentrated
under reduced pressure to yield 100 mg (51%) of 16 as a semi solid.
The crude product 16 was used directly in the next step without
further purification. .sup.1H NMR (CD.sub.3OD) .delta. 7.15 (m,
1H,), 6.79-6.75 (m, 2H), 6.65 (m, 1H), 3.70-3.30 (m, 3H), 2.70 (m,
1H), 2.45-1.70 (m, 8H), 0.87 (d, 3H, J=8.3 Hz).
[0265]
(1S*,5R*,9R*)-5-(m-Hydroxyphenyl)-9-methyl-2-[(phenylmethyl)carbony-
l]-2-azabicyclo [3,3,1] nonane (17): To a solution of 100 mg (0.43
mmol) of 16 and 190 mg (0.43 mmol) of BOP reagent and 0.19 mL (1.38
mmol) of triethylamine in 15 mL of THF was added phenylacetic acid
(70.25 mg, 0.52 mmol). The mixture was stirred at room temperature
for 1 h. The reaction was diluted with 10 mL of water and ether (10
mL). The aqueous layer was extracted with ether (2.times.). The
combined ether layers were washed with NaHCO.sub.3 and brine, and
dried over Na.sub.2SO.sub.4. Evaporation of solvent provided the
crude product 17 as a colorless oil. (A spectrum of .sup.1H NMR was
attached but the NMR data was not interpreted here due to the
rotamers).
[0266]
(1S*,5R*,9R*)-5-(m-Hydroxyphenyl)-9-methyl-2-(2'-phenylethyl)-2-aza-
bicyclo-[3,3,1] nonane (18): The crude amide 17 was dissolved in
THF (8 mL). The solution was cooled to 0.degree. C., and
Borane:methyl sulfide complex (0.4 mL, 0.8 mmol) was added
dropwise. After vigorous reaction ceased, the resulting mixture was
slowly heated to reflux and maintained at that temperature for 4 h.
The reaction mixture was cooled to 0.degree. C., 6 mL of methanol
was added, and the mixture was stirred for r 1 h. Anhydrous
hydrogen chloride in ether (1 mL) was added to attain a pH<2,
and the resulting mixture was gently refluxed for 1 h. After the
mixture was cooled to room temperature, methanol was added and the
solvents were removed on a rotovapor. The residue obtained was made
basic (pH>12) by adding 25% NaOH and extracted with ether
(3.times.). The combined ether layers were dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure.
Separation by chromatography (1% Et.sub.3N/50% EtOAc/hexanes) gave
38 mg (71%) of amine 18 as a colorless oil. .sup.1H NMR
(CDCl.sub.3) .delta. 7.30-7.14 (m, 6H), 6.85 (m, 2H), 6.63 (m, 1H),
4.71 (br s, 1H), 3.05 (m, 2H), 2.88(m, 1H), 2.79 (s, 4H), 2.43-2.15
(m, 3H), 1.94-1.65 (m, 5H), 1.65-1.45 (m, 1H), 0.83 (d, 3H, J=8.2
Hz). .sup.13C NMR (CDCl3) .delta.155.7, 152.5, 140.9, 129.1, 128.8,
128.3, 125.9, 117.7, 113.0, 112.4, 57.4, 57.2, 49.5, 42.4, 40.0,
38.7, 34.1, 29.1, 26.2, 23.4, 14.7. Anal. Calcd for
C.sub.23H.sub.29NO.smallcircle.HC- l: Calcd: C, 74.27; H, 8.13; N,
3.77. Found: C, 74.16; H, 8.12; N, 3.71.
[0267]
(.+-.)-(2,8a)-Dimethyl-4a-(3-Methoxyphenyl)-Octahydrobenzo[e]Isoqui-
noline (19): To a dry three neck round bottomed flask was charged
500 mg(2.3 mmol) of 10 and 20 mL dry THF. This was cooled to
-78.degree. C. and to this was added 2.4 mL (3.12 mmol) s-BuLi
(1.3M in cyclohexane) via a syringe over 5 minutes. The flask was
then warmed to -20.degree. C. and aged for 30 min. The flask was
then cooled to -78.degree. C. and cannulated into a mixture of 40
mL dry ethyl ether and 1.3 g (7.59 mmol) a,a'-dichloro xylene at
-50.degree. C. over 20 min. This was aged for 20 min., and then
quench with ice-cold 1N HCl. The contents of the flask were then
transfered to a separatory funnel with ice-cold ether and ice-cold
1N HCl. The aqueous layer was removed and stored in an ice bath
while the organic layer was twice extracted with ice-cold 1N HCl.
The combined aqueous layers were placed into a new separatory
funnel and extracted twice with ice-cold ethyl ether. The aqueous
layer was then made basic with 50% NaOH at first and finally sat'd
NaHCO.sub.3 to pH 10. The aqueous layer was then extracted 3 times
with ice-cold ethyl ether and then discarded. The ether extracts
were dried over K.sub.2CO.sub.3 and then filtered into a round
bottom flask and the solvent removed on the rotavap at 0.degree. C.
After all of the solvent was removed, the residue was dissolved in
40 mL seive dried CH.sub.3CN and to this was added 870 mg NaI and
650 mg K.sub.2CO.sub.3. The flask was then attached to a reflux
condenser and a heating mantle and the system heated under reflux
for 3 hours.
[0268] After this time, the flask was cooled to room temperature
and filtered. The solvent was then removed on a rotavap and the
residue dissolved in 40 mL punctillious ethanol. To this mixture
was added 750 mg NaBH.sub.4 in one portion and the mixture allowed
to stir overnight. On the following day, 1N HCl was added to this
mixture until no further evolution of hydrogen was observed. This
was stirred for 10 min and then 50% NaOH and water were added until
the mixure was clear and basic. The volatiles were then removed on
a rotavap and the residue was extracted 3 times with 1:1 ethyl
ether: ethyl acetate. This was dried over K.sub.2CO.sub.3 and
Na.sub.2SO.sub.4. After filtration and solvent removal, a small
portion of the crude residue was dissolved in CHCL.sub.3 and
spotted on a silica gel plate. Elution with 50% CMA-80 in
CHCL.sub.3 revealed a compound in the mixture that gave a pale spot
when dipped in 5% PMA in EtOH at about 0.75 Rf. This is the
3.degree. amine product. No other 3.degree. amines were observed in
the mixure. .sup.1H NMR of the crude mixture revealed the desired
product as well as starting material 10 and other undesired
products. Chromatography on silica gel using 12.5% CMA-80 in
CHCL.sub.3 gave the desired product in the early fractions just
behind the solvent front but not in the solvent front. This gave
115 mg of the desired product as a slightly yellow oil. Yield
15.5%.
[0269] .sup.1H NMR (CDCl.sub.3): .delta. 0.993 (s, 3H); 1.404 (ddd,
1H, J=13.7, 2.6, 2.6 Hz); 2.149 (d, 1H, J=11.6 Hz); 2.229 (d, 1H,
J=17.0 Hz); 2.240 (s, 3H); 2.310 (dd, 1H, J=11.6, 1.5 Hz); 2.379
(ddd, 1H, J=12.1, 12.1, 3.2 Hz); 2.646 (d, 1H, J=17.0 Hz); 2.862
(dd, 1H, J=13.7, 4.7 Hz); 2.885 (d, 1H, J=18.3 Hz); 2.962 (m, 1H);
3.570 (d, 1H, J=18.3 Hz); 3.634 (s, 3H); 6.715 (ddd, 1H, J=8.1,
2.5, 0.9 Hz); 6.839 (m, 2H); 7.048 (d, 1H, J=7.6 Hz); 7.197-7.080
(m, 4H).
[0270] .sup.13C NMR (CDCl.sub.3): d 158.9, 148.9, 135.9, 135.6,
128.6, 128.36, 128.0, 125.9, 125.5, 120.0, 113.9, 110.8, 64.04,
54.9, 52.2, 46.6, 40.6, 40.11, 35.98, 31.5, 24.4.
[0271] (.+-.)-(2,
8a)-Dimethyl-4a-(3-Hydroxyphenyl)-Octahydrobenzo[e]Isoqu- inoline
(20): To a 10 mL single necked flask was added 100 mg (0.31 mmol)
of
(.+-.)-(2,8a)-dimethyl-4a-(3-methoxyphenyl)-octahydrobenzo[e]isoquinol-
ine and 0.8 mL of glacial acetic acid and 0.8 mL of 48% HBr. This
mixture was heated under reflux for 18 hours and then cooled to
room temperature. The pH was then adjusted to 10 with cooling
starting with 50% NaOH and finishing with sat'd NaHCO.sub.3. This
was extracted 2 times with CHCl.sub.3 and 2 times with 3:1
n-butanol:toluene. Both extracts were dried over K.sub.2CO.sub.3
and then the solvent was removed. The material from both extracts
was examined by .sup.1H NMR and was shown to contain the desired
product. The material from the CHCl.sub.3 layer was chromatographed
on silica gel eluting with 25% CMA-80 in CHCl.sub.3. This gave 27
mg of the desired product 20 (28% yield). The residue was dissolved
in MeOH and to this was added 3 equivalents of 1N HCl in dry ethyl
ether. The solvents were removed and several attempts were made to
crystallize form ethyl acetate/MeOH. This only provided an oil. The
same result was obtained with ethyl ether/MeOH. Finally, ethyl
acetate was added to the residue and warmed and the solvent removed
on a rotavap. This process was repeated 5 times and the solid thus
formed was placed on a high vacuum pump overnight. MP .degree. C.
270-275 (dec). C, H, N.
[0272] .sup.1H NMR (DMSO): .delta. 1.014 (s, 3H); 1.587 (d, 1H,
J=14.3 Hz); 2.072 (s, 3H); 2.358 (d, 1H, J=17.4 Hz); 2.498 (d, 1H,
J=17.4 Hz); 2.734 (s, 3H); 2.924-2.792 (m, 3H); 3.113 (d, 1H,
J=13.1 Hz); 3.602 (d, 1H, J=18.78 Hz); 6.562 (d, 1H, J=8.0 Hz);
6.611 (m, 2H); 6.993 (t, 1H, J=7.5 Hz); 7.081 (d, 1H, J=7.5 Hz);
7.148 (t, 1H, J=7.8 Hz); 7.269-7.193 (m, 2H); 9.30 (s, 1H); 9.898
(bs, 1H).
[0273] .sup.13C NMR (DMSO): .delta. 156.7, 146.4, 135.5, 133.3,
128.5, 128.4, 128.2, 126.2, 125.7, 117.6, 114.3, 113.5, 59.2, 49.4,
38.6, 35.4, 35.2, 31.0, 28.7, 22.8.
[0274] The butanol extracts contained 45 mg of the desired material
giving an overall yield of 74.6%.
8TABLE 7 Radioligand Binding Results at all Three Opioid Receptors
for New Antagonist Pharmacaphores Com- IC.sub.50 (nM .+-. SD) pound
[.sup.3H] [.sup.3H] [.sup.3H] # RTI # DAMGO.sup.a DADLE.sup.b
U69,593.sup.c (14) 5989-30 243.7 .+-. >10,000 1470 .+-. 21.9
28.4 (1.00 .+-. (0.89 .+-. 0.08) 0.06) (18) 5989-31 4.54 .+-. 457.4
.+-. 27.2 .+-. 0.21 50.5 1.89 (1.08 .+-. (0.88 .+-. (1.25 .+-.
0.05) 0.08) 0.11) (21) 5989-28 406 .+-. >10,000 306.4 .+-. 31.9
28.4 (1.02 .+-. (0.81 .+-. 0.07) 0.06) .sup.aTritiated ligand
selective for mu opioid receptor. .sup.bTritiated ligand selective
for delta opioid receptor. .sup.cTritiated ligand selective for
kappa opioid receptor.
[0275]
9TABLE 8 IC.sub.50 Data for New Antagonists Toward Reversal of
Agonist Stimulated GTP Binding IC.sub.50 (nM .+-. SD) Compound #
RTI # DAMGO.sup.a SNC 80.sup.b U69, 593.sup.c (14) 5989-30 288 .+-.
78 >1000 >1000 (18) 5989-31 5.96 .+-. 0.72 >1000 26.3 .+-.
83 (21) 5989-28 NA NA 1552 .+-. 164.sup. .sup.aAgonist selective
for mu opioid receptor. .sup.bAgonist selective for delta opioid
receptor. .sup.cAgonist selective for kappa opioid receptor.
Example 4
.kappa.-Selective N-Substituted Piperidines
[0276] Summary
[0277] The inhibition of radioligand binding and
[.sup.35S]GTP.gamma.S functional assay data for N-methyl- and
N-phenethyl-9.beta.-methyl-5-(3-h- ydroxyphenyl)morphans (5b and
5c) (FIG. 13) show that these compounds are pure antagonists at the
.mu., .delta., and .kappa. opioid receptors. Since 5b and 5c have
the 5-(3-hydroxyphenyl) group locked in a conformation comparable
to an equatorial group of a piperidine chair conformation, this
information provides very strong evidence that opioid antagonists
can interact with opioid receptors in this conformation. In
addition, it suggests that the
trans-3,4-dimethyl-4-(3-hydroxyphenyl)pipe- ridine class of
antagonist operates via a phenyl equatorial piperidine chair
conformation.
[0278] Chemistry
[0279] The synthesis of the N-methyl- and
N-phenethyl-9.beta.-methyl-5-(3-- hydroxyphenyl)-morphans (5b and
5c, respectively) was achieved as illustrated in FIG. 13..sup.1
Treatment of 1,2,6-trihydro-1,3-dimethyl-4-- (3-methoxy)pyridine
(6) with sec-butyl lithium followed by quenching with allyl bromide
provided the enamine adduct (7) which was cyclized without
isolation to give
2,9-dimethyl-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]non- -3-ene
(8a,b) in a 3:1 9.beta.- to 9.alpha.-methyl ratio, using
hydrochloric acid in tetrahydrofuran Reduction of unpurified 8a,b
using sodium borohydride triacetate followed by separation of the
major isomer gave 9. Subjection of 9 to O-demethylation using
hydrobromic acid in acetic acid provided the desired phenylmorphan
(5b). Single crystal X-ray analysis showed that 5b had the desired
9.beta.-methyl relative configuration (FIG. 14). The N-phenethyl
derivative (5c) was prepared from intermediate 9. Treatment of 9
with phenylchloroformate followed by hydrolysis of the resulting
urethane with potassium hydroxide followed by O-demethylation with
hydrobromic acid in acetic acid gave 10. Compound 10 was converted
to 5c by coupling with phenyl acetic acid in the presence of
benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium
hexafluorophosphate followed by borane reduction of the resulting
amide intermediate.
[0280] Biological Results
[0281] Table 9 lists the radioligand binding data for compounds 5b
and 5c along with data for naltrexone. While the binding of 5b to
all three opioid receptors was weak, it is particularly interesting
to note that changing the N-substituent from methyl to phenethyl
(5c) provided a dramatic increase in binding affinity, a feature
shared by the corresponding 4-(3-hydroxyphenyl)piperidine analogs
(4a and 4b, Table 10)..sup.2 Furthermore, the relative binding
affinities displayed by 5b and 5c for mu and kappa opioid receptors
are quite similar to that observed for 4a and 4b. These results
show that the binding affinities of 5b and 5c are not adversely
affected by the 1,5-carbon bridge present in these structures. In
addition, it suggests a common binding mode for the two types of
structures.
[0282] The increase in binding of [.sup.35S]GTP.gamma.S stimulated
by opioid agonists is an assay able to distinguish compounds of
differing efficacy and intrinsic activity..sup.3 The antagonist
properties of test compounds can be determined by measuring the
inhibition of this stimulation. To assess their potency as
antagonists and to verify that 5b and 5c retain pure antagonist
activity, the compounds were analyzed for either stimulation or
inhibition of agonist stimulated GTP binding in comparison with
naltrexone (Table 11). In this functional assay, neither 5b nor 5c
stimulated GTP binding as measured up to concentrations of 10
.mu.M, showing that both compounds were devoid of agonist
activity..sup.4 As mentioned previously, retention of pure
antagonist activity regardless of the N-substituent structure is a
key feature that separates the
3,4-dimethyl-4-(3-hydroxyphenyl)-piperidine class of antagonist
from oxymorphone-based antagonists which display pure antagonism
only for certain N-substituents such as the N-allyl or
N-cyclopropylmethyl derivatives. In their ability to reverse
agonist-stimulated GTP binding, compound 5c displayed a higher
potency than naltrexone. These results are striking since agonist
activity in several opioid ligands is enhanced by N-substituents
with two methylene groups terminated by a phenyl group
(N-phenethyl). It is evident that the antagonist activity of 5c is
due to factors different from those of the oxymorphone-type pure
antagonists.
[0283] The data in Table 11 also demonstrates that the N-methyl to
N-phenethyl change, 5b to 5c, results in a concomitant increase in
antagonist potency. Thus, as is the case for the
3,4-dimethyl-4-(3-hydrox- yphenyl)piperidines, the antagonist
potency and not the agonist/antagonist behavior of the
9.beta.-methyl-5-(3-hydroxyphenyl)morphans (5b and 5c) is mediated
by the N-substituent.
[0284] Discussion
[0285] These experiments demonstrated that N-methyl
9.beta.-methyl-5-(3-hydroxyphenyl)morphan (5b) is an opioid
receptor pure antagonist. In addition, replacing the N-methyl with
an N-phenethyl group to give 5c resulted in a 63-, 60-, and 70-fold
increase in antagonist potency at the mu, delta, and kappa opioid
systems. These results are particularly important since changing an
N-methyl to an N-phenethyl substituent in all opioid systems which
have the 3-hydroxyphenyl group in an axial relationship relative to
the piperidine ring results in an increase in opioid agonist
activity..sup.5 This information strongly suggests that 5b and 5c
are acting as conformationally rigid analogs of the
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid
antagonists where the 3-hydroxyphenyl group is in an equatorial
position relative to the piperidine ring.
[0286] In opioid alkaloids like naloxone (1a) and naltrexone (1b),
the 3-hydroxyphenyl ring is fixed in an axial orientation relative
to the piperidine ring by the rigid framework of the structure
(FIG. 15). The 3-hydroxyphenyl ring in the
3,4-dimethyl-4-(3-hydroxy-phenyl)piperidine analogs 4a can be
either in axial or equatorial positions (FIG. 15). .sup.1H and
.sup.13C NMR studies.sup.6,7 as well as molecular modeling
studies.sup.2 suggest a preference for the 3-hydroxyphenyl
equatorial conformation. 5-(3-Hydroxyphenyl)morphans like 5a-c are
sterically constrained 4-(3-hydroxyphenyl)piperidines with the
3-hydroxyphenyl ring fixed in the equatorial position (FIG. 15).
The pure antagonist activity of the morphans 5b and 5c strongly
suggests that opioid ligands of the phenyl piperidine class express
potent opioid antagonist activity with their 3-hydroxyphenyl group
in an equatorial position.
[0287] A comparison of the radioligand and [.sup.35S]GTP.gamma.S
binding properties of the N-substituted
9.beta.-methyl-5-(3-hydroxyphenyl)morphan- s (5b and 5c) to those
of the N-substituted 3,4-dimethyl-4-(3-hydroxypheny- l)piperidines
(4a and 4b) strongly suggests that these two types of compounds are
interacting with opioid receptors in a similar mode. The pure
antagonist activity of 5b, which is increased when the N-methyl
group is replaced by a phenethyl group to give 5c, properties
unique to the 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of
antagonist, strongly supports the hypothesis that this class of
opioid antagonist expresses pure antagonist activity with the
4-(3-hydroxyphenyl) group in an equatorial conformation..sup.8
[0288] In summary, 9.beta.-methyl-5-(3-hydroxyphenyl)morphans are a
new structural type of pure opioid antagonist. The data also
strongly supports the proposed 4-(3-hydroxyphenyl) equatorial
piperidine chair mode of interaction for the
trans-3,4-dimethyl-(3-hydroxyphenyl)piperidin- e class of opioid
antagonist.
[0289] Experimental Section
[0290] Melting points were determined on a Thomas-Hoover capillary
tube apparatus and are not corrected. Elemental analyses were
obtained by Atlantic Microlabs, Inc. and are within .+-.0.4% of the
calculated values. .sup.1H-NMR were determined on a Bruker WM-250
spectrometer using tetramethylsilane as an internal standard.
Silica gel 60 (230-400 mesh) was used for all column
chromatography. All reactions were followed by thin-layer
chromatography using Whatman silica gel 60 TLC plates and were
visualized by UV or by charring using 5% phosphomolybdic acid in
ethanol. All solvents were reagent grade. Tetrahydrofuran and
diethyl ether were dried over sodium benzophenone ketyl and
distilled prior to use.
[0291] The [.sup.3H]DAMGO, DAMGO, and
[.sup.3H][D-Ala.sup.2,D-Leu.sup.5]en- kephalin were obtained via
the Research Technology Branch, NIDA, and were prepared by Multiple
Peptide Systems (San Diego, Calif.). The [.sup.3H]U69,593 and
[.sup.35S]GTP.gamma.S (SA=1250 Ci/mmol) were obtained from DuPont
New England Nuclear (Boston, Mass.). U69,593 was obtained from
Research Biochemicals International (Natick, Mass.). Levallorphan
was a generous gift from Kenner Rice, Ph.D., NIDDK, NIH (Bethesda,
Md.). GTP.gamma.S and GDP were obtained from Sigma Chemical Company
(St. Louis, Mo.). The sources of other reagents are
published..sup.8
[0292]
1,2,3,4-Tetrahydro-4-allyl-1,5-dimethyl-4-(3-methoxyphenyl)pyridine
(7). To a solution of 500 mg (2.3 mmol) of
1,2,6-trihydro-1,3-dimethyl-4-- (3-methoxy)pyridine (6) in 15 mL of
THF at -42.degree. C. was added s-BuLi in cyclohexane (1.3M, 2.9
mmol). After 1 h, allyl bromide (2.3 mmol) was added, and the color
of the solution changed from dark red to yellow. After been stirred
for 1 h at -42.degree. C., the mixture was allowed to warmed to
0.degree. C. and then quenched with water (10 mL). Diethyl ether
(10 mL) was added, and the aqueous layer was extracted with ether
(2.times.). The combined ether layers were washed with water (10
mL), saturated NaHCO.sub.3, brine, and dried over Na2SO4.
Evaporation of solvent afforded 590 mg (.about.100%) of crude 7.
The crude product was used directly in the next step without
further purification. .sup.1H NMR (CDCl.sub.3) .delta. 7.26 (m,
1H), 7.01 (m, 2H), 6.74 (m, 1H), 5.89 (s, 1H), 5.82 (m, 1H), 5.13
(m, 2H), 3.80 (s, 3H), 2.68-2.40 (m, 3H), 2.55 (s, 3H), 2.22 (m,
1H), 1.66 (m, 2H), 1.52 (s, 3H). .sup.13C NMR (CDCl.sub.3) .delta.
159.2, 151.1, 136.7, 135.8, 128.7, 119.8, 117.4, 114.3, 110.1,
107.7, 55.1, 46.1, 43.1, 43.0, 41.7, 36.4, 17.3.
[0293]
2,9-Dimethyl-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]non-3-ene
(8a,b). A solution of 300 mg (1.17 mmol) of 7 in 6 mL of 85%
H.sub.3PO.sub.4/HCO2H (1:1) was stirred at room temperature for 72
h. The resulting dark-brown mixture was diluted with water (6 mL)
and cooled in an ice bath while NaOH (25% w/w) was added until pH
8. The aqueous solution was extracted with CHCl.sub.3 (3.times.).
The combined organic layers were washed with aqueous NaHCO.sub.3
and brine and dried over Na.sub.2SO.sub.4. Evaporation of the
solvent gave 270 mg (90%) of crude products 8a and 8b in a ratio of
3:1. The crude products were used directly in the next step without
further purification. .sup.1H NMR (CDCl.sub.3) of the mixture:
.delta. 7.24-6.70 (m, 4H), 6.16 (d, 1H, J=9.2 Hz), 4.34 (d, 1H,
J=7.0 Hz), 4.13 (d, 1H, J=9.1 Hz), 3.80 (s, 3H), 2.80 (s, 3H),
3.10-1.40 (m, 8H), 0.74 (d, 3H, J=8.6 Hz), 0.57 (d, 3H, J=8.1
Hz).
[0294]
2,9.beta.-Dimethyl-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonane
(9). A solution of 270 mg (1.05 mmol) of 8a and 8b mixture and
acetic acid (1.05 mmol, 0.061 mL) in 5 mL of dichloroethane was
treated with NaBH(OAc).sub.3 under N.sub.2 atmosphere. The reaction
was stirred at room temperature for 2 h. The reaction was quenched
by adding 10% NaOH to pH.about.10. The mixture was extracted with
ether (3.times.), washed with water and brine. The organic phase
was dried over Na.sub.2SO.sub.4 and concentrated under reduced
pressure. Isolation of the major isomer by chromatography (1%
Et.sub.3N/EtOAc) gave 135 mg (50%) of 9 as a colorless oil. .sup.1H
NMR (CDCl.sub.3) of 9 .delta. 7.26 (m, 1H), 6.94(m, 2H), 6.70 (m,
1H), 3.80 (s, 3H), 3.05-2.90 (m, 2H), 2.71 (m, 1H), 2.43 (s, 3H),
2.42-2.30 (m, 2H), 2.28-2.15 (m, 1H), 2.00-1.35 (m, 6H), 0.86 (d,
3H, J=8.25 Hz). .sup.13C NMR (CDCl.sub.3) of 9 159.2, 152.0, 128.9,
118.0, 112.3, 109.6, 59.7, 55.1, 51.1, 43.1, 42.5, 40.0, 38.3,
29.1, 25.6, 23.4, 14.8. Anal. (C.sub.17H.sub.25NO): C, H, N.
[0295]
2,9.beta.-Dimethyl-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonane
(5b). Compound 9 was treated with 4 mL of glacial acetic acid and 4
mL of 48% aqueous hydrobromic acid at reflux temperature for 20 h.
The reaction was cooled to room temperature and diluted with 10 mL
of water. The pH was adjusted to 10 by using 50% NaOH with ice
cooling. The product was extracted into a mixture of 3:1
1-butanol/toluene, dried over Na.sub.2SO.sub.4, and concentrated
under reduced pressure. Separation by chromatography [50% (80%
CHCl.sub.3, 18% MeOH, 2% NH.sub.4OH) in chloroform] provided 199 mg
(84%) of 5b as a white solid. .sup.1H NMR (CDCl.sub.3) .delta. 7.15
(m, 1H), 6.87-6.75 (m, 2H), 6.61 (m, 1H), 3.10-2.90 (m, 2H), 2.77
(m, 1H), 2.44 (s, 3H), 2.50-2.30 (m, 2H), 2.25-2.10 (m, 1H),
2.00-1.60 (m, 5H), 1.60-1.40 (m, 1H), 0.80 (d, 3H, J=8.3 Hz).
.sup.13C NMR (CDCl.sub.3) .delta. 155.9. The hydrochloride salt was
prepared and crystallized from ether/methanol using 1N HCl in ethyl
ether. 152.0, 129.1, 117.5, 113.0, 112.4, 59.7, 51.0, 43.0, 42.0,
40.2, 38.0, 29.0, 25.6, 23.2, 14.6. The structure of this compound
was determined by single crystal X-ray analysis. Anal.
(C.sub.16H.sub.24ClNO): C, H, N.
[0296] 5-(3-Hydroxyphenyl)-9.beta.-methyl-2-azabicyclo[3.3.1]nonane
(1-0). A solution of 200 mg (1.28 mmol) of phenyl chloroformate was
added dropwise to 300 mg (1.16 mmol) of 9 in 10 mL of
dichloromethane at room temperature under a nitrogen atmosphere.
The reaction was heated to reflux for 6 h. Since the reaction was
not complete by TLC, the solvent was then changed to dichloroethane
and the reflux was continued for another 12 h. The mixture was
cooled to room temperature and concentrated under reduced pressure.
The resulting oil was treated with 10 mL of 1N NaOH and stirred
with slight warming for 15 min. The product carbamate was then
extracted with ether, and the ether layer was washed with 1N HCl
and water. The organic phase was dried over Na.sup.2SO.sub.4 and
concentrated under reduced pressure. The residue was then treated
with 5 mL of ethanol and 1.5 mL of 50% aqueous KOH at reflux for 70
h. The mixture was cooled and concentrated under reduced pressure.
The resulting concentrate was extracted with ether (2.times.), and
the ether layers were concentrated in vacuo. The resulting oil was
dissolved into 10 mL of 1 N HCl and washed with ether. The aqueous
layer was then made strongly basic (pH>12) with 50% NaOH with
ice cooling. The desired amine was extracted into ether (2.times.),
and the ether extracts were washed, dried over Na.sub.2SO.sub.4,
and concentrated under reduced pressure to give 207 mg (70%) of a
light yellow oil. This was treated with 4 mL of glacial acetic acid
and 4 mL of 48% aqueous hydrobromic acid at reflux temperature for
20 h. The reaction was cooled to room temperature and diluted with
10 mL of water. The pH was adjusted to 10 by using 50% NaOH with
ice cooling. The product was extracted into a mixture of 3:1
1-butanol/toluene, dried over Na.sub.2SO.sub.4, and concentrated
under reduced pressure to yield 100 mg (51%) of 10 as a semisolid.
The crude product 10 was used directly in the next step without
further purification. .sup.1H NMR (CD.sub.3OD) .delta. 7.15 (m,
1H), 6.79-6.75 (m, 2H), 6.65 (m, 1H), 3.70-3.30 (m, 3H), 2.70 (m,
1H), 2.45-1.70 (m, 8H), 0.87 (d, 3H, J=8.3 Hz).
[0297]
5-(3-Hydroxyphenyl)-9.beta.-methyl-2-(2'-phenylethyl)-2-azabicyclo[-
3.3.1]nonane (5c). To a solution of 100 mg (0.43 mmol) of 10 and
190 mg (0.43 mmol) of BOP reagent and 0.19 mL (1.38 mmol) of
triethylamine in 15 mL of THF was added phenylacetic acid (70.25
mg, 0.52 mmol). The mixture was stirred at room temperature for 1
h. The reaction was diluted with 45 mL of water and ether (45 mL).
The aqueous layer was extracted with ether (2.times.). The combined
ether layers were washed with NaHCO.sub.3 and brine, and dried over
Na.sub.2SO.sub.4. Evaporation of solvent provided the crude product
as a colorless oil. The crude amide Was dissolved in THF (8 mL).
The solution was cooled to 0.degree. C., and borane: methyl sulfide
complex (0.4 mL, 0.8 mmol) was added dropwise. After vigorous
reaction ceased, the resulting mixture was slowly heated to reflux
and maintained at that temperature for 4 h. The reaction mixture
was cooled to 0.degree. C., 6 mL of methanol was added, and the
mixture was stirred for 1 h. Anhydrous hydrogen chloride in ether
(1 mL) was added to attain a pH<2, and the resulting mixture was
gently refluxed for 1 h. After the mixture was cooled to room
temperature, methanol was added, and the solvents were removed on a
rotovap. The residue obtained was made basic (pH>12) by adding
25% NaOH and extracted with ether (3.times.). The combined ether
layers were dried over Na.sub.2SO.sub.4 and concentrated under
reduced pressure. Separation by chromatography (1% Et.sub.3N/50%
EtOAc/hexanes) gave 38 mg (71%) of amine 5c as a colorless oil.
.sup.1H NMR (CDCl.sub.3) .delta. 7.30-7.14(m, 6H), 6.85 (m, 2H),
6.63 (m, 1H), 4.71 (br s, 1H), 3.05 (m, 2H), 2.88 (m, 1H), 2.79 (s,
4H), 2.43-2.15 (m, 3H), 1.94-1.65 (m, 5H), 1.65-1.45 (m, 1H), 0.83
(d, 3H, J32 8.2 Hz). .sup.13C NMR (CDCl.sub.3) .delta. 155.7,
152.5, 140.9, 129.1, 128.8, 128.3, 125.9. The hydrochloride salt
was prepared and crystallized from ether/methanol using 1N HCl in
ethyl ether. 117.7, 113.0, 112.4, 57.4, 57.2, 49.5, 42.4, 40.0,
38.7, 34.1, 29.1, 26.2, 23.4, 14.7. Anal. (C.sub.23H.sub.30ClNO):
C, H, N.
[0298] Opioid Binding Assays. Mu binding sites were labeled using
[.sup.3H][D-Ala.sup.2-MePhe.sup.4, Gly-ol.sup.5]enkephalin
([.sup.3H]DAMGO) (2.0 nM, SA=45.5 Ci/mmol), and delta binding sites
were labeled using [.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkephalin
(2.0 nM, SA 47.5 Ci/mmol) using rat brain membranes prepared as
described..sup.9 Kappa-1 binding sites were labeled using
[.sup.3H]U69,593 (2.0 nM, SA=45.5 Ci/mmol) and guinea pig membranes
pretreated with BIT and FIT to deplete the mu and delta binding
sites..sup.8
[0299] [.sup.3H]DAMGO binding proceeded as follows: 12.times.75 mm
polystyrene test tubes were prefilled with 100 .mu.L of the test
drug which was diluted in binding buffer (BB: 10 mM Tris-HCl, pH
7.4, containing 1 mg/mL BSA), followed by 50 .mu.L of BB, and 100
.mu.L of [.sup.3H]DAMGO in a protease inhibitor cocktail (10 mM
Tris-HCl, pH 7.4, which contained bacitracin (1 mg/mL), bestatin
(100 .mu.g/mL), leupeptin (40 .mu.g/mL), and chymostatin (20
.mu.g/mL). Incubations were initiated by the addition of 750 .mu.L
of the prepared membrane preparation containing 0.2 mg/mL of
protein and proceeded for 4 to 6 h at 25.degree. C. The ligand was
displaced by 10 concentrations of test drug, in triplicate,
2.times.. Nonspecific binding was determined using 20 .mu.M
levallorphan. Under these conditions, the K.sup.d of [.sup.3H]DAMGO
binding was 4.35 nM. Brandel cell harvesters were used to filter
the samples over Whatman GF/B filters, which were presoaked in
wash-buffer (ice-cold 10 mM Tris-HCl, pH 7.4).
[0300] [.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkephalin binding
proceeded as follows: 12.times.75 mm polystyrene test tubes were
prefilled with 100 .mu.L of the test drug which was diluted in BB,
followed by 100 .mu.L of a salt solution containing choline
chloride (1 M, final concentration of 100 mM), MnCl.sub.12 (30 mM,
final concentration of 3.0 mM), and, to block mu sites, DAMGO (1000
nM, final concentration of 100 nM), followed by 50 .mu.L of
[.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkephalin in the protease
inhibitor cocktail. Incubations were initiated by the addition of
750 .mu.L of the prepared membrane preparation containing 0.41
mg/mL of protein and proceeded for 4 to 6 h at 25.degree. C. The
ligand was displaced by 10 concentrations of test drug, in
triplicate, 2.times.. Nonspecific binding was determined using 20
.mu.M levallorphan. Under these conditions the K.sub.d of
[.sup.3H][D-Ala.sup.2,D-Leu.sup.5]enkepha- lin binding was 2.95 nM.
Brandel cell harvesters were used to filter the samples over
Whatman GF/B filters, which were presoaked in wash buffer (ice-cold
10 mM Tris-HCl, pH 7.4).
[0301] [.sup.3H]U69,593 binding proceeded as follows: 12.times.75
mm polystyrene test tubes were prefilled with 100 .mu.L of the test
drug which was diluted in BB, followed by 50 .mu.L of BB, followed
by 100 .mu.L of [.sup.3H]U69,593 in the standard protease inhibitor
cocktail with the addition of captopril (1 mg/mL in 0.1N acetic
acid containing 10 mM 2-mercapto-ethanol to give a final
concentration of 1 .mu.g/mL). Incubations were initiated by the
addition of 750 .mu.L of the prepared membrane preparation
containing 0.4 mg/mL of protein and proceeded for 4 to 6 h at
25.degree. C. The ligand was displaced by 10 concentrations of test
drug, in triplicate, 2.times.. Nonspecific binding was determined
using 1 .mu.M U69,593. Under these conditions the K.sub.d of
[.sup.3H]U69,593 binding was 3.75 nM. Brandel cell harvesters were
used to filter the samples over Whatman GF/B filters, which were
presoaked in wash buffer (ice-cold 10 mM Tris-HCl, pH 7.4)
containing 1% PEI.
[0302] For all three assays, the filtration step proceeded as
follows: 4 mL of the wash buffer was added to the tubes, rapidly
filtered and was followed by two additional wash cycles. The
tritium retained on the filters was counted, after an overnight
extraction into ICN Cytoscint cocktail, in a Taurus beta counter at
44% efficiency.
[0303] [.sup.35S]-GTP.gamma.S Binding Assay. Ten frozen guinea pig
brains (Harlan Bioproducts for Science, Inc, Indianapolis, Ind.)
were thawed, and the caudate putamen were dissected and homogenized
in buffer A (3 mL/caudate) (Buffer A 10 mM Tris-HCl, pH 7.4 at
4.degree. C. containing 4 .mu.g/mL leupeptin, 2 .mu.g/mL
chymostatin, 10 .mu.g/mL bestatin, and 100 .mu.g/mL bacitracin)
using a polytron (Brinkman) at setting 6 until a uniform suspension
was achieved. The homogenate was centrifuged at 30,000.times.g for
10 min at 4.degree. C. and the supernatant discarded. The membrane
pellets were washed by resuspension and centrifugation twice more
with fresh buffer A, aliquotted into microfuge tubes, and
centrifuged in a Tomy refrigerated microfuge (model MTX 150) at
maximum speed for 10 min. The supernatants were discarded, and the
pellets were stored at -80.degree. C. until assayed.
[0304] For the [.sup.35S]GTP.gamma.S binding assay, all drug
dilutions were made up in buffer B [50 mM TRIS-HCl, pH 7.7/0.1%
BSA]. Briefly, 12.times.75 mm polystyrene test tubes received the
following additions: (a) 50 .mu.L buffer B with or without an
agonist, (b) 50 .mu.L buffer B with or without 60 .mu.M GTP.gamma.S
for nonspecific binding, (c) 50 .mu.L buffer B with or without an
antagonist, (d) 50 .mu.L salt solution which contained in buffer B
0.3 nM [.sup.35S]GTP.gamma.S, 600 mM NaCl, 600 .mu.M GDP, 6 mM
dithiothreitol, 30 mM MgCl.sub.2, and 6 mM EDTA, and (e) 100 .mu.L
membranes in buffer B to give a final concentration of 10 .mu.g per
tube. The final concentration of the reagents were 100 mM NaCl, 5
mM MgCl.sub.2, 1 mM EDTA, 1 mM dithiothreitol, 100 .mu.M GDP, 0.1%
BSA, 0.05-0.1 nM [.sup.35S]GTP.gamma.S, 500 nM or 10 .mu.M
agonists, and varying concentrations (at least 10different
concentrations) of antagonists. The reaction was initiated by the
addition of membranes and terminated after 4 h by addition of 3 mL
ice-cold (4.degree. C.) purified water (Milli-Q uv-Plus, Millipore)
followed by rapid vacuum filtration through Whatman GF/B filters
presoaked in purified water. The filters were then washed once with
5 mL ice-cold water. Bound radioactivity was counted by liquid
scintillation spectroscopy using a Taurus (Micromedic) liquid
scintillation counter at 98% efficiency after an overnight
extraction in 5 mL Cytoscint scintillation fluid. Nonspecific
binding was determined in the presence of 10 .mu.M GTP.gamma.S.
Assays were performed in triplicate, and each experiment was
performed at least 3.times..
[0305] Data Analysis. The data of the two separate experiments
(opioid binding assays) or three experiments
([.sup.35S]-GTP.gamma.S assay) were pooled and fit, using the
nonlinear least-squares curve-fitting language MLAB-PC (Civilized
Software, Bethesda, Md.), to the two-parameter logistic
equation.sup.10 for the best-fit estimates of the IC.sub.50 and
slope factor. The K.sub.i values were then determined using the
equation: IC.sub.50/1+([L]/K.sub.d).
[0306] Single-Crystal X-Ray Analysis of 5b. Crystals of 5b were
grown from ethyl ether/methanol. Data were collected on a
computer-controlled automatic diffractometer, Siemens P4, with a
graphite monochromator on the incident beam. Data were corrected
for Lorentz and polarization effects, and a face-indexed absorption
correction was applied. The structure was solved by direct methods
with the aid of program SHELXS.sup.11 and refined by full-matrix
least-squares on F2 values using program SHELXL..sup.11 The
parameters refined included the coordinates and anisotropic thermal
parameters for all nonhydrogen atoms. Hydrogen atoms on carbons
were included using a riding model in which the coordinate shifts
of their covalently bonded atoms were applied to the attached
hyrdogens with C--H=0.96 .ANG.. H angles were idealized and Uiso(H)
set at fixed ratios of Uiso values of bonded atoms. Coordinates
were refined for H atoms bonded to nitrogen and oxygen. Additional
experimental and structural analysis including an ORTEP figure,
tables of atomic coordinates, bond lengths, and angles are
available as supplementary material. Atomic coordinates are also
available from the Cambridge Crystallographic Data Centre
(Cambridge University Chemical Laboratory, Cambridge CB2 1EW,
UK).
REFERENCES
[0307] (I) Evans, D. A.; Mitch, C. H.; Thomas, R. C.; Zimmerman, D.
M.; Robey, R. L. Application of metalated enamines to alkaloid
synthesis. An expedient approach to the synthesis of morphine-based
analgesics. J. Am. Chem. Soc. 1980, 102, 5955-5956. WARNING: read
the background information relating to analogs of MPTP including
refferences for Zimmerman et al., J. Med. Chem. 1986, 29, 1517-1520
and references cited in reference 2.
[0308] (2) Zimmerman, D. M.; Leander, J. D.; Cantrell, B. E.; Reel,
J. K.; Snoddy, J.; Mendelsohn, L. G.; Johnson, B. G.; Mitch, C. H.
Structure-activity relationships of the
trans-3,4-dimethyl-4-(3Hydroxyphe- nyl)piperidine antagonists for
.mu. and .kappa. opioid receptors. J. Med. Chem. 1993,36(20),
2833-2841.
[0309] (3) Thomas, J. B.; Mascarella, S. W.; Rothman, R. B.;
Partilla, J. S.; Xu, H.; McCullough, K. B.; Dersch, C. M.;
Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Investigation of
the N-substituent conformation governing potency and .mu. receptor
subtype-selectivity in
(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid
antagonists. J. Med. Chem. 1998, 41(11), 1980-1990.
[0310] (4) Xu, H.; Lu, Y. -F.; Partilla, J. S.; Brine, G. A.;
Carroll, F. I.; Rice, K. C.; Lai, J.; Porreca, F.; Rothman, R. B.
Opioid peptide receptor studies. 6. The 3-methylfentanyl congeners
RTI-4614-4 and its enantiomers differ in efficacy, potency, and
intrinsic efficacy as measured by stimulation of
[.sup.35S]GTP-.gamma.-S binding using cloned .mu.-opioid receptors.
Analgesia 1997, 3, 35-42.
[0311] (5) Aldrich, J. V. Analgesics. In Burger's Medicinal
Chemistry and Drug Discovery, Wolff, M. E. Eds.; John Wiley &
Sons, Inc.: 1996; Vol. 3: Therapeutic Agents.
[0312] (6) Casy, A. F.; Dewar, G. H.; Al-Deeb, O. A. A.
Stereochemical influences upon the opioid ligand activities of
4-alkyl-4-arylpiperidine derivatives. Chirality 1989, 1,
202-208.
[0313] (7) Casy, A. F.; Dewar, G. H.; Al-Deeb, O. A. A.
Stereochemical studies of the 4-alkyl-4-arylpiperidine class of
opioid ligand. Magn. Reson. Chem. 1989, 27, 964-972.
[0314] (8') Rothman, R. B.; Bykov, V.; de Costa, B. R.; Jacobson,
A. E.; Rice, K. C.; Brady, L. S. Interaction of endogenous opioid
peptides and other drugs with four kappa opioid binding sites in
guinea pig brain. Peptides 1990, 11, 311-331.
[0315] (9) Rothman, R. B.; Xu, H.; Seggel, M.; Jacobson, A. E.;
Rice, K. C.; Brine, G. A.; Carroll, F. I. RTI-4614-4: an analog of
(+)cis-3-methylfentanyl with a 27,000-fold binding selectivity for
mu versus delta opioid binding sites. Life Sci. 1991, 48,
PL111-PL-116.
[0316] (10). Rodbard, D.; Lenox, R. H.; Wray, H. L.; Ramseth, D.
Statistical characterization of the random errors in the
radioimmunoassay dose-response variable. Clin. Chem. 1976, 22,
350-358.
[0317] (11) SHELXTL-Plus, Release 5.03, Sheldrick, G. M., Siemens
Analytical X-ray Instruments, Inc., Madison, Wis., 1995.
10TABLE 9 Radioligand Binding Results at the Mu, Delta, and Kappa
Opioid Receptors for N-Methyl- and
N-Phenethyl-9p-methyl-5-(3-hydroxyphenyl)morphans Ki (nM .+-. SD)
.mu. .delta. .kappa. Compd [.sup.3H]DAMGO.sup.a
[.sup.3H]DADLE.sup.b [.sup.3H]U69,593.sup.c 5b 166 .+-. 15
>10,000 816 .+-. 66 5c 3.11 .+-. 0.21 .sup. 272 .+-. 30 14.5
.+-. 0.99 1b, naltrexone 1.39 .+-. 0.40 .sup. 94.9 .+-. 6.6 4.71
.+-. 0.7 .sup.a[.sup.3H]DAMGO
[(D-Ala.sup.2,MePhe.sup.4,Gly-ol.sup.5)enkephalin]. Tritiated
ligand selective for mu opioid receptor. .sup.b[.sup.3H]DADLE
[(D-Ala.sup.2,D-Leu.sup.5)enkephalin]. Tritiated ligand selective
for delta opioid receptor. .sup.c[.sup.3H]U69,593
{[.sup.3H](5.alpha.,7.alpha.,8.beta.)-(-)-N-methyl-N-[7-(1-pyrrolidinyl)--
1-oxaspiro[4,5]dec-8-yl]benzeneacetamide}. Tritiated ligand
selective for kappa opioid receptor.
[0318]
11TABLE 10 Affinities of the
N-Substituted-3,4-dimethyl-(3'-hydroxyphenyl)piperidine Antagonists
for the Mu and Kappa Opioid Receptors.sup.a Ki (nM) .mu. .kappa.
Compd [.sup.3H]Nal.sup.b [.sup.3H]EKC.sup.c 4a 80 833 4b 1.5 52 1b,
naltrexone 0.56 3.9 .sup.aData taken from reference 2.
.sup.b[.sup.3H]Naloxone (.mu. receptor assay).
.sup.c[.sup.3H]Ethylketocyclazocine (.kappa. receptor assay).
[0319]
12TABLE 11 Inhibition by Antagonists of [.sup.35S]GTP.gamma.S
Binding in Guinea Pig Caudate Stimulated by DAMGO (mu), SNC80
(delta), and U69,593 (kappa) Selective Opioid Agonists.sup.a Ki (nM
.+-. SD) .mu. .delta. .kappa. Compd (DAMGO).sup.a (SNC80).sup.b
(U69,593).sup.c 5b 21.2 .+-. 2.30 750 .+-. 85.9 105 .+-. 10.9 5c
0.338 .+-. 0.028 12.6 .+-. 1.01 1.34 .+-. 0.084 1b, naltrexone
0.930 .+-. 0.21 19.3 .+-. 2.25 2.05 .+-. 0.21 .sup.aDAMGO
[(D-Ala.sup.2,MePhe.sup.4,Gly-ol.sup.5)enkephalin]. Agonist
selective for mu opioid receptor. .sup.bSNC-80
([(+)-4-[(.alpha.R)-.alpha.-(2S,-
5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzam-
ide). Agonist selective for delta opioid receptor. Agonist
selective for delta opioid receptor. .sup.cU69,593
(trans-3,4-dichloro-N-methyl-
[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide). Agonist selective
for kappa opioid receptor.
[0320] Appendix
13 Elemental Analysis Calcd. Found Compd C H N C H N 9
C.sub.17H.sub.25NO 78.72 9.71 5.40 78.79 9.75 5.34 5b
C.sub.16H.sub.24ClNO 68.19 8.53 4.91 68.25 8.53 5.03 5c
C.sub.23H.sub.30ClNO 74.27 8.13 3.77 74.16 8.12 3.71
[0321] X-Ray Crystallographic Data and Analysis for Compound 5b
14TABLE S1 Crystal data and structure refinement for 5b. Empirical
formula C.sub.16H.sub.24ClNO Formula weight 281.81 Temperature
293(2) K Wavelength 1.54178 .ANG. Crystal system Monoclinic Space
group P2(1)/c Unit cell dimensions a = 14.183(1) .ANG. .alpha. =
90.degree.. b = 9.996(1) .ANG. .beta. = 90.33(2).degree.. c =
11.126(1) .ANG. .gamma. = 90.degree.. Volume 1577.5(2) .ANG..sup.3
Z 4 Density (calculated) 1.187 Mg/m.sup.3 Absorption coefficient
2.072 mm.sup.-1 F(000) 608 Crystal size 0.40 .times. 0.26 .times.
0.24 mm.sup.3 Theta range 3.12 to 57.49.degree.. for data
collection Index ranges -15 <= h <= 3, -10 <= k <= 1,
-12 <= l <= 12 Reflections collected 2651 Independent 2154
[R(int) = 0.0312] reflections Absorption correction Integration
Max. and min. 0.6449 and 0.5284 transmission Refinement method
Full-matrix least-squares on F.sup.2 Data/restraints/ 2153/0/180
parameters Goodness-of-fit on F.sup.2 1.047 Final R indices R1 =
0.0472, wR2 = 0.1367 [I > 2sigma(I)] R indices (all data) R1 =
0.0598, wR2 = 0.1493 Largest diff. 0.213 and -0.228 e..ANG..sup.-3
peak and hole
[0322]
15TABLE S2 Atomic coordinates (.times. 10.sup.4) and equivalent
isotropic displacement parameters (.ANG..sup.2 .times. 10.sup.3)
for 5b. U(eq) is defined as one third of the trace of the
orthogonalized U.sup.ij tensor. x y z U(eq) Cl(1) 6176(1) 534(1)
8837(1) 56(1) C(1) 6136(2) -4826(3) 7545(2) 44(1) N(2) 6354(2)
-5819(2) 6563(2) 45(1) C(2) 5733(3) -7019(3) 6587(3) 64(1) C(3)
7374(2) -6184(3) 6510(3) 54(1) C(4) 8010(2) -4963(3) 6522(3) 49(1)
C(5) 7760(2) -3857(3) 7430(2) 40(1) C(6) 7948(2) -4300(3) 8752(2)
48(1) C(7) 7345(2) -5466(3) 9198(3) 58(1) C(8) 6319(2) -5367(3)
8813(2) 56(1) C(9) 6690(2) -3545(2) 7321(2) 39(1) C(9A) 6394(2)
-2839(3) 6157(2) 48(1) C(10) 8344(2) -2595(3) 7206(2) 43(1) C(11)
8071(2) -1398(3) 7730(3) 49(1) O(12) 8256(2) 962(2) 8052(3) 79(1)
C(12) 8549(2) -214(3) 7554(3) 56(1) C(13) 9351(2) -206(4) 6853(3)
68(1) C(14) 9646(2) -1386(4) 6351(3) 72(1) C(15) 9160(2) -2568(3)
6503(3) 60(1)
[0323]
16TABLE S3 Bond lengths [.ANG.] and angles [.degree.] for 5b.
C(1)--N(2) 1.509(3) C(1)--C(9) 1.524(4) C(1)--C(8) 1.532(4)
N(2)--C(2) 1.488(4) N(2)--C(3) 1.494(4) C(3)--C(4) 1.517(4)
C(4)--C(5) 1.540(4) C(5)--C(10) 1.530(4) C(5)--C(9) 1.553(3)
C(5)--C(6) 1.558(4) C(6)--C(7) 1.530(4) C(7)--C(8) 1.518(4)
C(9)--C(9A) 1.533(3) C(10)--C(11) 1.387(4) C(10)--C(15) 1.401(4)
C(11)--C(12) 1.378(4) O(12)--C(12) 1.365(4) C(12)--C(13) 1.383(5)
C(13)--C(14) 1.371(5) C(14)--C(15) 1.379(5) N(2)--C(1)--C(9)
109.1(2) N(2)--C(1)--C(8) 113.6(2) C(9)--C(1)--C(8) 111.2(2)
C(2)--N(2)--C(3) 112.2(2) C(2)--N(2)--C(1) 113.1(2)
C(3)--N(2)--C(1) 113.1(2) N(2)--C(3)--C(4) 112.3(2)
C(3)--C(4)--C(5) 116.4(2) C(10)--C(5)--C(4) 111.0(2)
C(10)--C(5)--C(9) 110.5(2) C(4)--C(5)--C(9) 108.8(2)
C(10)--C(5)--C(6) 107.4(2) C(4)--C(5)--C(6) 112.1(2)
C(9)--C(5)--C(6) 107.0(2) C(7)--C(6)--C(5) 115.5(2)
C(8)--C(7)--C(6) 113.3(2) C(7)--C(8)--C(1) 116.1(2)
C(1)--C(9)--C(9A) 112.7(2) C(1)--C(9)--C(5) 108.9(2)
C(9A)--C(9)--C(5) 114.9(2) C(11)--C(10)--C(15) 116.8(3)
C(11)--C(10)--C(5) 119.4(2) C(15)--C(10)--C(5) 123.8(2)
C(12)--C(11)--C(10) 122.9(3) O(12)--C(12)--C(11) 122.1(3)
O(12)--C(12)--C(13) 118.5(3) C(11)--C(12)--C(13) 119.4(3)
C(14)--C(13)--C(12) 118.6(3) C(13)--C(14)--C(15) 122.2(3)
C(14)--C(15)--C(10) 120.0(3)
[0324]
17TABLE S4 Anisotropic displacement parameters (.ANG..sup.2 .times.
10.sup.3)for 5b. The anisotropic displacement factor exponent takes
the form: -2.pi..sup.2[h.sup.2a*.sup.2U.sup.- 11 + . . . + 2 h k a*
b* U.sup.12] U.sup.11 U.sup.22 U.sup.33 U.sup.23 U.sup.13 U.sup.12
Cl(1) 62(1) 59(1) 48(1) 3(1) -5(1) 10(1) C(1) 47(2) 39(2) 45(2)
1(1) -1(1) -1(1) N(2) 58(2) 34(1) 43(1) 3(1) -7(1) -4(1) C(2) 88(2)
42(2) 62(2) 5(2) -8(2) -21(2) C(3) 67(2) 44(2) 52(2) -7(1) -4(1)
11(2) C(4) 52(2) 47(2) 50(2) -7(1) -1(1) 9(1) C(5) 41(1) 36(1)
42(1) -2(1) -2(1) 5(1) C(6) 50(2) 48(2) 45(2) -1(1) -9(1) 7(1) C(7)
80(2) 51(2) 43(2) 8(1) -8(2) -2(2) C(8) 70(2) 53(2) 45(2) 4(1) 4(1)
-16(2) C(9) 39(1) 35(1) 42(1) 0(1) -1(1) -1(1) C(9A) 50(2) 40(2)
56(2) 6(1) -8(1) 1(1) C(10) 36(1) 48(2) 45(2) 2(1) -2(1) -2(1)
C(11) 41(2) 44(2) 62(2) -3(1) 4(1) -4(1) O(12) 73(2) 40(1) 124(2)
-6(1) 8(2) -10(1) C(12) 48(2) 49(2) 69(2) 2(2) -8(2) -8(1) C(13)
54(2) 65(2) 85(2) 7(2) -2(2) -22(2) C(14) 44(2) 92(3) 83(2) -1(2)
14(2) -19(2) C(15) 45(2) 68(2) 68(2) -9(2) 5(2) -2(2)
[0325]
18TABLE S5 Hydrogen coordinates (.times. 10.sup.4) and isotropic
displacement parameters (.ANG..sup.2 .times. 10.sup.3) for 5b. x y
z U(eq) H(1A) 5464(2) -4606(3) 7484(2) 52 H(2) 6227(18) -5389(28)
5805(27) 48(8) H(2A) 5086(3) -6741(3) 6621(3) 97 H(2B) 5881(3)
-7550(3) 7282(3) 97 H(2C) 5832(3) -7540(3) 5874(3) 97 H(3A) 7489(2)
-6694(3) 5783(3) 65 H(3B) 7531(2) -6749(3) 7191(3) 65 H(4A) 8004(2)
-4574(3) 5723(3) 59 H(4B) 8649(2) -5258(3) 6687(3) 59 H(6A) 8607(2)
-4549(3) 8829(2) 57 H(6B) 7843(2) -3538(3) 9274(2) 57 H(7A) 7605(2)
-6297(3) 8894(3) 70 H(7B) 7378(2) -5497(3) 10069(3) 70 H(8A)
5994(2) -4795(3) 9381(2) 67 H(8B) 6040(2) -6250(3) 8870(2) 67 H(9A)
6538(2) -2934(2) 7981(2) 46 H(9AA) 6762(2) -2041(3) 6057(2) 73
H(9AB) 5738(2) -2608(3) 6196(2) 73 H(9AC) 6496(2) -3425(3) 5487(2)
73 H(11A) 7544(2) -1394(3) 8222(3) 59 H(12) 7646(36) 906(46)
8364(40) 110(15) H(13A) 9683(2) 583(4) 6724(3) 82 H(14A) 10192(2)
-1389(4) 5893(3) 87 H(15A) 9374(2) -3347(3) 6139(3) 72
[0326] This Example is described in Thomas et al, J. Med. Chem., V.
41, No. 21, 4143-4149 (1998) incorporated herein by reference,
inclusive of the "Supporting Information Available" described at p.
4149.
Example 5
Synthesis of 9.beta.-methyl-2-alkyl-7-oxo-5-arylmorphans
[0327] Summary
[0328] A convergent synthetic-approach to
9.beta.-methyl-2-alkyl-7-oxo-5-a- rylmorphans has been developed
utilizing alkylation of the metalloenamine of
1,2,3,6-tetrahydro-4-aryl-1-alkylpyridines with
2-(chloromethyl)-3,5-dioxahex-1-ene (Okahara's reagent).
[0329] Chemistry
[0330] Thus, treatment of the lithium salt of 15a with 18 provided
16a (not isolated) which cyclized on acidification with
hydrochloric acid in tetrahydrofuran to give a 10:1 mixture of 17a
and 17d as determined by .sup.1H NMR analysis (FIG. 16). Separation
by silica gel chromatography provided 43% of 17a. Proton
assignments were made using a combination of HMQC, HMBC, and, COSY.
The 9.beta. stereochemical assignments for 17a were made using
NOESY techniques. In particular, the axial 9.beta.-methyl group was
observed to show an NOE interaction with the 4.beta.
proton..sup.1
[0331] To expand this method to the ring unsubstituted derivatives
and to explore potential limitations of the chemistry, compounds
17b (47%) and 17c (42%) were also prepared. It was shown earlier
that differences in reactivities exist between unsubstituted and
substituted systems, 15b,c and 15a. For example, s-BuLi is needed
to effectively deprotonate 15a as opposed to 15b and 15c which
require only n-BuLi..sup.2 This is a convenient route to the
7-oxo-phenylmorphan derivatives from either substituted or
unsubstituted 4-phenyl-1,2,3,6-tetra-hydropyridines from
intermediates which can be prepared in bulk and stored for long
periods of time.
[0332] In summary, the 9.beta.-methyl-7-oxo-5-arylmorphan 17a can
be prepared in a convergent manner from tetrahydropyridine 15a by
alkylation with 2-(chloromethyl)-3,5-dioxahex-1-ene 18 followed by
cyclization under acidic conditions. This method provides the first
reported access to the 9.beta.-methyl substituted system with good
control of the stereochemistry. Application of the method to 15b
and 15c provides a higher yielding route to the unsubstituted
7-oxo-phenylmorphan ring system and is amenable to large-scale
synthesis.
REFERENCES AND NOTES
[0333] 1. .sup.1H NMR (CDCl.sub.3) .delta. 0.92 (d, 3H,
9-CH.sub.3), 1.76 (d, 1H, H4.alpha.), 2.23 (dd, 1H, H8), 2.33 (s,
3H, NCH.sub.3), 2.37 (dd, 1H, H4.beta.), 2.38 (dd, 1H, H3), 2.43
(d, 1H, H6), 2.50 (q, 1H, H9), 2.62 (d 1H, H6), 2.72 (m, 1H, H3),
2.97 (d, 1H, H8), 3.10 (m, 1H, H1), 3.78 (s, 3H, OCH.sub.3), 6.75
(dd, 1H, ArH), 6.87 (s, 1H, ArH), 6.92 (d, 1H, ArH), 7.25 (dd, 1H,
ArH).
[0334] 2. Barnett, C. J.; Copley-Merriman, C. R.; Maki, J. J. Org.
Chem. 1989, 54,4795-4800.
[0335] Supplementary Information
[0336] Melting points were determined on a Thomas-Hoover capillary
tube apparatus and are not corrected. Elemental analyses were
obtained by Atlantic Microlabs, Inc. and are within .+-.0.4% of the
calculated values. .sup.1H-NMR spectra were determined on a Bruker
WM-250 spectrometer using tetramethylsilane as an internal
standard. Radial chromatography was performed on a Harrison
Research Chromatron model 7924T. All reactions were followed by
thin-layer chromatography using Whatman silica gel 60 TLC plates
and were visualized by WV or by charring using 5% phosphomolybdic
acid in ethanol or by iodine staining. All solvents were reagent
grade. In reactions, tetrahydrofuran and diethyl ether were dried
over sodium benzophenone ketyl and distilled prior to use.
[0337] Note: The choice of piperidone in this synthesis is
important in order to avoid the production of neurotoxic
tetrahydropyridines such as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). It has been
demonstrated that the neurotoxic properties associated with MPTP or
m-methoxy-MPTP are eliminated by any one of the following:
N-substituents larger than methyl, piperidine ring substitution,
and/or aryl substituents larger than methoxy..sup.1-3
[0338]
2,9-Dimethyl-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-7-one
(17a): To a solution of 1500 mg (6.9 mmol) of tetrahydropyridine
15a and TMEDA (2.1 mL, 13.8 mmol) in 30 mL of THF at -42.degree. C.
was added s-BuLi in cyclohexane (1.3 M, 8.9 mmol). After 1 h,
2-(chloromethyl)-3,5-dioxa-1-hexene 18 (1.32 g, 9.7 mmol) was
added, and the color of the solution changed slowly from dark red
to yellow. After being stirred for 1 h at -42.degree. C. and kept 3
h at -23.degree. C., the mixture was allowed to warm to 0.degree.
C. and then quenched with 1N HCl (20 mL). Diethyl ether (20 mL) was
added, and the aqueous layer was extracted with ether (2.times.).
The aqueous layer was adjusted to pH 10 and extracted with diethyl
ether (3.times.). The combined ether layers were washed with water
(10 mL), saturated NaHCO.sub.3, brine, and dried over
Na.sub.2SO.sub.4. Evaporation of solvent afforded 1.31 g
(.about.60%) of crude 16a2. The crude product was used directly in
the next step without further purification. .sup.1H NMR
(CDCl.sub.3) .delta. 7.27 (t, 1H, J=9.6 Hz), 7.02 (m, 2H), 6.72 (m,
1H), 5.83 (s,1H), 4.93 (s, 2H), 3.81 (s, 3H), 3.43 (s, 3H),
2.70-2.40 (m, 8H), 2.52 (s, 3H), 1.61 (s, 3H). A solution of 500 mg
of 16a in 3 mL of 6 M HCl and 25 mL of THF was stirred at room
temperature for 72 h. The resulting brown mixture was neutralized
with 10% NaOH (10 mL) until pH>9. The aqueous solution was
extracted with diethyl ether (3.times.). The combined organic
layers were washed with aqueous NaHCO.sub.3 and brine. The orgarunc
phase was dried over Na.sub.2SO.sub.4 and concentrated under
reduced pressure. The NMR shows that the ratio of 17a to 17d is
about 10:1. Separation by chromatography [10% (80% chloroform, 18%
methanol, 2% NH.sub.4OH)/chloroform] gave 310 mg of 17a as a
colorless oil (43% from 15a). .sup.1H NMR (CDCl.sub.3) .delta. 7.28
(t, 1H, J=9.5 Hz), 6.93 (m, 1H), 6.86 (m, 1H), 6.76 (dd, 1H, J=2.2,
9.7 Hz), 3.81 (s, 3H), 3.13 (m, 1H), 3.0 (d, 1H, J=20.5 Hz), 2.76
(m, 1H), 2.66-2.17 (m, 6H), 2.36 (s, 3H), 1.76 (m, 1H), 0.93 (d,
3H, J=8.2 Hz). .sup.13C NMR (CDCl.sub.3) 210.5, 159.6, 148.7,
129.4, 117.6, 112.2, 110.3, 61.7, 55.9, 55.0, 47.1, 42.8, 41.4,
39.6, 29.5, 13.8. Anal. Calcd. for C.sub.17H.sub.23NO.sub.2:.
Found: C, 76:72; H, 8.62; N, 5.23.
[0339] 2-Ethyl-5-(3-methoxyphenyl)-2-2-azabicyclo[3.3.1]nonan-7-one
(17b): To a solution of 500 mg (2.3 mmol) of tetrahydropyridine 15b
[1] and tetramethylethylene diamine (TMEDA) (0.69 mL, 4.6 mmol) in
15 mL of THF at -42.degree. C. was added n-BuLi in hexanes (2.5M,
2.9 mmol). After 1 h, 2-(chloromethyl)-3,5-dioxa-1-hexene 18 (440
mg, 3.2 mmol) was added, and the color of the solution changed
slowly from dark red to yellow. After being stirred for 1 h at
-42.degree. C. and kept 3 h at -23.degree. C., the mixture was
allowed to warm to 0.degree. C. and then quenched with 1N HCl (10
mL). Diethyl ether. (10 mL) was added, and the aqueous layer was
extracted with ether (2.times.). The aqueous layer was adjusted to
pH 10 and extracted with diethyl ether (3.times.). The combined
ether layers were washed with water (10 mL), saturated NaHCO.sub.3,
brine, and dried over Na.sub.2SO.sub.4. Evaporation of solvent
afforded 510 mg (.about.70%) of crude 16b. The crude product was
used directly in the next step without further purification.
.sup.1H NMR (CDCl.sub.3) .delta. 7.20 (t, 1H, J=9.1 Hz), 6.97 (m,
2H), 6.67 (dd, 1H, J=1.9, 8.4 Hz), 6.03 (d, 1H, J=9.8 Hz), 4.74 (s,
2H), 4.69 (d, 1H, J=9.6 Hz), 3.79 (s, 3H), 3.26 (s, 3H), 2.86 (q,
2H, J=8.6 Hz), 2.80-2.39 (m, 6H), 2.12 (m, 2H), 1.02 (t, 3H, J=8.6
Hz). A solution of 510 mg of 16b in 3 mL of 6 M HCl and 25 mL of
THF was stirred at room temperature for 72 h. The resulting brown
mixture was neutralized with 10% NaOH (10 mL) until pH>9. The
aqueous solution was extracted with diethyl ether (3.times.). The
combined organic layers were washed with aqueous NaHCO.sub.3 and
brine. The organic phase was dried over Na.sub.2SO.sub.4 and
concentrated under reduced pressure. Separation by chromatography
[10% (80% chloroform, 18% methanol, 2% NH.sub.4OH)/chloroform] gave
352 mg (80%, 47% from 15b) of 17b as colorless oil. .sup.1H NMR
(CDCl.sub.3) .delta. 7.28 (t, 1H, J=9.6 Hz), 6.92 (m, 2H), 6.78
(dd, 1H, J=3.0, 9.7 Hz), 3.81 (s, 3H), 3.60 (m, 1H), 2.82 (m, 3H),
2.55 (q, 2H, J 8.6 Hz), 2.44-1.92 (m, 7H), 1.10 (t, 3H, J=8.6 Hz).
.sup.13C NMR (CDCl.sub.3) 209.4, 158.7, 149.0, 128.5, 115.9, 54.1,
52.4, 52.2, 47.4, 44.4, 38.2, 37.6, 37.1, 36.7, 12.7. Anal. Calcd.
for C.sub.17H.sub.23NO.sub.2: C, 74.69; H, 8.48; N, 5.12. Found: C,
74.78; H, 8.60; N, 5.24.
[0340] 2-Benzyl-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-7-one
(17c): 3-Bromoanisole (50.0 g, 0.264 mol) was dissolved in 150 mL
of THF and then chilled to -78.degree. C. n-Butyllithium (1.6M, 175
mL, 0.276 mol) was then added while maintaining the reaction
temperature at -70.degree. C. or below. After complete addition,
the reaction mixture was stirred for an additional 60 min.
1-Benzyl-4-piperidone in 150 mL of THF was then added at such a
rate as to maintain the reaction temperature at -70.degree. C. or
below. The reaction was stirred at -70.degree. C. for an additional
15 min, then the dry ice-acetone bath was removed, and the reaction
was allowed to come to room temperature. Brine (400 mL) was added,
and the organic layer was separated and washed with an additional
300 mL of brine. The organic layer was separated, dried
(K.sub.2CO.sub.3), and concentrated in vacuo. 6N HCl (250 mL) was
added to the oily residue which was then washed with EtOAc. The
aqueous layer was separated, basified with 50% NaOH, and extracted
with EtOAc. The EtOAc layer was separated, dried (K.sub.2CO.sub.3),
and concentrated in vacuo to give 75.7 g of
4-(3-methoxyphenyl)-1-benzyl-4-piperidinol as an orange oil. A
sample was chromatographed on silica gel using hexane/EtOAc (7:3)
mixtures as the eluent to afford a yellow oil which was dissolved
in ether and treated with ethereal hydrochloric acid to give
4-(3-methoxyphenyl)-1-benzyl-4-piperidinol hydrochloride as a white
solid (mp 195-197.degree. C.). .sup.1H NMR (CDCl.sub.3) (free base)
.delta. (ppm) 1.64-1.75 (m, 2H), 2.09-2.21 (m, 2H), 2.41-2.51 (m,
2H), 2.71-2.80 (m, 2H), 3.51 (s, 2H), 3.80 (s, 3H), 6.77-6.81 (m,
1H), 7.06-7.09 (m, 2H), 7.23-7.35 (m, 6H). Anal. Calcd for
C.sub.9H.sub.23NO.sub.2 HCl .smallcircle.1/2 H.sub.2O: C, 66.56; H,
7.06; N, 4.09. Found: C, 66.41; H, 7.31; N, 4.33.
[0341] This material, 4-(3-methoxyphenyl)-1-benzyl-4-piperidinol
(75.7 g, 0.25 mol), was dissolved in 400 mL of toluene, tosic acid
(101.4 g, 0.53 mol) was added, and the mixture was heated under
reflux in a Dean Stark trap for 90 min. The reaction mixture was
cooled to room temperature, and water (400 mL) was added. The
bottom layers were separated, made basic with 5N NaOH, and
extracted with EtOAc. The EtOAc layer was separated, washed with
brine, dried (K.sub.2CO.sub.3), and concentrated in vacuo to give
73.0 g of a red-orange oil. The oil was chromatographed on silica
gel using hexane/EtOAc (4:1) mixtures as the eluent to afford 54.2
g of 1,2,3,6-tetrahydro-4-(3-methoxyphenyl)-1-benzylpyridine 15c
(78%) as an orange oil. A sample of the free base was converted to
its hydrochloride salt (ethereal HCl) to give
1,2,3,6-tetrahydro-4-(3-methoxyphenyl)-1-benz- ylpyridine
hydrochloride as a white solid, (mp 196-196.degree. C.). .sup.1H
NMR (CDCl.sub.3) (free base) .delta. (ppm) 2.54-2.57 (br m, 2H),
2.68-2.73 (m, 2H), 3.14-3.18 (m, 2H), 3.63 (s, 2H), 3.78 (s, 3H),
6.04-6.07 (m, 1H), 6.79 (dd, 1H), 6.91-7.00 (m, 2H), 7.19-7.39 (m,
6H). Anal. Calcd. for
C.sub.19H.sub.21NO.smallcircle.HCl.smallcircle.1/4 H.sub.2O: C,
71.46; H, 6.79; N, 4.39. Found: C, 71.63; H, 6.97; N, 4.42.
[0342] 1,2,3,6-Tetrahydro-4-(3-methoxyphenyl)-1-benzylpyridine 15c
(5.0 g, 0.018 mol) was dissolved in 70 mL of THF and chilled to
-78.degree. C. in a dry ice-acetone bath. N-Butyllithium (1.6M,
12.0 mL, 0.0193 mol) was added to the reaction mixture at a rate
that would maintain the temperature at -70.degree. C. or below.
After complete addition, the reaction was stirred for an additional
15 min, and the dry ice bath was replaced with a salt-ice bath.
When the temperature rose to -15.degree. C.,
2-(chloromethyl)-3,5-dioxahex-1-ene 18 (3.2 g, 0.023 mol) in 40 mL
of THF was added while keeping the reaction temperature at
-10.degree. C. or below and stirring for an additional 15 min at
-15.degree. C. The bath was removed, and the reaction was stirred
at room temperature for an additional 17 h. The reaction was
quenched with 30 mL of brine, the organic layer was separated,
washed with 2.times.100 mL of brine, separated, dried
(K.sub.2CO.sub.3), and concentrated in vacuo to get 6.8 g of an
orange oil. This was dissolved in 100 mL of THF, and 20 mL of 6N
HCl was added. This reaction was stirred at room temperature
overnight. The reaction mixture was neutralized with aqueous
NaHCO.sub.3, added 100 mL of EtOAc, and separated the organic
layer. The organic layer was washed with 10% NaHCO.sub.3, brine,
then separated, dried (K.sub.2CO.sub.3), and concentrated in vacuo
to give 4.8 g of 17c as a red oil. The oil was chromatographed on
silica gel using hexane/EtOAc (65:35) mixtures, as the eluent, to
yield an oil which crystallized upon addition of ether to give 2.5
g (42%) of 5-(3-methoxyphenyl)-2-benzyl-2-a-
zabicyclo-[3.3.1]nonan-7-one 17c as a beige solid (mp
108-109.degree. C.). .sup.1H NMR (CDCl.sub.3) .delta. (ppm)
1.88-1.91 (m, 2H), 2.12-2.21 (m, 2H), 2.31-2.49 (m, 3H), 2.75-2.99
(m, 314), 3.49 (br m, 1H), 3.60-3.72 (q, 2), 3.80 (s, 3H),
6.75-6.80 (m, 1H), 6.88-6.96 (m, 2H), 7.25-7.34 (m, 6H).
.sup.13CNMR (CDCl.sub.3) .delta. 210.4, 159.8, 150.2, 138.7, 129.5,
128.6, 128.3, 127.0, 117.0, 111.3, 111.0, 59.0, 55.2, 53.7, 53.3,
45.5, 39.2, 38.7, 38.0, 37.7. Anal. Calcd. for
C.sub.22H.sub.25NO.sub.2: C, 78.77; H, 7.51; N, 4.18. Found: C,
78.76; H, 7.59; N, 4.20.
REFERENCES
[0343] [1] Zimmerman D M, Cantrell B E, Reel J K, Hemrick-Luecke S
K, Fuller R W. J. Med. Chem. 1986;29:1517-1520.
[0344] [2] Fuller R W. 1986.
[0345] [3] Fries D S, de Vries J, Hazelhoff B, Horn A S. J. Med.
Chem. 1986;29:424.
[0346] [4] Barnett C J, Copley-Merriman C R, Maki J. J. Org. Chem.
1989;54:4795-4800.
[0347] This Example is described in Thomas et al, Tetrahedron
Letters, V. 39, 7001-7004 (1998), incorporated herein by
reference.
Example 6
Selective Delta Opioid Receptor Agonists
[0348] Chemists
[0349] Preparation of 3a,b began with reductive amination of
1,3-dimethyl-4-piperidone with aniline using titanium (IV)
isopropoxide.sup.1 which gave 5a,b as a mixture of cis and trans
diastereomers in 75% yield in a ratio of 70:30 (FIG. 17). These
were separated by column chromatography and carried forward
independently. These intermediates were then coupled to the
butylated hydroxyanisole (BHA) ester of 4-fluorobenzoic acid to
give (6a,b) in 91% and 68% yields..sup.2 Removal of the BHA group
was accomplished by transesterification with refluxing sodium
methoxide in toluene/N-methylpyrrolidinone followed by
saponification of the methyl ester. The zwitterionic intermediates
were isolated as HCl salts and converted directly into
diethylamides using benzotriazol-1-yl-oxy-tris-(d- imethylamino)
phosphonium hexafluorophosphate (BOP a.k.a. Castro's reagent),
diethylamine, and triethylamine in a tetrahydrofuran (THF) slurry
to give 7a and 7b in 90% and 59% yields, respectively. Conversion
to the N-allyl group was accomplished by treating 7a,b with phenyl
chloroformate followed by hydrolysis of the resulting carbamates
with potassium hydroxide in isopropyl alcohol. N-Alkylation with
allyl bromide then gave 3a,b in 40% and 20% yield, respectively.
Stereochemical assignments for 3a were made using NOESY spectra and
vicinal coupling constants. Proton and carbon assignments were made
using a combination of COSY and HETCORR spectra. A large coupling
constant (J=13.0 Hz) between H5 and H4 indicated a diaxial
arrangement between these protons showing that the 4-diarylamine is
in the equatorial position. The NOESY spectrum contained a strong
interaction between 5H-axial and the 3-methyl showing that the
methyl group is also axial. The axial equatorial relationship
between the methyl and the 4-diarylamine group established the cis
relative stereochemistry for 3a.
[0350] Biological Activity
[0351] The binding affinities of the compounds for the .mu.,
.delta., and .kappa. opioid receptors were determined using
competitive binding assays following previously reported
procedures..sup.3 The results are listed in Table 12.
[0352] Results and Discussion
[0353] The radioligand binding data for the compounds 3a,b along
with comparative data for BW373U86 (1) and the two enantiomers of
cis-3-methylfentanyl 4 are shown in Table 12. Compound 3a (the cis
isomer) is more potent and more selective for the .delta. opioid
receptor relative to both the .mu. and .kappa. opioid receptors
than 3b (the trans isomer). This difference in selectivity is due
to a significantly lower affinity of the trans isomer for the
.delta. receptor relative to the .mu. or .kappa. opioid receptors.
The 11.9 nM Ki values for 3a combined with the 1212 nM Ki value at
the .mu. receptor compare favorably to the Ki values for 1
(BW373U86) particularly when one considers that 3a is racemic and
does not possess all the structural features present in 1, namely
the 3'-hydroxy group on the aromatic ring and a methyl group
comparable to the piperazine 2-methyl group.
[0354] A comparison of the binding data of 3a to that of
cis-3-methylfentanyl, particularly the more potent 3R,4S-isomer 4b,
is even more striking than the comparison of 3a to 1. Compound 4b
gave a 3900-fold selectivity for the .mu. receptor relative to the
.delta. receptor, whereas 3a possesses a 102-fold .delta.
selectivity relative to the .mu. receptor. This results from a
sevenfold increase in affinity at the .delta. receptor (11.9 nM vs.
77.3 nM) and a >60,000-fold loss in affinity at the .mu.
receptor. Thus changing the propanamido and phenethyl groups
present in 4b to the 4-diethylcarboamidophenyl and allyl in 3a
converts a highly .mu.-selective fentanyl analog to a
.delta.-selective ligand. It is highly likely that the gain in
.delta.-receptor potency is due to the change of the propanamido
group of 4 to the diethylcarboxamidophenyl group in 3a. The loss is
.mu.-receptor potency may be due to both changes. Regardless of the
reason for the .delta. opioid receptor selectivity, compound 3a
represents a novel ligand for the .delta. opioid receptor.
REFERENCES
[0355] (I) Mattson, R. J.; Pham, K. M.; Leuck, D. J.; Cowen, K. A.
An improved method for reductive alkylation of amines using
titanium(IV) isopropoxide and sodium cyanoborohydride. J. Org.
Chem. 1990, 55, 2552-2554.
[0356] (2) Hattori, T.; Satoh, T.; Miyano, S. Convenient synthesis
of triarylamines via ester-mediated nucleophilic aromatic
substitution. Synthesis 1995, 514-518.
[0357] (3) Thomas, J. B.; Zheng, X.; Mascarella, S. W.; Rothman, R.
B.; Dersch, C. M.; Partilla, J. S.; Flippen-Anderson, J. L.;
George, C. F.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I.
N-Substituted 9.beta.-methyl-5-(3-hydroxyphenyl)morphans are opioid
receptor pure antagonists. J. Med. Chem. 1998,
41(21),4143-4149.
[0358] (4) Xu, H.; Kim, C. -H.; Zhu, Y. C.; Weber, R. J.; Rice, K.
C.; Rothman, R. B. (+)-cis-Methylfentanyl and its analogs bind
pseudoirreversibly to the mu opioid binding site: Evidence for
pseudoallosteric modulation. Neuropharmacology 1991, 30,
455-462.
19TABLE 12 Radioligand Binding Results at the .mu., .delta., and
.kappa. Opioid Receptors for (.+-.)-4-[(N-Allyl-3-met-
hyl-4-piperidinyl)- phenylamino]N,N-diethylbenzamides Ki (nM .+-.
SD) .delta. Compd .mu. [.sub.3H]DAMGOa [.sub.3H]DADLEb .kappa.
[.sub.3H]U69,593c .mu./.delta. 1, BW373U86 36 .+-. 3.4 0.91 .+-.
0.05 NA 40 3a, (.+-.)-cis-isomer 1212 .+-. 132 11.9 .+-. 0.9 3284
.+-. 299 102 3b, (.+-.)-trans-isomer 1589 .+-. 86 126 .+-. 5 8695
.+-. 978 13 4a, (3S,4R)-isomerd 30.6 .+-. 5.13 >1000 NA 0.03 4b,
(3R,4S)-isomerd 0.020 .+-. 0.005 77.3 .+-. 6.7 57.4 .+-. 6.1 0.0003
a[.sub.3H]DAMGO [(D-Ala2,MePhe4,Gly-ol5)enkephalin]. Tritiated
ligand selective for .mu. opioid receptor. b[.sub.3H]DADLE
[(D-Ala2,D-Leu5)enkephalin]. Tritiated ligand selective for .delta.
opioid receptor. c[.sub.3H]U69,593 {[.sub.3H](5.alpha.,7.alpha.,8-
.beta.)-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]benzene-
acetamide}. Tritiated ligand selective for .kappa. opioid receptor.
dData taken from reference 4. In this experiment, .mu. sites were
labeled with [.sub.3H]FOXY
([.sub.3H]6.beta.-fluoro-6-desoxyoxymorphone).
[0359]
20TABLE 13 Elemental Analyses % Calculated % Found Compound (C %, H
%, N %) (C %, H %, N %) Melting point .degree. C. 7a 66.42, 8.36,
9.68 66.20, 8.31, 9.76 193-194 7b 65.73, 8.39, 9.58 65.69, 8.33,
9.62 199-201 3a 69.93, 8.24, 9.41 70.06, 8.30, 9.10 221-225.5 3b
69.93, 8.24, 9.41 69.66, 8.31, 9.31 177-178
[0360] Experimental
[0361] (.+-.)-(3RS,4SR)-4-Phenylamino-1,3-dimethylpiperidine (5a)
and (.+-.)-(2RS,3RS)-4-phenylamino-1,3-dimethylpiperidine (5b):
[0362] 1,3-Dimethyl-4-piperidone (11.77 g, 92.68mmol), aniline (8.5
mL, 93.4 mmol), and titanium isopropoxide (35 mL, 117.7 mmol) were
heated at 55.degree. C. for 20 h under a nitrogen atmosphere. The
reaction mixture was allowed to cool and diluted with ethanol (100
mL). Sodium borohydride (5.0 g, 131.6 mmol) was then added, and the
reduction was allowed to proceed at room temperature for 4 h. The
reaction was quenched by addition of water, filtered over celite,
and the filtrate was washed with ethanol. After evaporation of the
solvent under reduced pressure, the white residue was taken up in
ethyl acetate and again filtered over celite. After evaporation of
the solvent under reduced pressure and chromatography on silica gel
using ethyl acetate in hexanes (20:80), a 70:30 mixture of
diastereomers (5a and 5b) (13.80 g, 73%) was obtained. Further
separation by chromatography using the same system afforded first
5a (8.46 g) as a yellow oil, tentatively assigned a cis relative
stereochemistry, and then 5b (2.04 g) as a white solid. 1H NMR 5a
(CDCl.sub.3) .delta. 0.98 (d, 3H, J=6.9 Hz), 1.671.89 (m, 2H),
2.03-2.58 (m, 4H), 2.18 (s, 3H), 3.413.68 (m, 2H), 6.60 (dd, 2H,
J=0.9 Hz, J=8.6 Hz), 6.67 (dd, 1H, J=0.9 Hz, J=7.3 Hz), 7.15 (t,
2H, J=7.3 Hz). 1H NMR 5b (CDCl.sub.3) .delta. 0.98 (d, 3H, J=6.3
Hz), 1.19-1.48 (m, 1H), 1.58-1.62 (m, 1H), 1.77 (t, 1H, J=11.0 Hz),
1.96-2.15 (m, 2H), 2.27 (s, 3H), 2.78-2.93 (m, 3H), 3.27-3.41 (m,
1H), 6.57 (dd, 2H, J=1.0 Hz, J=8.6 Hz), 6.66 (dd, 1H, J=1.0 Hz,
J=7.3 Hz), 7.12 (t, 2H, J=7.3 Hz).
[0363]
(.+-.)-2,6-Di-tert-butyl-4-methoxyphenyl-4-[N-{(3RS,4SR)--N,3-dimet-
hyl-4-piperidinyl}-phenylamino]benzoate (6a)
[0364] (.+-.)-(3RS,4SR)-4-Phenylamino-1,3-dimethylpiperidine (5a)
(3.41 g, 16.72 mmol) was dissolved in dry tefrahydrofuran (THF, 13
mL) and dry hexamethylphosphoramide (HMPA, 5 mL), and cooled to
-42.degree. C. A 2.5 M solution of n-butyllithium in hexanes (7.7
mL, 19.25 mol) was slowly added, and the reaction mixture was kept
at 0.degree. C. for 1 h. The reaction mixture was cannulated into a
solution of (2,6-di-tert-butyl-4-methoxyphenyl) 4 fluorobenzoate
(6.0 g, 16.76 mmol) in dry THF (13 mL) and dry HMPA (5 mL) at room
temperature then heated to 45-50.degree. C. for 5 h. The reaction
mixture was cooled then quenched with a solution of NH.sub.4Cl and
diluted with ether. The aqueous layer was made basic (pH=14) with
NaOH 25%, extracted with ether (200 mL), and the ethereal layer was
washed with water three times. After drying with MgSO.sub.4 and
evaporation of the solvents under reduced pressure, a crude brown
oil was afforded. Chromatography on silica gel using ethyl acetate
in hexanes (20:80) gave 6a (8.20 g, 91%) as a yellow solid: 1H NMR
(CDCl.sub.3) .delta. 1.21 (d, 3H, J=6.9 Hz), 1.31 (s, 18H),
1.53-1.71 (m, 2H), 1.89-1.97 (m, 1H), 2.04 (s, 3H), 2.03-2.32 (m,
1H), 2.59-2.88 (m, 3H), 3.81 (s, 3H), 4.00-4.06 (m, 1H), 6.58 (d,
2H, J=9.1 Hz), 6.89(s, 2H), 7.22 (d, 2H, J=8.2 Hz), 7.33 (d, 2H,
J=7.2 Hz), 7.41 (t, 1H, J=7.2 Hz), 7.97 (d, 2H, J=9.0 Hz).
[0365] (.+-.)-2,6-Di-tert-butyl-4-methoxyphenyl-4-[N-{(3RS,
4RS)--N,3-dimethyl-4-piperidinyl}phenylamino]benzoate (6b)
[0366] (.+-.)-(2RS,3RS)-4-Phenylamino-1,3-dimethylpiperidine (5b)
(2.65 g, 12.99 mmol) was treated with a 2.5 M solution of
n-butyllithium in hexanes (6 mL, 15 mol) in dry THF (10 mL) and dry
HMPA (4 mL) and coupled with
(2,6-di-tert-butyl-4-methoxyphenyl)-4-fluorobenzoate (4.65 g, 12.99
mmol) in dry THF (10 mL) and dry HMPA (4 mL) as before.
Purification afforded 6b (4.80 g, 68%) as a yellow solid: 1H NMR
(CDCl.sub.3) .delta. 1.07 (d, 3H, J=5.6 Hz), 1.31 (s, 18H),
1.63-2.15 (m, 5H), 2.25 (s, 3H), 2.85-2.97 (m, 2H), 3.68-3.78 (m,
1H), 3.81 (s, 3H), 6.63 (d, 2H, J=9.1 Hz), 6.88 (s, 2H), 7.19 (d,
2H, J=7.1 Hz), 7.33 (t, 1H, J=7.1 Hz), 7.44 (t, 2H, J=7.7 Hz), 7.95
(d, 2H, J=9.1 Hz).
[0367]
(.+-.)-4-[N-{(3RS,4SR)--N,3-Dimethyl-4-piperidinyl}phenylamino]-N-d-
iethylbenzamide (7a)
[0368]
(.+-.)-2,6-Di-tert-butyl-4-methoxyphenyl-4-[N-{(3RS,4SR)--N,3-dimet-
hyl-1 piperidinyl}phenylamino]benzoate (6a) (6.5 g, 11.99 mmol) in
toluene (150 mL) and N-methylpyrrolidinone (NMP, 40 mL) was added
to freshly prepared sodium methoxide (120 mmol) and heated at
reflux for 4 h. After evaporation of the toluene under reduced
pressure, the residue was dissolved in a mixture of MeOH and
H.sub.2O (12:1, 150 mL) and heated at reflux for 1 h. After
evaporation of the alcohol, the residue was taken up in water (400
mL) and extracted with hexanes (2.times.100 mL). The aqueous layer
was made acidic (pH=1) with 10% HCl, saturated with NaCl, and
extracted with a mixture of CH.sub.2Cl.sub.2 and THF (3:1, 5' 200
mL). After drying over Na.sub.2SO.sub.4, the solvents were
evaporated under reduced pressure. This was then treated with
diethylamine (1.2 mL),
benzotriazol-1-yl-oxy-tris-(dimethylamino)phosphonium
hexafluorophosphate (BOP a.k.a. Castro's reagent) (5.0 g, 11.31
mmol)), and triethylamine (4.2 mL) in THF (100 mL) for 30 min. The
reaction mixture was next diluted with ether (300 mL), washed with
water (2.times.75 mL), saturated NaHCO.sub.3 (75 mL), and dried
over Na.sub.2SO.sub.4 providing a black oil following evaporation
of the solvents under reduced pressure. Chromatography on silica
gel using hexanes/ethyl acetate/ethanol/triethyl- amine (60:40:2:2)
afforded 7a (4.10 g, 90%) as a yellow liquid. This was converted to
the hydrochloride salt using 1N HCl in ether. .sup.1H NMR
(CD.sub.3OD) .delta. 1.07-1.38 (m, 12H), 1.421.61 (m, 1H),
1.68-1.92 (m, 1H), 2.86 (s, 3H), 3.033.21 (m, 1H), 3.273.60 (m,
6H), 4.304.48 (m, 1H), 6.80 (d, 2H, J=8.3 Hz), 7.14 (d, 2H, J=7.7
Hz), 7.26 (t, 3H, J=7.5 Hz), 7.40 (t, 2H, J=7.4 Hz); .sup.13C NMR
(CD.sub.3OD) .delta. 12.2, 25.6, 30.4, 44.5, 55.7, 56.0, 60.2,
119.4, 127.4, 128.8, 130.7, 130.8, 146.1, 150.8, 173.8. Anal.
(C.sub.24H.sub.34ClN.sub.3O.H.sub.2O): C, H, N.
[0369]
(.+-.)4-[N-{(3RS,4RS)--N,3-Dimethyl-4-piperidinyl}phenylamino]-N,N--
diethylbenzamide (7b)
[0370]
(.+-.)-2,6-Di-tert-butyl-4-methoxyphenyl-4-[N-{(3RS,4RS)--N,3-dimet-
hyl-4 piperidinyl}phenylamino]benzoate (6b) (7.38 g, 13.62 mmol)
was transesterified with sodium methoxide (135 mmol) in toluene
(150 mL) and NMP (40 mL) and then hydrolyzed with MeOH and H.sub.2O
(12:1, 165 mL) as before. The resulting acid was dissolved in THF
(200 mL) with triethylamine (5 mL), diethylamine (2 mL), and BOP
reagent (6.1 g, 13.80 mmol) as above. Work-up and chromatography on
silica gel as above afforded 7b (3.02 g, 59%) as a yellow liquid.
Conversion to the hydrochloride salt was done with 1 N HCl in
ether. .sup.1H NMR (CD.sub.3OD) .delta. 1.10-1.25 (m, 12H),
1.76-2.28 (s, 3H), 2.99 (t, 1H, J=12.5 Hz), 3.12-3.29 (m, 1H),
3.31-3.58 (m, 7H), 4.12-4.29 (m, 1H), 6.78 (d, 2H, J=8.8 Hz), 7.18
(d, 2H, J=7.3 Hz), 7.22 (d, 2H, J=8.8 Hz), 7.33 (t, 1H, J=7.4 Hz),
7.48 (t, 2H, J=7.5 Hz); .sup.13C NMR (CD.sub.3OD) .delta. 16.1,
29.0, 35.3, 43.8, 55.3, 58.7, 60.7, 116.9, 127.3, 127.8, 129.1,
130.7, 131.2, 144.0, 152.0, 173.9. Anal. (C.sub.24H.sub.34ClN.sub.-
3O.1.25H.sub.2O): C, H, N.
[0371]
(.+-.)-4-[N-{(3RS,4SR)--N-Allyl-3-methyl-4-piperidinyl}phenylamino]-
-N,N-diethyl-benzamide (3a).
[0372]
(.+-.)-4-[N-{(3RS,4SR)--N,3-Dimethyl-4-piperidinyl}phenylamino]-N,N-
-diethyl-benzamide (7a) (4.1 g, 10.82 mmol) was treated with phenyl
chloroformate (1.25 mL, 11.13 mmol) in 1,2-dichloroethane (35 mL)
at room temperature for 24 h. The reaction was quenched with water
and NaOH 30% then extracted with CHCl.sub.3. After drying over
Na.sub.2SO.sub.4 and evaporation of the solvents under reduced
pressure, the crude product was chromatographed on silica gel to
give a mixture of starting material and product which was then
treated with methanol (100 mL), water (60 mL), isopropanol (50 mL),
and NaOH 50% (30 mL) at reflux for 5 h. The alcohols were
evaporated under reduced pressure, and the aqueous layer was
extracted with CHCl.sub.3/THF (3:1). After drying with
Na.sub.2SO.sub.4, the solvents were evaporated under reduced
pressure. Chromatography on silica gel using hexanes/ethyl
acetate/ethanol/triethylamine (50:50:3:3) afforded starting
material (6a), (548 mg, 13%), as a yellow oil followed by the
N-demethylated material (924 mg, 30%) as a yellow oil using
ethanol/triethylamine (80:20) as eluent. The latter material was
dissolved in ethanol (40 mL) and treated with allyl bromide (220
.mu.L, 2.54 mmol) and K.sub.2CO.sub.3 (1.0 g, 7.24 mmol) at room
temperature for 24 h. After evaporation of the ethanol under
reduced pressure, the residue was chromatographed on silica gel
using hexanes/ethyl acetate/ethanol/triethylamine (50:50:3:3) to
give 3a (950 mg, 93%) as a yellow oil. This was converted to the
hydrochloride as previously described: .sup.1H NMR
(.delta..sub.4-MeOH) 1.18 (m, 6H), 1.23 (d, 3H, J=7.4 Hz), 1.54 (d,
1H, J=13.0 Hz), 1.81 (ddd, 1H, J=13.0 Hz, 13.0 Hz, 11.0 Hz), 2.91
(m, 1H), 3.09 (dd, 1H, J=13.0 Hz, 13.0 Hz), 3.44(m, 7H), 3.75 (d,
1H, 7.4 Hz), 4.38 (d, 1H, J=13.5 Hz), 5.59 (d, 1H, J=9.9 Hz), 5.60
(d, 1H, J=17.0 Hz), 6.00 (ddd, 1H, J=17.0 Hz, 17.0 Hz, 7.4 Hz),
6.79 (d, 2H, J=8.5 Hz), 7.14 (d, 2H J=8.0 Hz), 7.23 (d, 2H, J=8.5
Hz), 7.28 (dd, 1H, J=8.0 Hz, 8.0 Hz), 7.40 (dd, 2H, J=8.0 Hz, 8.0
Hz)..sup.13C NMR (d4-MeOH) 11.3, 13.2 (broad), 24.5, 29.3, 45.0
(broad), 52.4, 55.2, 56.7, 59.6, 118.3, 125.9, 126.4, 126.6, 127.7,
129.7, 145.0, 149.8, 172.7. Anal
(C.sub.26H.sub.36ClN.sub.3O.0.25H.sub.2O): C, H, N.
[0373]
(.+-.)-4-[N-{(3RS,4RS)--N-Allyl-3-methyl-4-piperidinyl}phenylamino]-
-N,N-diethyl-benzamide (3b).
[0374]
(.+-.)-4-[N-{(3RS,4RS)--N,3-Dimethyl-4-piperidinyl}phenylamino]-N,N-
-diethyl-benzamide (7b) (502 mg, 1.32 mmol) was treated with phenyl
chloroformate (170 .mu.L, 1.51 mmol) in 1,2-dichloroethane (4 mL)
at room temperature for 24 h. The product was worked-up as above,
and chromatography on silica gel using hexanes/ethyl
acetate/ethanol/triethyl- amine (75:25:1:1) afforded first the
phenylcarbamate as a white solid followed by the starting material
(117 mg, 23%) as a yellow liquid. The carbamate was treated with
methanol (20 mL), water (15 mL), isopropanol (10 mL), and NaOH 50%
(5 mL) and worked-up as above to give the crude N-demthylated
intermediate as a yellow oil. This was dissolved in ethanol (5 mL)
and treated with allyl bromide (100 .mu.L, 1.15 mmol) and
K.sub.2CO.sub.3 (500 mg, 3.62 mmol) for 16 h at room temperature.
Work-up and purification as above afforded 3b (70 mg, 15% overall)
as a yellow oil. This was converted to the hydrochloride salt as
previously described: .sup.1H NMR (CD.sub.3OD) .delta. 1.10-1.26
(m, 9H), 1.741.96 (m, 1H), 1.98-2.29(m, 2H), 2.88-3.01 (m, 1H),
3.10-3.22 (m, 1H), 3.35-3.61 (m, 7H), 3.73 (d, 2H, J=7.3 Hz), 4.20
(dt, 1H, J=3.4 Hz, J=11.5 Hz), 5.55 (s, 1H), 5.61 (d, 1H, J=5.4
Hz), 5.85-6.03 (m, 1H), 6.78 (d, 2H, J=8.8 Hz), 7.19 (d, 2H, J=7.8
Hz), 7.23 (d, 2H, J=8.8 Hz), 7.34 (t, 1H, J=7.4 Hz), 7.51 (t, 2H,
J=7.6 Hz); .sup.13C NMR (CD.sub.3OD) .delta. 11.9, 13.9, 16.2,
28.9, 35.2, 52.9, 58.3, 59.1, 60.1, 117.0, 126.8, 127.6, 127.8,
129.0, 130.7, 131.2, 144.1, 151.8, 173.9. Anal.
(C.sub.26H.sub.36ClN.sub.3O.0.25H.sub.2O): C, H, N.
Example 7
N-alkyl-4.beta.-methyl-5-phenylmorphans
[0375] Summary
[0376] A convergent, highly stereoselective synthetic approach to
N-alkyl-4.beta.-methyl-5-phenylmorphans has been developed
utilizing alkylation of the metalloenamine of
N-alkyl-1,2,3,6-tetrahydro-4-phenylpy- ridines with
2-(chloromethyl)-3,5-dioxahex-1-ene (Okahara's reagent) followed by
Clemmensen reduction.
[0377] Chemistry
[0378] 4.beta.-methyl-(3-hydroxyphenyl)morphans were
stereoselectively synthesized as shown in FIG. 18. Alkylation of
8.sup.1 with 2-(chloromethyl)-3,5-dioxohex-1-ene (Okahara's
reagent).sup.2 followed by hydrolysis of the methoxymethyl
protecting group (FIG. 18) gives enamine 12. In the alkylation
reaction, the methyl group apparently exerts a powerful directing
effect since enamine 12 is the sole product. Cyclization under
acidic conditions occurs regiospecifically on carbon 1
(phenylmorphan numbering) due to the specific migration of the
double bond during the alkylation reaction. Furthermore, since the
oxidation state of carbon 7 does not change following cyclization,
no hydride shift occurs and the stereogenic center of carbon 4 is
preserved providing
2,4.beta.-dimethyl-7-oxo-5-(3-methoxyphenyl)morphan (13) as a
single diastereomer. Clemmensen reduction.sup.3 and deprotection of
the phenol.sup.4 then completes the synthesis of
2,4.beta.-dimethyl-5-(3-hydr- oxyphenyl)morphan (3, R.dbd.CH.sub.3)
in 48% overall yield from 8. The stereochemical assignments for 3
(R.dbd.CH.sub.3) were made using NOESY spectra of a sealed degassed
sample obtained with mixing time of 1.500 sec and an interpulse
delay of 4 sec..sup.5 A strong interaction between the 4-methyl
group and the 9.beta. and 3.beta. protons established the
4.beta.-stereochemistry.
[0379] A requirement for significant quantities of 3 and, its
analogs for in vivo testing coupled with the usefulness of
intermediates similar to 13 in the preparation of delta opioid
receptor selective agonists,.sup.6,7 suggested improving the
overall yield of the alkylation/cyclization sequence.
Experimentation with a variety of conditions revealed that addition
of the metalloenamine of 8 to a solution of Okahara's reagent,
rather than the reverse, gave much higher yields in the
metalloenamine alkylation. In combination with an extractive workup
to remove formaldehyde (formed by hydrolysis of the methoxymethyl
group) and cyclization conditions similar to those defined by
Bonjoch et al.,.sup.8 the overall yield of the
alkylation/cyclization sequence for 13 was significantly improved
(75% for this work vs. 30% using the one-pot procedure)..sup.9
[0380] In summary, this example provides a highly
diastereoselective synthetic approach to the
N-alkyl-4.beta.-methyl-5-(3-hydroxyphenyl)morph- an system as well
as providing a higher yielding route to the useful
7-oxo-5-(3-methoxyphenyl)morphan opioid intermediates.
REFERENCES AND NOTES
[0381] 1. Werner, J. A.; Cerbone, L. R.; Frank, S. A.; Ward, J. A.;
Labib, P.; Tharp-Taylor, R. W.; Ryan, C. W. J. Org. Chem. 1996, 61,
587-597.
[0382] 2. Gu, X. -P.; Nishida, N.; Ikeda, I.; Okahara, M. J. Org.
Chem. 1987, 52, 3192-3196.
[0383] 3. Bosch, J.; Bonjoch, J. Heterocycles 1980, 14,505.
[0384] 4. Rice, K. C. J. Med. Chem. 1977, 20, 164-165.
[0385] 5. Proton assignments for 3 were made using a combination of
COSY and HETCORR spectra .sup.1H NMR (d4-MeOH) .delta. 0.782 (d,
3H, J=7.5 Hz), 1.65 (m, 1H), 1.78 (m, 1H), 1.85 (m, 1H), 2.02 (d,
1H, J=15 Hz), 2.08 (m, 1H), 2.24 (m, 1H), 2.29(m, 1H), 2.46 (q, 1H,
J=7.5 Hz), 2.54 (d, 1H, J=15.0 Hz), 2.92 (s, 3H), 3.26 (d, 1H,
J=13.6 Hz), 3.70 (m, 1H), 3.86 (dd, 1H, J=13.6 Hz, 5.3 Hz), 6.67
(m, 1H), 7.15 (t, 3H, J=7.9 Hz).
[0386] 6. Bertha, C. M.; Flippen-Anderson, J. L.; Rothman, R. B.;
Porreca, F.; Davis, P.; Xu, H.; Becketts; K.; Cha, X. -Y.; Rice, K.
C. J. Med. Chem. 1995, 38, 1523-1537.
[0387] 7. Bertha, C. M.; Ellis, M.; Flippen-Anderson, J. L.;
Porreca, F.; Rothman, R. B.; Davis, P.; Xu, H.; Becketts, K.; Rice,
K. C. J. Med. Chem. 1996, 39,2081-2086.
[0388] 8. Bonjoch, J., Casamitjana, N.; Gracia, J., Bosch, J.
Tetrahedron Lett. 1989, 30, 5655-5658.
[0389] 9. General Procedure for Alkylation/Cyclization Sequence:
(CAUTION: Read reference 4 and references cited therein for
information on N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP
and its derivatives.) The appropriate tetrahydropyridine derivative
(1 eq) is dissolved in THF (20 mL/g) and cooled to -10.degree. C.
n-Butyl lithium (1.6M in hexanes) is slowly added until a red color
is maintained followed by an addition of 1.1 eq. This material is
stirred for 1 h at -10.degree. C. and then cannulated quickly into
a solution of Okahara's reagent (distilled to high purity) in THF
(15 mL/g, 1.1 eq) at -78.degree. C. followed by stirring for 2 h.
The temperature should be kept below -30.degree. C. during
cannulation. This material is then poured into 2N HCl and extracted
twice with ethyl ether. The aqueous layer is allowed to stand for
15 min followed by addition of 50% NaOH to pH 14 and extraction
(3.times.) with ethyl ether. The ether is then washed (1N NaOH,
H.sub.2O) and the solvent removed under vacuum. The resulting
residue of product and water is dissolved in MeOH (30 mL/g) and
nitrogen is bubbled through the solution for 5 min. To this is
added concentrated HCl (2 mL/g), and the mixture is allowed to
stand at room temperature until the reaction is complete as
indicated by TLC (up to 7 days). TLC condition: SiO.sub.2; elution
with 50% (80% CHCl.sub.3:18% CH.sub.3OH:2% NH.sub.4OH) in
CHCl.sub.3. Detection: 5% phosphomolybdic acid in ethanol. All
compounds gave satisfactory .sup.1H and .sup.13C NMR and mass
spectra.
[0390] This Example is described in Thomas et al, Tetrahedron
Letters, Vol. 40, pp. 403-406 (1999), incorporated herein by
reference.
[0391] Obviously, numerous modifications and variations of the
present invention are possible in light of the above teachings. It
is therefore to be understood that within the scope of the appended
claims, the invention may be practiced otherwise than as
specifically described herein.
[0392] All references cited above are incorporated into this
application by reference in their entirety unless noted
otherwise.
* * * * *